

## CURRICULUM VITAE

**Gil I. Wolfe, MD, FAAN**

Professor and Chairman of Neurology

Irvin and Rosemary Smith Chair

State University of New York Distinguished Professor

Department of Neurology

Jacobs School of Medicine and Biomedical Sciences, Univ. at Buffalo/SUNY

1010 Main St., 2<sup>nd</sup> Floor

Buffalo, NY 14202-1102

### Education

- Medical School: University of Texas Southwestern Medical School,  
Dallas, Texas, 1985-1989.  
Degree: M.D. (June 1989).  
GPA 4.0 (A=4.0), Class rank 1 of 197.
- Graduate (incomplete): University of Texas at Dallas, 2011  
Masters of Science in Management and Administrative Sciences  
Completed 12 credit hours, GPA 4.0 (A=4.0)
- Undergraduate: Princeton University, Princeton, New Jersey, 1981-1985.  
Degree: A.B., Biology (June 1985).  
Graduated cum laude, GPA 3.8 (A=4.0).  
Senior thesis: "The plastic response of the somatosensory  
cortex to peripheral nerve damage."
- High School: St. Mark's School of Texas, Dallas, Texas, 1977-1981.  
Elected to Cum Laude Society, April 1980.

### Postgraduate Training

- Fellowship: Neuromuscular Disease and Electromyography  
Department of Neurology  
University of Pennsylvania Medical Center  
Philadelphia, PA, July 1993 - June 1994.
- Residency: Department of Neurology  
University of Pennsylvania Medical Center  
Philadelphia, PA, July 1990 - June 1993.
- Internship: Department of Internal Medicine  
University of Pennsylvania Medical Center  
Philadelphia, PA, June 1989 - June 1990.

### Academic Appointments

- Professor and Chairman Department of Neurology  
Univ at Buffalo Jacobs School of Medicine and Biomedical Sciences,  
SUNY, Buffalo, New York,  
Professor with tenure, January 2012 to present.
- Faculty: Genetics, Genomics and Bioinformatics Graduate Program

Endowed Chair: Univ at Buffalo Jacobs School of Medicine and Biomedical Sciences, SUNY, Buffalo, New York, August 2013 to present.  
Irvin and Rosemary Smith Professor and Chair  
Univ. at Buffalo Jacobs School of Medicine and Biomedical Sciences, SUNY, Buffalo, New York, January 2012 to present.

Endowed Chair: Dr. Bob and Jean Smith Foundation Distinguished Chair in Neuromuscular Disease Research  
University of Texas Southwestern Medical School  
Dallas, Texas, September 2004 to Dec. 2011.

Professor Department of Neurology  
University of Texas Southwestern Medical School  
Dallas, Texas, September 2007 to December 2011.  
Professor with tenure, September 2011 to December 2011.

Associate Professor: Department of Neurology  
University of Texas Southwestern Medical School  
Dallas, Texas, September 2000 to August 2007.

Assistant Professor: Department of Neurology  
University of Texas Southwestern Medical School  
Dallas, Texas, July 1994 to August 2000.

Co-Director: Muscular Dystrophy Association Clinic  
University of Texas Southwestern Medical School  
Dallas, Texas, October 2000 to December 2011.

Director: Peripheral Neuropathy Clinic  
University of Texas Southwestern Medical School  
Dallas, Texas, October 2000 to December 2011.  
Co-Director: September 1995 to September 2000.

### **Administrative Appointments**

Chairman: Department of Neurology, Univ. at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, January 2012 to present.

Chief of Service: Neurology, Kaleida Health, Buffalo, NY, January 2012 to present.

Chair: Neurosurgery Chairman Search Committee, Univ. at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, November 2012-May 2013.

Vice Chair: Department of Neurology, University of Texas Southwestern Medical School, Dallas, Texas, August 2005 to December 2011.

Medical Director: Department of Neurology, University of Texas Southwestern Medical School, Dallas, Texas, November 2006 to August 2010.

Section Chief: Neuromuscular Division, University of Texas Southwestern Medical School, Dallas, Texas, January 2001 to December 2011.

Program Director: Neuromuscular Medicine Fellowship Program, University of Texas Southwestern Medical School, Dallas, Texas, July 2000 to Dec. 2011.

Program Director: Clinical Neurophysiology Fellowship Program, University of Texas Southwestern Medical School, Dallas, TX, July 2000 to September 2005.

Program Director: Neurology Residency Training Program, University of Texas Southwestern

Medical School, Dallas, Texas, July 1995 to June 2000.

Program Co-Director: July 2000 to June 2006.

Assistant Program Director: July 1994 to June 1995.

Member:

UBMD Conventus Steering/Operations Committee, Univ. at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, January 2016 to present; Chair, September 2016 to present.

UBMD Communications and Contracting Committees, Univ. at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, November 2014 to present.

UBA Executive Committee, Univ. at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, June 2014 to present.

UBA Board of Directors, Univ. at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, June 2014 to present.

Pharmacy and Therapeutics Committee, Kaleida Health, Buffalo, NY, November 2014 to present.

Medical/Dental Staff Executive Committee, Kaleida Health, Buffalo, NY, January 2012 to present.

Quality Committee, Optimum Physician Alliance, HealthNow NY, Inc. Buffalo, NY, July 2013 to June 2015.

Executive Committee, Univ. at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, January 2012 to present.

UBMD Management Council, Univ. at Buffalo School of Medicine And Biomedical Sciences, Buffalo, NY, January 2012 to May 2014.

Neurology Education Committee, University of Texas Southwestern Medical School, Dallas, Texas, July 1994 to December 2011.

Graduate Medical Education Committee, University of Texas Southwestern Medical School, Dallas, Texas, July 1995 to June 2000.

Institutional Review Board, University of Texas Southwestern Medical Center, Dallas, Texas, January 1999 to August 2004; November 2006 to October 2007.

**Board Certifications**

Federal Licensing Examination (FLEX)

June 1989

Diplomate of American Board of Psychiatry and Neurology, board certified in Neurology, #40560

November 1994  
Recertified August 2004  
Recertified February 2014

Diplomate of American Board of Psychiatry and Neurology, Added Qualifications in Clinical Neurophysiology, #760

April 1996  
Recertified August 2006  
Recertified May 2016



Inaugural Keynote Address, First Annual MDA Muscle Summit, Hershey, PA, 2013  
The Leading Physicians of the World, 2013, 2015, 2016  
Distinguished Lecturer, 4<sup>th</sup> Annual Myasthenia Gravis Patient Education Conference, Houston  
Methodist Neurological Institute, 2013  
Keynote Speaker, Second Annual Wright State University and Premier Health Neuroscience Institute  
Symposium, Wright State University Boonshoft School of Medicine, Dayton, OH, 2013  
Teacher of the Year Award, Univ at Buffalo/SUNY Adult Neurology Residents, 2014  
Doctor of the Year Award, Myasthenia Gravis Foundation of America, 2015  
Annual Warren Wisner Lecture in Myasthenia Gravis, Dept. of Neurology, Univ. of Alberta, 2016  
CTSA Clinical Research Achievement Award Top Awardee, Univ. at Buffalo/SUNY, 2016  
New England Journal of Medicine Journal Watch, Neurology Top Stories of 2016 (MGTX Trial)  
Clinical Research Forum, Semi-Finalist for Top-Ten Award, 2017  
University at Buffalo Distinguished Professor, 2017  
Chancellor's Award for Excellence in Scholarship and Creative Activities, State University of  
New York, 2018  
D'Youville College School of Pharmacy Excellence in Teaching Pharmacy Students award, 2018  
Carrell-Krusen 42<sup>nd</sup> Annual Neuromuscular Symposium Keynote Speaker Award, 2020.  
Reiner Lecture, Plenary of Annual Meeting of American Association of Neuromuscular and  
Electrodiagnostic Medicine, 2020.  
CTSI Clinical Research Achievement Award Finalist, Univ. at Buffalo/SUNY, 2020.  
Certificate of Recognition for Distinguished Service, State of NY Executive Chamber, Gov. Andrew  
Cuomo, 2020  
Top Doctors, Neurologist, 2021  
State University of New York Distinguished Professor, 2022  
10<sup>th</sup> Annual Mathilda Karel Spak Lecture, Univ. of California Irvine School of Medicine, 2022  
Dr. Morris B. Bender Grand Rounds annual lectureship, Icahn School of Medicine at Mt. Sinai, 2024

## Teaching and Clinical Responsibilities

### National/International

Member, MDA Clinical Conference Planning Committee, Chicago, IL, March 16-19, 2014  
Co-Chair, Muscle Study Group Annual Scientific Meeting, Novel Molecular Mechanisms of Neuromuscular  
Disease: Implications for Therapy, Lady Margaret Hall, Oxford, UK, September 16-18, 2013  
Co-Organizer, 12<sup>th</sup> International Conference on Myasthenia Gravis and Related Disorders, New York, NY,  
May 21-23, 2012  
Co-Director, Carrell Krusen Neuromuscular Symposium, 2006-2011  
Director, Neuromuscular Junction Disorders Course, American Academy of Neurology, 2006-2009  
Secretary/Chair, Neuromuscular Update Course, AANEM, 2006-2010  
Program Committee, International Congress of Neuromuscular Diseases, 2016 (Toronto), 2018 (Vienna), 2020  
(Valencia), 2022 (Brussels)  
Course Director, Development of New Neuromuscular Therapies program, AANEM, 2017  
Program Committee, 13<sup>th</sup> International Conference on Myasthenia Gravis and Related Disorders, New York,  
2017  
Course Director, Core Concepts in Pain Management, Virtual Annual Meeting, American Academy of  
Neurology, 2021  
Course Director, Core Concepts in Pain Management, Annual Meeting, American Academy of  
Neurology, 2022  
Course Director, Evolving Autoantibodies and Treatment Landscape in Myasthenia Gravis, 17<sup>th</sup> International  
Congress on Neuromuscular Diseases, 2022  
Course Director, Core Concepts in Pain Management, Annual Meeting, American Academy of  
Neurology, 2023  
Course Director, Novel Strategies for Clinical Trial Recruitment and Participation, MDA Clinical and  
Scientific Conference, 2024.  
Course Director, Core Concepts in Pain Management, Annual Meeting, American Academy of

## Neurology, 2024

Local through Dec. 2011

Neurology ward and consult service, Parkland Memorial Hospital, 1-2 months each year.  
 Neurology ward and consult service, UT Southwestern University Hospital, 1-2 months each year.  
 Neurology residents clinic, Parkland Memorial Hospital, throughout the year.  
 Neuromuscular/MDA clinic attending throughout the year.  
 Electromyography laboratory attending, UT Southwestern and Children's Medical Center, throughout year.  
 Autonomic laboratory director, 1994-2006  
 Peripheral neuropathy clinic director, 1997-2011  
 Intraoperative monitoring, UT Southwestern University Hospitals, daily  
 Lectures for medical students on sensory receptors, neurologic examination, neuromuscular disorders.  
 Lectures for residents and fellows on clinical neurology, neuromuscular disorders, autonomic disorders, electrophysiology, muscle and nerve biopsy.

Local, current since 2012

Neuromuscular medicine conference, weekly  
 Neuromuscular clinic and electromyography clinic, Buffalo General Medical Center, weekly  
 Intraoperative monitoring, Buffalo General Medical Center & Oishei Children's Hospital, daily  
 University at Buffalo MDA Clinic Co-Director  
 CME Course Director, Neurology Update for the Primary Care Professional, March 2015  
 Lectures for residents and fellows on clinical neurology, neuromuscular disorders, autonomic disorders, electrophysiology, muscle and nerve biopsy  
 See others below

<b>Medical School Courses</b>	<b>Topic/etc.</b>	<b>Location/years</b>
Neuroanatomy and Neurophysiology	Sensory receptors	UT Southwestern, 1994-2011
Neurology Clerkship	Neuromuscular disorders	UT Southwestern, 1994-2011
Neurology Clerkship (NEU 801)	Neuromuscular disorders	Univ at Buffalo, 2012-present
NeuroSims Workshop (NEU 801)	Motor, coordination, gait examination	Univ at Buffalo, 2021-present
CPM 1 Preceptor	History and physical examination training for medical students	Univ at Buffalo, 2021-present
<b>Resident and Fellowship Courses</b>	<b>Topic/etc.</b>	<b>Location/years</b>
Neurophysiology Lecture Series	Neuromuscular and autonomic disorders; electromyography; quantitative sensory testing; muscle/nerve biopsy	UT Southwestern, 1994-2011
Neurophysiology Lecture Series	Neuromuscular and autonomic disorders; electromyography; quantitative sensory testing; muscle/nerve biopsy	Univ at Buffalo, 2012-present
Resident Didactic Lecture Series	Neuromuscular disorders	UT Southwestern, 1994-2011
Resident Didactic Lecture Series	Neuromuscular disorders	Univ at Buffalo, 2012-present
<b>Clinical Teaching</b>	<b>Topic/etc.</b>	<b>Location/years</b>
Neurology inpatient and consult services	6-12 weeks/year supervising medical students to housestaff	UT Southwestern, 1994-2011
General neurology inpatient service	2-6 weeks/year supervising medical students to housestaff	Univ at Buffalo, 2012-present
Morning Report/Professor Rounds/CPC	2x/month; case reviews	Univ at Buffalo, 2015-present
CPM mentor for MS1s	2-3x/month; clinic	Univ at Buffalo, 2019-present

<b>Clinical/Research Mentees (selected from &gt;200; I served as program director or chairman)</b>	<b>Year/training program</b>	<b>Faculty positions, etc.</b>
Sharon Nations, MD	1995/UT Southwestern neurophysiology fellow	Professor of Neurology, UT Southwestern
Waleed El-Feky, MD	1998/UT Southwestern chief neurology resident & neurophysiology fellow	Texas Neurology, Baylor University Medical Center
Choon Cha, MD	1998/UT Southwestern neurophysiology fellow	Instructor of Neurology, UT Southwestern; Senior Director for neurodegenerative diseases, EMD Serono
David Saperstein, MD	1998/UT Southwestern neurophysiology fellow	Assistant Professor of Neurology, Univ of Kansas; Banner Health, Univ Medical Center Phoenix
Anwarul Haq, MD	1998/UT Southwestern neurology resident & neurophysiology fellow	Baylor Scott and White Health
Jaya Trivedi, MD	2000/UT Southwestern neuromuscular fellow	Professor of Neurology, UT Southwestern
Zahid Cheema, MD	2002/UT Southwestern neuromuscular & neurophysiology fellow	Assistant Professor of Neurology, Univ of Oklahoma; SSM Health
Pravin Khemani, MD	2003/UT Southwestern resident	Dept of Neurology, Univ. of Washington
Mounzer Kassab, MD	2003/UT Southwestern resident & neurophysiology fellow	Vice Chair of Neurology, Michigan State University; Chairman of Neurology, Univ. of Tennessee Chattanooga COM
Mike Singer, MD, PhD	2005/UT Southwestern neuromuscular fellow	Assistant Professor of Neurology, UT Southwestern; FDA
Srikanth, Muppidi, MD	2009/UT Southwestern neuromuscular fellow	Associate Professor of Neurology, Stanford
Hamid Sadeghian, MD	2010/UT Southwestern neuromuscular fellow	Assistant Professor of Neurology, Virginia Commonwealth University; UHN Toronto
Cristian Ionita, MD	2010/UT Southwestern neuromuscular fellow	Associate Professor of Pediatrics/Neurology, Yale
Diana Castro, MD	2012/UT Southwestern neuromuscular fellow	Associate Professor of Pediatrics/Neurology, UT Southwestern
Lauren Phillips, MD	2012/UT Southwestern resident	Associate Professor of Neurology, UT Southwestern
Osman Farooq, MD	2012/Univ at Buffalo neurophysiology fellow	Associate Professor of Child Neurology, section chief, Univ at Buffalo
Tareq Kass-Hout, MD	2012/Univ at Buffalo neurology resident	Assistant Professor of Neurology, Univ of Chicago
Omar Kass-Hout, MD	2012/Univ at Buffalo neurology resident	Adjunct Associate Professor of Neurology, UNC-Chapel Hill
Ping Li, MD, MSc	2013/Univ at Buffalo neurophysiology fellow	Associate Professor of Neurology, Neurophysiology/epilepsy fellowship program director, Univ at Buffalo
Rajesh Gupta, MD	2014/Univ at Buffalo neurology resident	Assistant Professor of Neurology, UT Houston
Mohammad Waqas Masud, MD	2015/Univ at Buffalo neurology resident	Assistant Professor of Neurology, Univ of Tennessee-Knoxville
Deeya Gaindh, MD	2015/Univ at Buffalo neurology resident	Assistant Professor of Neurology, Rutgers University
Cynthia Beatty, MD	2015/Univ at Buffalo child neurology resident	Assistant Professor of Child Neurology, Univ at Buffalo
Pooja Sofat, MD	2016/Univ at Buffalo chief	Assistant Professor of Neurology, Univ at

	resident & neurophysiology fellow	Buffalo
Haris Kamal, MD	2016/Univ at Buffalo neurology chief resident	Assistant Professor of Neurology, UT Houston
Arangzeb Memon, MBBS	2016/Univ at Buffalo neurology chief resident	Assistant Professor of Neurology, Emory University
Mahmoud Abdelrazek, MD	2016/Univ at Buffalo neurology resident	Instructor of Neurology, Harvard
Svetlana Primma Eckert, MD	2018/Univ at Buffalo chief neurology resident	Assistant Professor of Neurology, Univ at Buffalo
Daniela Zambrano, MD	2018/Univ at Buffalo neurology chief resident	Assistant Professor of Neurology, Univ of Vermont
Ashley Alex, MD	2020/Univ at Buffalo chief neurology resident	Assistant Professor of Neurology, Univ at Buffalo
Daniel Sirica, Jr., MD	2020/Univ at Buffalo chief neurology resident	Assistant Professor of Neurology, Univ at Buffalo
Evelyn Berman, MD, MSc	2020/Univ at Buffalo resident & epilepsy fellow	Assistant Professor of Neurology & Pediatrics, Univ of Rochester
Aaron Taylor, MD	2022/Univ at Buffalo chief neurology resident; stroke fellow	Assistant Professor of Neurology, Univ at Buffalo
Chindo Mallum, MD	2022/Univ. at Buffalo neurophysiology fellow	Community Practice, Terre Haute, IN
Amanda Schwandt, DO	2022/Univ. at Buffalo neurology resident & epilepsy fellow	Assistant Professor of Neurology, Univ at Buffalo
Alexus Ludwig, DO	2023/Univ. at Buffalo chief neurology resident & epilepsy/IOM fellow	Assistant Professor of Neurology, Univ at Buffalo

### Professional Societies

American Academy of Neurology	1991 to present
AANEM	1993 to present
Alpha Omega Alpha Honor Medical Society	1988 to present
American Autonomic Society	1998 to 2005
Peripheral Nerve Society	2000 to 2010
Texas Neurological Society	2003 to 2011
American Neurological Association	2004 to present
American Society of Pain Educators	2005 to present
New York State Neurological Society	2012 to present

### Professional Boards

The Neuropathy Association, center director	1996 to 2011
Idiopathic Neuropathies Work Group	1998 to 1999
Myasthenia Gravis Foundation of America	
Medical/Scientific Advisory Board	2001 to 2022
Scientific Program Chair	2005 to 2007
Assistant Secretary/Secretary of M/SAB	2005 to 2009
Vice Chair of M/SAB	2009 to 2011
Chair of M/SAB	2011 to 2013
Immediate Past Chair of M/SAB	2013 to 2015
Medical/Scientific Advisory Council	2023 to present
Charcot-Marie-Tooth Association	
Medical Advisory Board	2001 to 2012
Muscle Study Group, Investigator	2001 to present
AANEM	
Neuromuscular Update Course Task Force	2006 to 2010



Chair of Neuromuscular Update Committee	2007 to 2010
Practice Issues Review Panel	2010 to 2015
Program Committee	2016 to 2021
Co-Chair of Program Committee	2019 to 2021
Abstract Review Committee	2023 to present
American Board of Psychiatry and Neurology	
Neuromuscular Medicine Board Committee	2009 to 2020
Part II Examiner	2004-2008
Neuropathy Action Foundation	
Medical Advisory Board	2009 to 2014
American Academy of Neurology	
Neuropathy Measures Workgroup	2011-2012
Government Relations Committee	2015 to 2018
Federal Advocacy Work Group	2015 to 2018
Advocacy Committee	2019 to 2021
Grassroots Advocacy Work Group	2019 to 2021
Western ALS Study Group, Investigator	2012 to present
GBS-CIDP Foundation International	
Global Medical Advisory Board	2012 to 2020
Center of Excellence	2012 to present
Association of University Professors of Neurology	2012 to present
Councilor, Executive Council	2014 to 2017
Member, Nominating Committee	2015 to 2017
Member, Branding Task Force	2019 to 2020
New York State Neurological Society	
Board of Directors	2012 to present
Vice President	2017 to 2018
President	2018 to 2020
Immediate Past President	2020 to present
International Congress of Neuromuscular Diseases	
Program Committee	2016 to present
Co-Chair, Neuromuscular Junction Disorders	2023 to present

### Research Review Committees

Neuromuscular Section, American Academy of Neurology, 2000 to present  
 Neuromuscular Section, American Neurological Association, 2006 to present  
 Myasthenia Gravis Foundation of America, 2007 to 2012  
 Department of Defense, 2003  
 Myositis Association 2012, 2014  
 NIH/NINDS Adult Neuromuscular Disease Common Data Elements Subgroup, Member, 2011-2012  
 NIH/NINDS Myasthenia Gravis Common Data Elements Group, Co-Chair, 2012 to present  
 NIH/NINDS NeuroNEXT Recruitment, Retention and Diversity Committee, Member, 2012 to 2020;  
     Co-Chair 2020-2023.  
 NIH/NINDS Neuromuscular Disease Common Data Elements Oversight Committee, 2013 to present  
 Safety Monitoring Committee for CY4023study in myasthenia gravis, Cytokinetics, Inc., 2011-2012  
 Data Safety Monitoring Board for Phase 2 study of rasagaline in ALS, WALIS, 2013 to 2017  
 Prinses Beatrix Spierfonds, the Netherlands, 2013  
 Clinical and Translational Science Award Program (NIH) Clinical Research Achievement Award Committee,  
     2016 to present  
 Clinical and Translational Science Award Program (NIH) pilot study reviews, 2017 to present  
 Data Safety Monitoring Board for Phase 2 study of arimoclomol in IBM, 2017 to 2021; Chair 2017 to 2019  
 Data Safety Monitoring Board for Phase 3 study of arimoclomol in ALS, 2018 to 2021, Chair 2018-2019  
     External Advisory Committee for MGNet, NINDS/NIH-funded rare disease network, 2019 to present  
 Food & Drug Administration, Cellular, Tissue, Gene Therapy Advisory Committee, Special Government

Employee, 2021 to present

Data Safety Monitoring Board for CAR-T trial in myasthenia gravis, Cartesian Therapeutics, 2021 to present  
 Trial Steering Committee, Co-Chair, Phase 3 trial of satralizumab in myasthenia gravis, Roche, 2022 to present  
 NIH/NINDS Special Emphasis Panel in Clinical Trial Readiness for Rare Neurological and Neuromuscular  
 Diseases and Functional Neurological Disorders, 2023

**Editorial Boards**

Journal of Clinical Neuromuscular Disease	2001 to 2012
The Gale Encyclopedia of Neurological Disorders	2003 to 2010
Muscle Nerve, Associate Editor	2008 to 2016
RRNMF Neuromuscular Journal, Facilitator	2020 to present

**Ad hoc Reviewing**

Neurology, 1996 to present  
 Archives of/ JAMA Neurology, 1997 to present  
 Journal of the Neurological Sciences, 1998 to present  
 Journal of Clinical Neuromuscular Disease, 1999 to present  
 Muscle and Nerve, 1999 to present  
 Journal of Neuroscience Methods, 2001  
 Cochrane Neuromuscular Disease Group, 2002 to present  
 Journal of Neurology, Neurosurgery and Psychiatry, 2005 to present  
 Pain Medicine, 2010  
 Annals of Neurology 2010 to present  
 Annals of the New York Academy of Sciences 2012, 2017  
 Pediatric Neurology 2013  
 Autoimmunity 2015  
 Nature Reviews Neurology 2018  
 Therapeutic Advances in Neurological Disorders 2018  
 Annals of Clinical and Translational Neurology 2019  
 Lancet Neurology 2019 to present  
 New England Journal of Medicine 2020 to present  
 RRNMF Journal 2020 to present

**Research Experience**

Co-investigator: Pilot study to evaluate measures for ocular manifestations in myasthenia gravis. Unfunded.  
 Status: in progress.

Principal Investigator: Phase 3 randomized, double-blind, parallel-group study comparing SAR442168 to placebo in generalized myasthenia gravis. Funded by Sanofi. Status: on hold.

Principal Investigator: Phase 2 randomized, double-blind, placebo-controlled multicenter study of ALXN2050 in generalized myasthenia gravis. Funded by Alexion: \$7694 per patient. Status: commencing.

Principal Investigator: Phase 3 randomized, double blind, placebo-controlled multicenter study to evaluate satralizumab in generalized myasthenia gravis (LUMINESCE). Funded by Roche. Status: in progress.

Principal Investigator: Phase 3 multicenter, randomized, controlled trial to evaluate zilucoplan in generalized myasthenia gravis (RAISE). Funded by Ra Pharma: \$24,321 per subject. Status: completed 2023.

Principal Investigator: Phase 2A multicenter, randomized, controlled study of RVT-1401 in myasthenia gravis patients. Funded by Immunovant: \$35,170 per subject. Status: completed 2021.

Principal Investigator: Phase 3 ADAPT Study of ARGX-113 in myasthenia gravis with generalized muscle

weakness. Funded by ArgenX: \$9224 per subject. Status: completed 2019.

Principal Investigator: Phase 2 multicenter, randomized, controlled study to evaluate RA101495 in generalized myasthenia gravis. Funded by Ra Pharma: \$32,881 per subject. Status: completed 2019.

Principal Investigator: PROMISE-MG: Prospective multicenter observational cohort study of comparative effectiveness of disease-modifying treatments for myasthenia gravis. Funded by PCORI: \$3600 per subject. Status: completed 2021.

Co-investigator: Validation of CAP-PRI patient reported outcome in acquired and inherited neuropathies. Unfunded. Status: completed 2018.

Co-investigator: Open-label study of subcutaneous immunoglobulin in myasthenia gravis. Funded by CSL Behring: \$13,779 per subject. Status: completed 2018.

Principal Investigator: Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS), Funded by PCORI: \$2485 per subject. Status: completed 2017.

Co-investigator: Refinement of the MG-QOL15 quality-of-life survey for myasthenia gravis. Unfunded. Status: completed 2016.

Principal Investigator: Phase II trial of rituximab in myasthenia gravis, Funded by NeuroNEXT/NINDS: \$32,280 per subject (BEAT-MG). Status: completed 2019.

Principal Investigator: Safety and efficacy of eculizumab in subjects with refractory generalized myasthenia gravis (REGAIN), Funded by Alexion: \$27,520 per subject. Status: completed 2017.

Co-Investigator: Efficacy of Prednisone in the Treatment of Ocular Myasthenia (EPITOME). Funded by FDA: \$87,724. Status: completed 2016.

Co-Investigator: International GBS Outcome Study (IGOS). Funded by Prinses Beatrix Spierfonds: \$1008 per subject. Status: completed 2017.

Principal Investigator: Multicenter prospective PLS natural history study. Funded by SPF: \$1416 per subject. Status: in progress.

Principal Investigator: Genome-wide association study in myasthenia gravis. Funded by MGFA: \$167 per subject. Status: completed 2015.

Principal Investigator: Double-blind, placebo-controlled study of eculizumab in patients with generalized myasthenia gravis. Funded by Alexion: \$22,398 per subject. Status: completed 2013.

Co-Investigator: Prospective comparison of myasthenia gravis outcome measures. Unfunded. Status: completed 2016.

Co-Investigator: Controlled, double-blinded prospective study on the role of decompression of lower extremity nerves for symptomatic diabetic neuropathy. Funded locally by UT Southwestern: \$1450 per subject. Status: completed 2016.

Principal Investigator: Phase Ib, randomized, double-blind, placebo-controlled study to evaluate safety of MEDI-545 in adult patients with dermatomyositis and polymyositis. Funded by MedImmune. Status: completed 2009.

Principal Investigator: A pilot study of etanercept in dermatomyositis. Funded by NINDS: \$5800 per subject.

Status: completed 2011.

Principal Investigator: Multiple ascending dose, safety study of MYO-029 in adult muscular dystrophy. Funded by Wyeth. Status: completed 2008.

Principal Investigator: Two prospective trials of mycophenolate mofetil in myasthenia gravis. Funded by FDA, Roche, Aspreva: \$22,555 per subject. Status: completed 2008.

Principal Investigator: Prospective trial of Avonex in chronic inflammatory demyelinating polyradiculopathy. Funded by Biogen. Status: completed 2010.

Co-Investigator: Prospective trial of IGIV-Chromatography in chronic inflammatory demyelinating polyneuropathy. Funded by Bayer. Status: completed 2001.

Principal Investigator: Thymectomy Trial in Non-thymomatous MG Patients on Prednisone. Funded by NINDS, MDA, MGFA. Status: completed 2016.

Principal Investigator: Hyperhomocysteinemia and N5, N10-methylene tetrahydrofolate reductase deficiency in chronic cryptogenic sensory polyneuropathy. Unfunded. Status: completed 2008.

Principal Investigator: Magnetic stimulation in diabetic peripheral neuropathy. Status: completed 2001.

Co-Investigator: Sudomotor function in tuberous sclerosis complex. Unfunded. Status: completed 1999.

Principal Investigator: Two center study of cryptogenic sensory polyneuropathy, clinical features and course. Unfunded. Status: completed 1998.

Co-Investigator: Multicenter trial of intravenous gammaglobulin in myasthenia gravis. Funded by MDA and FDA. Status: terminated 1998.

Principal Investigator: Antiganglioside antibody panels in idiopathic polyneuropathy and motor neuron disease. Unfunded. Status: completed 1997.

Summer research fellow: Investigated disorders of language and higher cortical function with Elliott D. Ross, M.D., completed 1986.

Princeton University, Department of Biology: Junior and senior-year independent research under the direction of Don Ready, Ph.D. Studied plasticity in the visual and somatosensory cortex, 1983-85.

**Grant Support** (pharma/industry not included)

Texas State International Research Grant: BSRG 2-S07-RR05426-25  
University of Texas Southwestern Medical School, summer 1986.

Muscular Dystrophy Association Neuromuscular Disease Research Grant. Study of Intravenous Immunoglobulin in Myasthenia Gravis (Co-Investigator, prepared grant), 7/1/96-6/30/99, \$42,525.

FDA, Department of Health and Human Services: FD-R-001362-01-1, Study of Intravenous Immunoglobulin in Myasthenia Gravis (Co-Investigator, prepared grant), 1/1/97-12/31/99, \$739,150.

Muscular Dystrophy Association Neuromuscular Disease Research Grant. Study of Intravenous Immunoglobulin in Myasthenia Gravis (Co-Investigator, prepared grant), 1/1/98-12/31/99, \$100,000.

Myasthenia Gravis Foundation of America, Thymectomy Trial in Non-thymomatous Myasthenia Gravis

(Principal Investigator), 6/01, \$16,000

Muscular Dystrophy Association Neuromuscular Disease Research Grant. Thymectomy Trial in Non-thymomatous Myasthenia Gravis (Study Vice Chair, Principal Investigator), 7/1/01-6/30/04, \$139,872.

NIH/NINDS: U01 NS042685, Thymectomy Trial in Non-thymomatous MG Patients on Prednisone, (Study Vice Chair through 2007, assumed Study Clinical Chair in 2008, PI G. Cutter), 9/1/05-8/31/10, \$6,588,269. 2U01 NS042685, renewal of funding 9/30/10-7/31/11, \$995,762. Additional funding contingent on recruitment through 7/31/15.

Myasthenia Gravis Foundation of America, Genome-wide association study in myasthenia gravis (Principal Investigator). 7/29/09-6/30/11, Per patient reimbursement \$167.

NIH/NINDS: 3U01 NS042685, ARRA Supplement. Thymectomy Trial in Non-thymomatous MG Patients on Prednisone (Site Principal Investigator), 9/1/09-2/28/11, \$35,663.

NIH/NINDS: R13 NS077665, Support for 12th International Conference on Myasthenia Gravis and Related Disorders (Co-Principal Investigator). New York City, May 21-23, 2012, \$28,000.

NIH/NINDS: 1U10 NS077323, Network of Excellence in Neuroscience Clinical Trial: NeuroNEXT (Principal Investigator-UT Southwestern). 9/30/11-8/31/18, \$635,000 for first two years.

NIH/NINDS: U10 NS077378-02, Network of Excellence in Neuroscience Clinical Trial: NeuroNEXT (Site Principal Investigator-SUNY Buffalo, PI S. Levine), 9/30/11-8/31/18, \$50,000 per year.

FDA: R01FD003710, The Effectiveness of Prednisone for the Treatment of Ocular Myasthenia (EPITOME) (Site Principal Investigator, PI M. Benatar), 8/30/12-7/31/13, Per patient reimbursement \$6500.

Myasthenia Gravis Foundation of America, Consensus Conference for International MG Treatment Guidelines (Co-Principal Investigator), 3/1/14, \$25,000.

PCORI: 1306-02496, Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations-PAIN CONTRoLS (Site Principal Investigator, PI R. Barohn). 10/1/15-9/30/18, Per patient reimbursement \$2485.

PCORI: 1609-35953, PROMISE-MG: Prospective multicenter observational cohort study of comparative effectiveness of disease-modifying treatments for myasthenia gravis (Site Principal Investigator, PI D. Sanders). 1/1/18-12/31/19, Per patient reimbursement \$3600.

NIH/NINDS: 1U24NS107192-01, Network of Excellence in Neuroscience Clinical Trial: NeuroNEXT State University of New York, SUNY; (Site PI-Univ. at Buffalo; PI S. Levine), 7/1/18-6/30/23, \$50,000 per year. Continuing through 2028 as FFA site.

### **Invited Lectures and Presentations**

- 1) Gap Junctions and Charcot-Marie-Tooth Disease: What's the Connexin?  
University of Texas Southwestern Medical School, 11/17/93.  
University of Missouri-Columbia School of Medicine, 12/13/93.
- 2) Update on Myasthenia Gravis.  
Texas Tech University Health Sciences Center, HealthNet program, 9/22/94.
- 3) Ocular Myasthenia.

- Dallas-Fort Worth chapter of the Myasthenia Gravis Foundation, 2/5/95, 4/19/98.
- 4) Muscle Disease.  
Methodist Medical Center continuing education program, Dallas, TX, 2/22/95.
  - 5) Hereditary Neuropathy with Liability to Pressure Palsies.  
After Dinner Seminar: Unusual Diagnostic and Management Problems in Neuromuscular Disease, American Academy of Neurology Annual Meeting, 5/12/95.
  - 6) Diseases of Skeletal Muscle.  
St. Paul Medical Center, Dallas, TX, 5/19/95.
  - 7) Management of Myasthenic Crisis.  
Northwest Texas chapter of the Myasthenia Gravis Foundation, Hale Center, TX, 9/29/95.
  - 8) Muscle Disease.  
St. Paul Family Practice Center, St. Paul Medical Center, Dallas, TX, 10/13/95.
  - 9) Reversible Causes of Neuromuscular Weakness.  
Update in Neurology for Primary Care Physicians, Zale Lipshy University Hospital, Dallas, TX, 12/2/95.
  - 10) Antibody Panels in Polyneuropathy and Motor Neuron Disease.  
18th Annual Carrell-Krusen Symposium, Texas Scottish Rite Hospital for Children, Dallas, TX, 2/23/96.  
Faculty Research Conference, University of Texas Southwestern Medical School, Dallas, TX, 3/13/96.
  - 11) Introduction to Nerve Conduction Studies and Electromyography.  
Pain Management Lecture Series, Department of Anesthesiology and Pain Management, University of Texas Southwestern Medical School, Dallas, TX, 11/2/96.  
Geriatrics Grand Rounds, University of Texas Southwestern Medical School, Dallas, TX, 10/28/98.
  - 12) Intravenous Gammaglobulin in Generalized Myasthenia Gravis.  
Dallas-Fort Worth chapter of the Myasthenia Gravis Foundation, 2/2/97.
  - 13) Ataxic Sensory Neuropathy Associated with Sjögren's Syndrome.  
19th Annual Carrell-Krusen Symposium, Texas Scottish Rite Hospital for Children, Dallas, TX, 2/27/97.
  - 14) Chloroquine-induced Myopathy and Neuropathy.  
Dinner Seminar: Unusual Diagnostic and Management Problems in Neuromuscular Disease  
American Academy of Neurology Annual Meeting, Boston, MA, 4/12/97.
  - 15) Antibody Panels in Idiopathic Polyneuropathies and Motor Neuron Disease.  
Neuroscience Conference, Columbia Hospital at Medical City, Dallas, TX, 5/2/97.
  - 16) Diabetic Peripheral Neuropathy: Diagnosis and Management.  
Diabetes: The 1997 Approach, University of North Texas Health Science Center, Fort Worth, TX, 11/9/97.
  - 17) Granulomatous Myositis in Association with Ovarian Carcinoma.  
20th Annual Carrell-Krusen Symposium, Texas Scottish Rite Hospital for Children, Dallas, TX, 2/27/98.
  - 18) Chronic Cryptogenic Sensory and Sensorimotor Polyneuropathies: Concrete or Cryptic?  
Faculty Research Conference, University of Texas Southwestern Medical School, Dallas, TX, 3/11/98.

- 19) Muscle Cramps and Calf Hypertrophy in Charcot-Marie-Tooth Disease Type 1A.  
After-Dinner Seminar: Unusual Diagnostic and Management Problems in Neuromuscular Disease, American Academy of Neurology Annual Meeting, Minneapolis, MN, 5/1/98.
- 20) Peripheral Neuropathies: Diagnosis and Management.  
Geriatrics Grand Rounds, University of Texas Southwestern Medical School, Dallas, TX, 5/6/98.  
Physical Medicine and Rehabilitation Grand Rounds, University of Texas Southwestern Medical School, Dallas, TX, 6/19/98.
- 21) Neuromuscular Emergencies.  
McClellan County Medical Education and Research Foundation, Hillcrest Baptist Medical Center, Waco, TX, 9/8/98.
- 22) Clinical Applications of Quantitative Sensory Testing.  
American Association of Electrodiagnostic Medicine, 45th Annual Scientific Meeting, Orlando, FL, 10/15/98.
- 23) Oculopharyngeal Muscular Dystrophy: Case Presentation and Clinical Update.  
21st Annual Carrell-Krusen Symposium, Texas Scottish Rite Hospital for Children, Dallas, TX, 2/25/99.
- 24) Autoantibody Testing in Neuromuscular Disease: Peripheral Neuropathies.  
Course syllabus prepared. Education Program, American Academy of Neurology Annual Meeting, Toronto, Canada, 4/18/99.
- 25) Perineurial Hyperplasia in Progressive Polyneuropathy with Multiple Cranial Neuropathies.  
After-Dinner Seminar: Unusual Diagnostic and Management Problems in Neuromuscular Disease, American Academy of Neurology Annual Meeting, Toronto, Canada, 4/19/99.
- 26) Peripheral Neuropathy Course: Chronic Cryptogenic Sensory Polyneuropathy.  
Course syllabus prepared. American Academy of Neurology Annual Meeting, Toronto, Canada, 4/23/99.
- 27) Genetic Update for Charcot-Marie-Tooth Disease.  
Charcot-Marie-Tooth Association Regional Conference, Texas Scottish Rite Hospital for Children, Dallas, TX, 5/15/99.
- 28) Chronic Cryptogenic Sensory Polyneuropathy (CSPN).  
Neuroscience Conference, Medical City Dallas Hospital, Dallas, TX, 5/28/99.
- 29) Reversible Causes of Neuromuscular Weakness.  
Physical Medicine and Rehabilitation Grand Rounds, University of Texas Southwestern Medical School, Dallas, TX, 8/27/99.
- 30) EMG and Nerve Conduction Studies: Appropriate Use and Interpretation.  
Internal Medicine Visiting Professor Series, St. Paul Medical Center, Dallas, TX, 9/15/99.
- 31) Autoantibody Testing in Peripheral Neuropathy.  
Department of Neurology, Emory University School of Medicine, Atlanta, GA, 2/11/00.
- 32) Clinical and Neurophysiologic Features of Adrenomyeloneuropathy.  
22<sup>nd</sup> Annual Carrell-Krusen Symposium, Texas Scottish Rite Hospital for Children, Dallas, TX, 2/24/00.
- 33) Peripheral Neuropathy Course: The Use of Autoantibody Testing in the Approach to Peripheral Neuropathy. Course syllabus prepared. American Academy of Neurology Annual Meeting, San Diego, CA, 5/5/00.

- 34) Autoantibody Testing in Peripheral Neuropathies and Inflammatory Myopathies.  
Course syllabus prepared. Education Program, American Academy of Neurology Annual Meeting, San Diego, CA, 5/6/00.
- 35) The Treatment of Neuropathic Pain.  
Neuropathy Association's National Neuropathy Get Together, Branson, MO, 6/15/00.
- 36) Cryptogenic Sensory Polyneuropathies.  
General Internal Medicine Conference, University of Texas Southwestern Medical School, Dallas, TX, 6/20/00.
- 37) Management of Neuropathic Pain in the Year 2000.  
Department of Neurology Grand Rounds, University of Texas Southwestern Medical School, Dallas, TX, 9/27/00.
- 38) Diabetic Neuropathies and New Treatments.  
Diabetes Conference: A Look Forward, Harris Methodist Hospital System, Arlington, TX, 11/4/00.
- 39) Myofibrillar Myopathy Presenting as 3<sup>rd</sup> Degree AV Block.  
23<sup>rd</sup> Annual Carrell-Krusen Symposium, Texas Scottish Rite Hospital for Children, Dallas, TX, 2/22/01.
- 40) Peripheral Neuropathies.  
The Neurologist On Call radio talk show. Host: Dr. Quentin Mark Adams, Phoenix, AZ, 3/27/01.
- 41) Peripheral Neuropathies Associated with Idiopathic Thrombocytopenic Purpura.  
After-Dinner Seminar: Unusual Diagnostic and Management Problems in Neuromuscular Disease, American Academy of Neurology Annual Meeting, Philadelphia, PA, 5/11/01.
- 42) Peripheral Neuropathies.  
Continuing Education Program. Hillcrest Baptist Medical Center, Waco, TX, 6/12/01.
- 43) Pharmaceutical Treatment of Neuropathic Pain.  
Course syllabus prepared. Current Therapy of Peripheral Neuropathy, presented by Columbia University and the Neuropathy Association, Rome, Italy, 8/19/01.
- 44) Myasthenia Gravis: Diagnosis and Treatment.  
Dallas Internist Club, Dallas, TX, 11/1/01.
- 45) Pharmacologic Treatment of Neuropathic Pain.  
Texas Podiatric Medical Association Winter Conference, Dallas, TX, 1/10/02.
- 46) The Role of Thymectomy in Myasthenia Gravis.  
Course syllabus prepared. American Academy of Clinical Neurophysiology, 17<sup>th</sup> Annual Meeting, Santa Fe, NM, 2/15/02.
- 47) Electrophysiologic Outcome Measures in a Randomized, Placebo-Controlled Trial of Intravenous Immunoglobulin in Myasthenia Gravis. 24<sup>th</sup> Annual Carrell-Krusen Symposium, Texas Scottish Rite Hospital for Children, Dallas, TX, 2/22/02.
- 48) Neuromuscular Emergencies.  
2<sup>nd</sup> Annual Excellence in Emergency Medicine Course, Cityplace Conference Center, Dallas, TX, 3/15/02.
- 49) Multinational Thymectomy Trial in Non-Thymomatous Myasthenia Gravis.  
10<sup>th</sup> International Conference on Myasthenia Gravis and Related Disorders, Key Biscayne, FL, 6/1/02.



- Department of Neurology Grand Rounds, University of Texas Southwestern Medical School, Dallas, TX, 10/2/02.
- 50) Magnetic Field Therapy for Symptomatic Diabetic Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Trial. 79<sup>th</sup> Annual Meeting, American Congress of Rehabilitation Medicine, Philadelphia, PA, 10/5/02.
  - 51) Neuromuscular Junction and Muscle Disorders.  
Course syllabi prepared. 2003 American Academy of Neurology Winter Conference, Las Vegas, NV, 2/16/03.
  - 52) Interesting CMT (HMSN) Phenotypes.  
Clinical Genetics Conference, University of Texas Southwestern Medical School, Dallas, TX, 3/20/03.
  - 53) Pharmacologic Treatment of Neuropathic Pain.  
Medical Center Conference, Western Galilee Hospital, Naharia, Israel, 3/31/03.
  - 54) Treatment of Neuropathic Pain: Recent Advances.  
National Peripheral Neuropathy Conference, Dallas, TX, 5/19/03.
  - 55) Treatment of Diabetic Neuropathy.  
Diabetes: What's Hot in 2004, Texas Health Research Institute, Fort Worth, TX, 2/28/04.
  - 56) Overview of EMG.  
Dallas Internist Club, Dallas, TX, 3/4/04.
  - 57) Treatment of Myasthenia Gravis.  
Course syllabus prepared. Education Program, American Academy of Neurology Annual Meeting, San Francisco, CA, 4/25/04.
  - 58) Postherpetic Neuralgia: A Model for the Treatment of Neuropathic Pain.  
Course syllabus prepared. Texas Academy of Family Practice Primary Care Update. Austin, TX, 5/13/04.
  - 59) IVIG in Neurologic Disorders.  
CME program through University of Kentucky College of Pharmacy and Medicine. Birmingham, AL, 6/8/04.
  - 60) New Approaches in the Management of Postherpetic Neuralgia.  
CME program through Johns Hopkins University School of Medicine. Dallas, TX, 9/21/04.
  - 61) Treatment Options in Ocular Myasthenia Gravis.  
Presented as part of the Carol F. Zimmerman, MD, Lectureship in Neuro-Ophthalmology. Univ. of Texas Southwestern Medical School. Dallas, TX, 10/16/04
  - 62) Update in Neuromuscular Disorders.  
Course syllabus prepared. 2004 American Academy of Neurology Fall Conference, New York, NY, 11/6/04.
  - 63) Neuropathies Associated with Hepatitis C Infection.  
Neuropathies Associated with Systemic Disease. Presented by Weill Medical College of Cornell University and the Neuropathy Association, St. Thomas, U.S. Virgin Islands, 12/30/04.
  - 64) Medical Management of Painful Peripheral Neuropathies.  
Course syllabus prepared. Education Program, American Academy of Neurology Annual Meeting, Miami, FL 4/10/05.
  - 65) Treatment of Myasthenia Gravis.

- Course syllabus prepared. Education Program, American Academy of Neurology Annual Meeting, Miami, FL, 4/15/05.
- 66) Update in Neuromuscular Junction Disorders and Myopathies. Update in Neurology II. Course syllabus prepared. American Academy of Neurology Annual Meeting, Miami, FL, 4/15/05.
- 67) Overview of Diabetic Neuropathy and Management of Neuropathic Pain. Preceptorship in Neuropathic Pain, Pfizer-sponsored educational program, Dallas, TX, 8/31/05.
- 68) Update on Clinical Trials in Muscular Dystrophy. MDA program, Texas Scottish Rite Hospital for Children, Dallas, TX, 11/7/05.
- 69) Pharmacologic Treatment of Neuropathic Pain. Geriatrics Grand Rounds, UT Southwestern Medical Center, Dallas, TX, 11/16/05.
- 70) Update in Neuromuscular Disorders. Course syllabus prepared. 2006 American Academy of Neurology Winter Conference, Las Vegas, NV, 1/15/06.
- 71) Neurologic Complications of Diabetes: Neuropathies. 7<sup>th</sup> Annual Neurology Update for Primary Care Providers, Dallas, TX, 3/3/06.
- 72) Treatment of Myasthenia Gravis. Course syllabus prepared. Education Program, American Academy of Neurology Annual Meeting, San Diego, CA, 4/2/06.
- 73) Neuromuscular Therapy: The Top Ten, Neuromuscular Junction Disorders. Course syllabus prepared. Education Program, American Academy of Neurology Annual Meeting, San Diego, CA, 4/6/06.
- 74) Medical Management of Painful Peripheral Neuropathies. Course syllabus prepared. Education Program, American Academy of Neurology Annual Meeting, San Diego, CA, 4/7/06.
- 75) Rational Pharmacological Management of Neuropathic Pain. Course syllabus prepared. Texas Neurological Society Summer Retreat, Austin, TX, 7/21/06.
- 76) Treatment Options for the Management of Diabetic Painful Neuropathy and Postherpetic Neuralgia. Neurology Conference, Park Plaza Hospital and Medical Center, Houston, TX, 8/17/06.
- 77) Clinical Diagnosis of Myasthenia Gravis. Fundacion Miastenia Gravis de Argentina, II International Symposium, Buenos Aires, Argentina, 9/25/06.
- 78) Neuropathic Pain Therapy. Dallas Internist Club Lecture Series, Dallas, TX, 10/12/06.
- 79) Workup of Neuropathy. Update in Internal Medicine, UT Southwestern CME Course, Dallas, TX, 11/9/06.
- 80) Treatment Options for Myasthenia Gravis: UnMuSKing a New Phenotype. Univ. of Kansas Medical Center, Dept. of Neurology/Neurosurgery Grand Rounds, Kansas City, KS, 4/6/07. Univ. of Texas Southwestern Medical Center, Dept. of Neurology Grand Rounds, Dallas, TX, 9/26/07.
- 81) Treatment of Myasthenia Gravis. Course syllabus prepared. Education Program, American Academy of Neurology Annual Meeting, Boston,

MA, 5/4/07.

- 82) Clinical Phenotype of MuSK-Antibody-Positive MG.  
11<sup>th</sup> International Conference on Myasthenia Gravis and Related Disorders, Chicago, IL, 5/14/07.
- 83) Diabetic Neuropathies: Clinical Features and Treatments.  
Neurology Conferences, Karachi, Lahore, and Islamabad, Pakistan, 6/26, 6/27 & 6/29/07.
- 84) Treatment Options for Myasthenia Gravis: UnMuSKing a New Phenotype.  
Robert Wood Johnson Medical School, Univ. of Medicine & Dentistry of New Jersey, Dept. of Neurology Grand Rounds, New Brunswick, NJ, 12/5/07.
- 85) Clinical Approach to Peripheral Neuropathy.  
Medical Staff Conference, Western Galilee Medical Center, Naharia, Israel, 1/2/08.
- 86) Peripheral Neuropathy Update 2008.  
9<sup>th</sup> Annual Neuroscience Update, Four Seasons Resort, Dallas, TX, 2/15/08.
- 87) Neurology Update I: Update in Neuromuscular Junction Disorders and Myopathies.  
Course syllabus prepared. Education Program, American Academy of Neurology Annual Meeting. Chicago, IL, 4/13/08.
- 88) Treatment of Myasthenia Gravis.  
Course syllabus prepared. Education Program, American Academy of Neurology Annual Meeting. Chicago, IL, 4/14/08.
- 89) Treatment Options for Myasthenia Gravis: UnMuSKing a New Phenotype.  
Univ. of Alabama School of Medicine, Dept. of Neurology Grand Rounds, Birmingham, AL, 4/29/08.
- 90) Update in Neuromuscular Junction Disorders and Myopathies.  
Dallas Internist Club Lecture Series, Dallas, TX, 5/8/08.
- 91) Therapeutic Approaches in Neuromuscular Junction Diseases.  
Course syllabus prepared. New Therapeutics in Neuromuscular Disease, MedLogix Communications Program, Providence, RI, 9/18/08.
- 92) Oculobulbar Weakness.  
Course syllabus prepared. Neuromuscular Update I. American Association of Neuromuscular and Electrodiagnostic Medicine Annual Meeting, Providence, RI, 9/18/08.
- 93) Update on Thymectomy Trial.  
Myasthenia Gravis Foundation of America Scientific Session, Salt Lake City, UT, 9/20/08.
- 94) Novel Treatments for Myasthenia Gravis.  
Internal Medicine Neurology Update, Research and Education Institute for Texas Health Resources, Presbyterian Hospital, Dallas, TX, 9/24/08.
- 95) Rationale for the Thymectomy Trial in Non-thymomatous Myasthenia Gravis.  
9<sup>th</sup> International Congress of Neuroimmunology, Plenary Session, Fort Worth, TX, 10/29/08.
- 96) Neuropathic Pain Mechanisms and Neuropathy: New Insights.  
Geriatrics Grand Rounds, Univ. of Texas Southwestern Medical School, Dallas, TX, 12/3/08.
- 97) Treatment Update in Myasthenia Gravis and Other Disorders of the Neuromuscular Junction.

- Update in Neuromuscular Diseases 2009, Oregon Health and Science University, Portland, OR, 1/31/09.
- 98) Chronic Inflammatory Demyelinating Polyneuropathy and Treatment with Immune Globulin Intravenous.  
Accredo Health Group Meeting, Fort Worth, TX, 2/25/09.
- 99) Evaluating Outcome Measures in Myasthenia Gravis.  
Distinguished Professor Lecture Series, Dept. of Clinical Sciences, UT Southwestern Medical Center, Dallas, TX, 4/16/09.
- 100) Pharmacologic Therapy for Neuropathic Pain.  
Resident conference, Dept. of Anesthesiology, UT Southwestern Medical Center, Dallas, TX, 4/16/09.
- 101) Treatment of Myasthenia Gravis.  
Course syllabus prepared. Education Program, American Academy of Neurology Annual Meeting. Seattle, WA, 5/1/09.
- 102) Autoimmune Neuromuscular Diseases: A Case-based Didactic Guide.  
CME Program sponsored by DIME, United Regional Health Care System, Wichita Falls, TX, 5/7/09.
- 103) Update on MG Treatments: “UnMuSKing a New Phenotype and the Thymectomy Trial.  
Japanese Society of Neurology, 50<sup>th</sup> Annual Meeting, Sendai, Japan, 5/20/09.
- 104) Update on Treatments for CIDP: Focus on IVIG.  
GBS/CIDP Support Group Meeting, Dallas, TX, 6/6/09.
- 105) Neuropathy 101 For Patients.  
Neuropathy Action Foundation, 3<sup>rd</sup> Annual Neuropathy Action Awareness Day, Sacramento, CA, 6/25/09.
- 106) Cymbalta for the Management of Fibromyalgia.  
PriMed Access with American College of Physicians, Dallas, TX, 7/11/09.
- 107) Update for Myasthenia Gravis.  
Arizona Neurological Society Summer CME Conference, Sedona, AZ, 8/1/09.
- 108) Taking a Stand on Neuromuscular Disease.  
DIME sponsored CME symposium, San Diego, CA, 10/8/09.
- 109) Hereditary Peripheral Neuropathy: Variability of Presentations.  
Course syllabus prepared. Neuromuscular Update II. American Association of Neuromuscular and Electrodiagnostic Medicine Annual Meeting, San Diego, CA, 10/9/09.
- 110) Commonly Prescribed Prescription Medications for Neuropathic Pain.  
Management of Neuropathic Pain Special Interest Group. American Association of Neuromuscular and Electrodiagnostic Medicine Annual Meeting, San Diego, CA, 10/10/09.
- 111) Update on Neuromuscular Disease: 2009.  
Univ. of Texas Southwestern Medical Center, Dept. of Neurology Grand Rounds, Dallas, TX, 10/21/09.
- 112) MuSK MG: Is it a Different Disease?  
Harris County Neurological Society, Houston, TX, 10/21/09.
- 113) Autoimmune Neuromuscular Diseases: A Case-based Didactic Guide.  
Medical Grand Rounds, UT Health Science Center at Tyler, Tyler, TX, 10/23/09.

- 114) Overview of CMT and Neuropathic Pain.  
CMT Association, Dallas Chapter, Dallas, TX, 10/24/09.
- 115) Neurology Update III: Neuromuscular Disease.  
Course syllabus prepared. 2009 American Academy of Neurology Fall Conference, Las Vegas, NV, 11/8/09.
- 116) Rational Pharmacological Management of Neuropathic Pain.  
Univ. of Kansas Medical Center, Dept. of Neurology/Neurosurgery Grand Rounds, Kansas City, KS, 11/13/09.
- 117) How Neurologists Develop Treatment Plans For Patients with Myasthenia Gravis.  
Myasthenia Gravis Association of Missouri and Kansas 49<sup>th</sup> Annual Meeting, keynote speaker, Kansas City, MO, 11/14/09.
- 118) Peripheral Neuropathy.  
Primary Care Toolbox, John Peter Smith Health Network CME series, Fort Worth, TX, 12/10/09.
- 119) Organization of an MDA Clinical Program.  
Muscular Dystrophy Association regional staff meeting, Dallas, TX, 1/6/10.  
Muscular Dystrophy Association regional staff meeting, Dallas, TX, 7/26/11.
- 120) Management of Neuropathic Pain.  
7<sup>th</sup> Annual Dallas Pain Symposium, Univ. of Texas Southwestern Medical Center, Dallas, TX, 1/16/10.
- 121) Myasthenia Gravis: UnMuSKing a New Phenotype.  
Grand Rounds, Dept. of Neurology, Univ. of Arkansas for Medical Sciences, Little Rock, AK, 1/25/10.
- 122) Neuropathic Pain.  
Current Trends in Family Medicine, CME Program, Univ. of Texas Health Science Center at Tyler, Tyler, TX, 2/6/10.
- 123) Overview of Pompe Disease.  
National Association of Pediatric Nurse Practitioners, Greater Texas Chapter. Dallas, TX, 3/24/10
- 124) Update on Neuromuscular Disease.  
Dept. of Neurology and Psychiatry Grand Rounds, St. Louis University School of Medicine, St. Louis, MO, 5/6/10.
- 125) State-of-the-Art Treatment for Myasthenia Gravis.  
Myasthenia Gravis Foundation of America 2010 National Conference, St. Louis, MO, 5/6/10.
- 126) Autoimmune Neuromuscular Diseases: A Case-based Didactic Guide.  
CME Program sponsored by DIME, Flagstaff Medical Center, Flagstaff, AZ, 5/11/10.
- 127) Immune-mediated Neuropathies: Treatment Concepts, Successes and Failures.  
Univ. of Kansas Medical Center, Dept. of Neurology/Neurosurgery Grand Rounds, Kansas City, KS, 9/3/10.
- 128) Antigens and Antibodies in Myasthenia Gravis.  
Rare Neuroimmunologic Disorders Symposium, UT Southwestern Medical Center, Dallas, TX, 9/24/10.
- 129) Clinical Decision Making in Autoimmune Neuromuscular Disease: Diagnosis, Treatment, and Management.  
DIME sponsored CME symposium, Quebec, Canada, 10/6/10.
- 130) Neuromuscular Vignettes.  
Course syllabus prepared. Neuromuscular Update II. American Association of Neuromuscular and

- Electrodiagnostic Medicine Annual Meeting, Quebec, Canada, 10/8/10.
- 131) Lessons Learned from the MG Thymectomy Trial.  
Consensus Conference on MG Study Design, Duke University Medical Center, Durham, NC, 11/19/10.
- 132) Chronic Inflammatory Demyelinating Polyneuropathy and Treatment with Immune Globulin Intravenous  
Israeli Neurological Association Annual Meeting, Eilat, Israel, 12/16/10.
- 133) Update on Neuromuscular Disease.  
Texas Neurological Society Winter Conference, Austin, Texas, 2/27/11.
- 134) Primer on Myasthenia Gravis.  
Department of Anesthesiology Morbidity and Mortality Conference, UT Southwestern Medical Center, Dallas, TX, 3/2/11.
- 135) Testing for Peripheral Neuropathies and Disorders of Neuromuscular Transmission.  
Course syllabus prepared. Diagnostic Testing in Neuromuscular Disease. Education Program. American Academy of Neurology Annual Meeting, Honolulu, HI, 4/9/11.
- 136) Myasthenia Gravis Treatment Update  
Muscular Dystrophy Association, Patient Support Group, Abilene, TX, 5/15/11.
- 137) Thymectomy in Immune Myasthenia Gravis  
UC Irvine MDA ALS and Neuromuscular Center Inaugural California Neuromuscular Colloquium, Newport Beach, CA, 5/20/11.
- 138) Limb-Girdle Muscle Weakness: A Window to Pompe Disease  
Department of Neurology conference series, LSU Health Sciences Center, New Orleans, LA, 6/13/11.  
MDA patient support services program, Texas Scottish Rite Hospital, Dallas, TX, 6/29/11.
- 139) Immune-mediated Neuropathies: Treatment Concepts, Successes and Failures.  
Texas Health Presbyterian Hospital Dallas Grand Rounds, Dallas, TX, 9/7/11.
- 140) Charcot-Marie-Tooth Disease: Background and Future Developments  
CMT Association, Dallas Chapter, CMT Awareness Month program, Dallas, TX, 9/10/11.
- 141) NIH Thymectomy Trial Update  
Myasthenia Gravis Foundation of America Scientific Session, San Francisco, CA, 9/14/11.
- 142) Advances in the Treatment of Autoimmune Neuromuscular Disease  
DIME sponsored CME symposium, San Francisco, CA, 9/15/11.
- 143) Navigating Diagnostic Pathways for Muscle Disorders  
CE Health Sciences and Postgraduate Institute of Medicine CME program, San Francisco, CA, 9/16/11.
- 144) Thymectomy in Immune Myasthenia Gravis: The Rationale for MGTX  
Univ. of California San Diego, Dept. of Neurology Grand Rounds, La Jolla, CA, 11/4/11.
- 145) Thymectomy Trial in Non-thymomatous Myasthenia Gravis Patients Receiving Prednisone (MGTX)  
Immune Globe International Conference of Nervous System Autoimmunity, Bangalore, India, 1/30/12.
- 146) Thymectomy in Immune MG: The Rationale for MGTX  
Installation, Irvin and Rosemary Smith Chair in Neurology, Univ. at Buffalo/SUNY SMBS, Buffalo, NY  
2/17/12.

- 147) UnMuSKing a New MG Phenotype  
Dept. of Neurology Grand Rounds, Univ at Buffalo/SUNY SMBS, Buffalo, NY, 3/29/12.
- 148) Treatment of Painful Peripheral Neuropathy  
Course syllabus prepared. Peripheral Neuropathy. Education Program. American Academy of Neurology Annual Meeting, New Orleans, LA, 4/23/12.
- 149) Pharmacological Treatment of Neuropathic Pain  
Dept. of Internal Medicine Grand Rounds, Univ at Buffalo/SUNY SMBS, Buffalo, NY, 5/3/12.
- 150) MGTX and INSIGHTS: A quick Update and Introduction  
New York MDA Clinic Directors' Meeting. University of Rochester Medical Center, Rochester, NY 5/12/12.
- 151) MGTX: Update on The Thymectomy Trial in Non-thymomatous Myasthenia Gravis  
12<sup>th</sup> International Conference on Myasthenia Gravis and Related Disorders, New York, NY 5/23/12.
- 152) Evaluation of Peripheral Neuropathies  
Dept. of Internal Medicine Resident Didactic Series, Univ. at Buffalo/SUNY SMBS, Buffalo, NY, 6/19/12.
- 153) Highlights from 12<sup>th</sup> International Conference on Myasthenia Gravis and Related Disorders  
Myasthenia Gravis Foundation of America Scientific Session, Orlando, FL, 10/3/12.
- 154) Myasthenia Gravis: UnMuSKing a New Phenotype  
Dept. of Neurology Grand Rounds, Univ of Rochester Medical Center, Rochester, NY, 11/2/12.
- 155) Peripheral Neuropathies 101: Focus on the Geriatric Population, Part 1 and Part 2  
Community Health Foundation of Western and Central New York Geriatric Clinical Practice Series, Buffalo, NY, 12/4/12.
- 156) Muscle Disease: Focus on Inflammatory Myopathies  
Dept. of Neurology Grand Rounds, Univ at Buffalo/SUNY SMBS, Buffalo, NY, 12/6/12.
- 157) Myasthenia Gravis Primer: Diagnostic and Treatment Update  
Mercy Hospital of Buffalo CME Series, Catholic Health System, Buffalo, NY, 12/8/12.
- 158) Immune-Mediated Neuropathies: Treatment Concepts, Successes and Failures  
Beth Israel Dept. of Neurology Grand Rounds, Albert Einstein College of Medicine, New York, NY 12/21/12.
- 159) Clinician-Based Neuropathy Outcome Measures  
Clinical Development Programs for Disease-Modifying Agents for Peripheral Neuropathy: Public Workshop, Food & Drug Administration, Silver Spring, MD, 2/11/13.
- 160) Myasthenia Gravis: UnMuSKing a New Phenotype  
Annual University of Toronto Neuromuscular Day, Toronto, Ontario, Canada, 2/22/13.
- 161) Status of the Trial for Thymectomy in Nonthymomatous Myasthenia Gravis Patients Receiving Prednisone  
International Workshop on Thymus, Myasthenia Gravis, Thymectomy, Palazzo de Bò, University of Padua, Padua, Italy, 3/15/13.
- 162) Myasthenia Gravis: UnMuSKing a New Phenotype  
Dept. of Neurology Grand Rounds, SUNY-Downstate Medical Center, New York, NY, 4/5/13.  
Dept of Neurology Grand Rounds, Univ. of Tennessee Health Science Center, Memphis, TN, 4/12/13.

- 163) Introduction of My MG Smartphone App  
Myasthenia Gravis Foundation of America National Conference, Miami, FL, 5/10/13.
- 164) Myasthenia Gravis Research Update  
Myasthenia Gravis Foundation of America National Conference, Miami, FL, 5/10/13.
- 165) Myasthenia Gravis: UnMuSKing a New Phenotype  
Dept. of Neurology Grand Rounds, Penn State Hershey Medical Center, Hershey, PA, 8/23/13.
- 166) Myasthenia Gravis Research Update-Keynote Address  
First Annual MDA Muscle Summit, Hershey, PA, 8/24/13.
- 167) Overcoming Hurdles of Developing and Performing Clinical Trials, Panel Moderator  
Muscle Study Group Annual Scientific Meeting, Oxford, UK, 9/17/13.
- 168) Staying Sharp: Ask the Experts  
Dana Alliance for Brain Initiatives, AARP and MetLife Foundation program, Buffalo, NY, 9/28/13.
- 169) Overview of Neuromuscular Disorders  
School of Pharmacy, D'Youville College, Buffalo, NY, 9/30/13.
- 170) Research Update in Myasthenia Gravis  
Fourth Annual Myasthenia Gravis Patient Education Conference, Houston Methodist Neurological Institute, Houston, TX, 10/5/13.
- 171) MGTX—The NIH-Funded Thymectomy Trial in Non-thymomatous Myasthenia Gravis: Why, What, and Where are We? Keynote Address, Second Annual Wright State University and Premier Health Neuroscience Institute Symposium, Wright State University Boonshoft School of Medicine, Dayton, OH, 11/5/13.
- 172) Research Update on Myasthenia Gravis and Status of the MGTX Trial.  
Department of Neurology Conference, Ichilov Hospital, Tel Aviv University Sackler School of Medicine, Tel Aviv, Israel, 12/31/13.
- 173) What's New in Managing Adult Myasthenia Gravis.  
Muscular Dystrophy Association Clinical Conference. Optimizing Care: Improving Lives Through Clinical Excellence, Chicago, IL, 3/18/14.
- 174) Myasthenia Gravis: UnMuSKing a New Phenotype  
Dept. of Neurology Grand Rounds, Rutgers-New Jersey Medical School, Newark, NJ, 3/26/14.
- 175) MGTX—The NIH-Funded Thymectomy Trial in Non-thymomatous Myasthenia Gravis: Why, What, and Where are We? Dept. of Neurology Grand Rounds, Stony Brook University School of Medicine, SUNY, Stony Brook, NY, 3/28/14.
- 176) Treatment of Painful Peripheral Neuropathy  
Course syllabus prepared. Peripheral Neuropathy. Education Program. American Academy of Neurology Annual Meeting, Philadelphia, PA, 5/2/14.
- 177) Case Presentation: Hereditary Neuropathy  
Peripheral Neuropathy. Education Program. American Academy of Neurology Annual Meeting, Philadelphia, PA, 5/2/14.
- 178) Understanding Pain and Neuropathy  
Orchard Park Senior Center, Orchard Park, NY, 5/6/14.



- Canterbury Woods, Williamsville, NY, 5/13/14.  
Clarence Senior Center, Clarence, NY, 10/20/14.  
Amherst Senior Center, Amherst, NY, 11/5/14.
- 179) Pharmacological Therapy for Neuropathic Pain  
Department of Family Medicine Quarterly Grand Rounds, Univ. at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, 5/8/14.
- 180) Myasthenia Gravis: UnMuSKing a New Phenotype  
Dept. of Neurology Grand Rounds, LSU Health Sciences Center-Shreveport School of Medicine, Shreveport, LA, 5/16/14.
- 181) Overview of Neuromuscular Disorders  
School of Pharmacy, D'Youville College, Buffalo, NY, 9/15/14.
- 182) What's New in Managing Myasthenia Gravis  
New York State Neurological Society Annual Fall Symposium, New York, NY, 10/18/14.
- 183) Myasthenia Gravis: UnMuSKing a New Phenotype  
Dept. of Neurology Grand Rounds, Albert Einstein College of Medicine, Montefiore Medical Center, New York, NY, 10/23/14.
- 184) What's New in Managing Myasthenia Gravis  
Dept. of Neurology Grand Rounds, Case Western Reserve University School of Medicine, Cleveland, OH, 11/7/14.
- 185) Myasthenia Gravis: UnMuSKing a New Phenotype  
Neuromuscular Grand Rounds, Case Western Reserve University School of Medicine, Cleveland, OH, 11/7/14.
- 185) Myasthenia Gravis: UnMuSKing a New Phenotype  
Dept. of Neurology Grand Rounds, Indiana University School of Medicine, Indianapolis, IN, 12/10/14.
- 186) Immune-Mediated Neuropathies: Treatment Concepts, Successes and Failures  
Dept. of Neurology Grand Rounds, Univ. at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, 1/8/15.
- 187) Myasthenia Gravis: UnMuSKing a New Phenotype  
Dept. of Neurology Grand Rounds, Univ. of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 2/25/15.
- 188) Treatment of Neuropathic Pain  
Neurology Update for the Primary Care Professional, CME Course, Dept. of Neurology, Univ. at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, 3/14/15.
- 189) Update on CIDP  
GBS/CIDP Foundation International regional meeting, Univ. at Buffalo Center for Tomorrow, Buffalo, NY, 5/13/15.
- 190) What's New in Treatment Strategies for MG in the New Era?  
Japanese Society of Neurology, 56<sup>th</sup> Annual Meeting, Niigata, Japan, 5/20/15.

- 191) Understanding Pain and Neuropathy  
Cheektowaga Senior Center, Cheektowaga, NY, 6/3/15.  
Ken-Ton Presbyterian Village, Kenmore, NY, 6/9/15.
- 192) Myasthenia Gravis: UnMuSKing a New Phenotype  
Mt. Sinai Beth Israel Mirken Dept. of Neurology Grand Rounds, New York, NY, 6/5/15.
- 193) What's New in Treatment Strategies for Myasthenia Gravis?  
Canadian Neurological Sciences Federation 50<sup>th</sup> Congress, Toronto, Ontario, Canada, 6/10/15.
- 194) Management Dilemmas in Neuroimmunological Conditions: Thymectomy in MG  
2<sup>nd</sup> World Congress on NeuroTherapeutics, Prague, Czech Republic, 9/6/15.
- 195) Myasthenia Gravis: UnMuSKing a New Phenotype  
Neuroscience Institute Grand Rounds, Albany Medical Center, Albany Medical College Albany, NY,  
10/1/15.
- 196) Myasthenia Gravis: UnMuSKing a New Phenotype  
Dept. of Neurology Grand Rounds, Winthrop University Hospital, Mineola, NY, 10/2/15.
- 197) Myasthenia Gravis: UnMuSKing a Phenotype  
Dept. of Neurology Grand Rounds, NYU School of Medicine, NYU Langone Medical Center, New York, NY,  
10/6/15.
- 198) The World Speaks: International Consensus Recommendations for Myasthenia Gravis Management  
Myasthenia Gravis Foundation of America Dinner Seminar, Honolulu, HI, 10/27/15.
- 199) The World Speaks: International Consensus Recommendations for Myasthenia Gravis Management  
Updates in Neuromuscular Transmission Disorders Symposium, American Association of Neuromuscular and  
Electrodiagnostic Medicine 62<sup>nd</sup> Annual Meeting, Honolulu, HI, 10/28/15.
- 200) Thymectomy in Non-thymomatous Myasthenia Gravis: Clinical Impact of the MGTX Study Results  
MGTX Trial investigator meeting held in memory of the late Alfred Jaretzki and John Newsom-Davis, St.  
Anne's College, Oxford, UK, 1/8/16.
- 201) The World Speaks: International Consensus Recommendations for Myasthenia Gravis Management  
Dept. of Neurology Grand Rounds, SUNY-Downstate Medical Center, New York, NY, 2/12/16.
- 202) Treatment of Myasthenia Gravis (Teaching Course)  
14<sup>th</sup> International Congress of Neuromuscular Diseases. Toronto, Ontario, Canada, 7/5/16.
- 203) Treatment of Myasthenia Gravis: General Treatment Approaches (Workshop)  
14<sup>th</sup> International Congress of Neuromuscular Diseases. Toronto, Ontario, Canada, 7/6/16.
- 204) Results of Thymectomy Trial in Myasthenia Gravis (Plenary Session/Hot Topics)  
14<sup>th</sup> International Congress of Neuromuscular Diseases. Toronto, Ontario, Canada, 7/7/16.
- 205) The World Speaks: An International Treatment Recommendation for Myasthenia Gravis  
VIII Simposio Internacional de Neurologia, Universidad de los Andes, Santiago, Chile, 7/20/16.
- 206) MGTX: Results of the Multinational Thymectomy Trial in Non-thymomatous Myasthenia Gravis  
VIII Simposio Internacional de Neurologia, Universidad de los Andes, Santiago, Chile, 7/20/16.
- 207) Pharmacological Treatment Update in Neuropathic Pain

- VIII Simposio Internacional de Neurologia, Universidad de los Andes, Santiago, Chile, 7/20/16.
- 208) MGTX: Results of the Multinational Thymectomy Trial in Non-thymomatous Myasthenia Gravis  
Annual Warren Wismer Lecture in Myasthenia Gravis, Dept. of Neurology, University of Alberta Faculty of Medicine and Dentistry, Edmonton, Canada, 9/23/16.
- 209) What's New in the Management of Myasthenia Gravis  
Plenary Address, 7<sup>th</sup> Annual Myasthenia Gravis Patient Education Day, Edmonton, Canada, 9/24/16.
- 210) MGTX: Results from the Thymectomy Trial in Non-thymomatous Myasthenia Gravis  
Muscle Study Group Annual Meeting, Snowbird, Utah, 9/26/16.
- 211) MGTX: Results from the Thymectomy Trial in Non-thymomatous Myasthenia Gravis  
Dept. of Neurology Grand Rounds, New York-Presbyterian/Weill Cornell Medical Center, New York, NY, 11/9/16.
- 212) Myasthenia Gravis: Antibody Revolution to Treatment Evolution  
New York State Neurological Society Fall Conference, New York, NY, 11/12/16.
- 213) The World Speaks: An International Treatment Recommendation for Myasthenia Gravis  
Meir Medical Center, Kfar Saba, Israel, 1/12/17.
- 214) The World Speaks: An International Treatment Recommendation for Myasthenia Gravis  
Dept. of Neurology Grand Rounds, Univ. at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, 1/19/17.
- 215) Thymectomy in Non-Thymomatous Myasthenia Gravis: Results from MGTX, a Randomized, Controlled Trial  
Dept. of Neurology & Neurosciences Grand Rounds, Stanford University Medical Center, Palo Alto, CA, 1/27/17.
- 216) Thymectomy in Non-Thymomatous Myasthenia Gravis: Results from MGTX, a Randomized, Controlled Trial  
Dept. of Neurology Grand Rounds, Univ. of California Irvine School of Medicine, Orange, CA, 2/17/17.
- 217) Results from the Thymectomy Trial  
Myasthenia Gravis Foundation of America National Conference, New Orleans, LA, 3/27/17.
- 218) Randomized Trial of Thymectomy in Myasthenia Gravis  
Univ. at Buffalo Clinical and Translational Science Institute Annual Forum, Buffalo, NY, 3/28/17.
- 219) MGTX: Results of the Multinational Thymectomy Trial in Non-thymomatous Myasthenia Gravis  
American Academy of Neurology Annual Meeting, Clinical Trials Plenary Session, Boston, MA, 4/25/17.
- 220) MGTX Primary and Secondary Outcomes  
13<sup>th</sup> International Conference on Myasthenia Gravis and Related Disorders, New York, NY, 5/16/17.
- 221) Comparing and Contrasting Treatment Strategies around the World  
13<sup>th</sup> International Conference on Myasthenia Gravis and Related Disorders, New York, NY, 5/16/17.
- 222) Myasthenia Gravis: Advances in Therapy  
4<sup>th</sup> Ottawa International Conference on Neuromuscular Disease and Biology, Ottawa, Canada, 9/8/17.
- 223) An International Consensus Guidance Statement for the Management of Myasthenia Gravis (replaced D. Sanders)  
4<sup>th</sup> Ottawa International Conference on Neuromuscular Disease and Biology, Ottawa, Canada, 9/8/17.

- 224) New Neuromuscular Therapies: Snapshot of Immunotherapeutic Developments  
2017 American Association of Neuromuscular and Electrodiagnostic Medicine Annual Meeting, Phoenix, AZ, 9/14/17.
- 225) Thymectomy in Non-Thymomatous Myasthenia Gravis: Results from MGTX, a Randomized, Controlled Trial  
Dept. of Neurology Grand Rounds, Jacobs School of Medicine and Biomedical Sciences, Univ. at Buffalo/SUNY, Buffalo, NY, 10/19/17.
- 226) Treatment Approach in Painful Peripheral Neuropathy  
3<sup>rd</sup> Annual UT Southwestern Neurotherapeutics Update, Dept. of Neurology, Univ. of Texas Southwestern Medical Center, Dallas, TX, 10/28/17.
- 227) Management of Myasthenic Crisis  
54<sup>th</sup> Congreso Argentino de Neurologia, Mar del Plata, Buenos Aires, Argentina, 11/28/17.
- 228) Update in the Treatment of Myasthenia Gravis  
54<sup>th</sup> Congreso Argentino de Neurologia, Mar del Plata, Buenos Aires, Argentina, 11/29/17.
- 229) Treatment of Myasthenia Gravis: Update and Future Directions  
Dept. of Neurology Grand Rounds, University of Virginia School of Medicine, Charlottesville, VA, 12/15/17.
- 230) Myasthenia Gravis Today: Treatment Update and Future Directions  
Immunotherapy for Neurologic Disorders 2018, University of Pennsylvania Health System & Penn Presbyterian Medical Center, Philadelphia, PA, 5/18/18.
- 231) Evolution of Monoclonal Antibody Treatment Approaches in Myasthenia Gravis  
15<sup>th</sup> International Congress on Neuromuscular Diseases, Vienna, Austria, 7/10/18.
- 232) Overview of Treatment Guidelines for Myasthenia Gravis  
15<sup>th</sup> International Congress on Neuromuscular Diseases, Vienna, Austria, 7/10/18.
- 233) Randomized Controlled Trial of Thymectomy: A Deeper Dive into Data  
15<sup>th</sup> International Congress on Neuromuscular Diseases, Vienna, Austria, 7/10/18.
- 234) Neuropathic Pain Management in Clinical Practice  
NerveCon III 2018, Hyderabad, India, 8/24/18.
- 236) Clinical Implications of Old and New Pathogenic Players in Myasthenia Gravis  
NerveCon III 2018, Hyderabad, India, 8/26/18.
- 237) Therapeutic Landscape with Novel Therapies on the Horizon for Myasthenia Gravis  
NerveCon III 2018, Hyderabad, India, 8/26/18.
- 238) What's New in Myasthenia Gravis Therapy?  
Myasthenia Gravis Symposia, Muscular Dystrophy Association regional conference, King of Prussia, PA, 9/15/18.
- 239) MGTX: A Deeper Dive into Outcomes from the Thymectomy Trial in Non-thymomatous Myasthenia Gravis  
Dept. of Neurology Grand Rounds, University of Pittsburgh School of Medicine, Pittsburgh, PA, 9/26/18.
- 240) Multi-specialty Case Presentation  
Immunoglobulin National Society 7<sup>th</sup> National Conference, Dallas, TX, 10/18/18.
- 241) Immunotherapeutic Developments in Myasthenia Gravis

- Immunoglobulin National Society 7<sup>th</sup> National Conference, Dallas, TX, 10/19/18.
- 242) Neuropathic Pain Management in Clinical Practice  
Medical Center Conference, Galilee Medical Center, Naharia, Israel, 10/29/18.
- 243) MGTX: A Closer Look at Data from the Randomized Trial of Thymectomy in Myasthenia Gravis  
Neurosciences Update 2018, University of Kansas Health System, Overland Park, KS, 11/10/18.
- 244) Management of Neuromuscular Emergencies and Myasthenic Crisis  
Mercy Hospital of Buffalo CME Series, Catholic Health System, Buffalo, NY, 11/17/18.
- 245) Update in Myasthenia Gravis Therapy and Indication of Thymectomy  
2019 Texas Neurological Society Winter Conference, Austin, TX, 2/2/19.
- 246) Management of Neuromuscular Emergencies and Myasthenic Crisis  
Sisters of Charity Hospital, Catholic Health System, Dept. of Internal Medicine Grand Rounds, Buffalo, NY, 3/12/19.
- 247) Intraoperative Neurophysiologic Monitoring  
Dept. of Neurology Grand Rounds, Stony Brook University Renaissance School of Medicine, SUNY, Stony Brook, NY, 3/15/19.
- 248) Practical Implementation of New Therapies: Treatment Landscape in Myasthenia Gravis  
2019 MDA Clinical and Scientific Conference, Orlando, FL, 4/15/19.
- 249) Neurology Update I: Neuromuscular Disease  
Course syllabus prepared. American Academy of Neurology Annual Meeting, Philadelphia, PA, 5/5/19.
- 250) Primer on Myasthenia Gravis  
25<sup>th</sup> Neurology Time Conference, Peking Union Medical College, Beijing, China, 5/25/19.
- 251) Evolution of Pathogenic Players and Treatment in Myasthenia Gravis  
25<sup>th</sup> Neurology Time Conference, Peking Union Medical College, Beijing, China, 5/26/19.
- 252) Respiratory and Crisis Management in Myasthenia Gravis  
5<sup>th</sup> Neurorespiratory Conference, Weizmann Institute, Rehovot, Israel, 5/29/19
- 253) Therapeutic Landscape and Novel Therapies for Myasthenia Gravis  
Mini-symposium on Myasthenia Gravis, Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv, Israel, 5/31/19.
- 254) Examining Treatment Strategies for Myasthenia Gravis: A Specialty Pharmacist's Review  
National Association of Specialty Pharmacy Annual Meeting, Washington, DC, 9/10/19.
- 255) Therapeutic Landscape and Novel Therapies for Myasthenia Gravis  
Dept. of Neurology Grand Rounds, Jacobs School of Medicine and Biomedical Sciences, Univ. at Buffalo/SUNY, Buffalo, NY 12/5/19.
- 256) MGTX: A Closer Look into Outcomes from the Thymectomy Trial in Myasthenia Gravis  
Dept. of Neurology Grand Rounds, University of Maryland School of Medicine, Baltimore, MD, 1/15/20.
- 257) MGTX: A Closer Look into Outcomes from the Thymectomy Trial in Myasthenia Gravis  
Dept. of Neurology Grand Rounds, University of Washington Medical Center, Seattle, WA, 1/23/20.

- 258) MGTX: A Closer Look into Outcomes from the Thymectomy Trial in Myasthenia Gravis  
Dept. of Neurology and Neurotherapeutics Grand Rounds, University of Texas Southwestern Medical Center, Dallas, TX, 2/19/20.
- 259) Carrell-Krusen Keynote Lecture: Novel Therapies for Myasthenia Gravis  
42<sup>nd</sup> Annual Carrell-Krusen Neuromuscular Symposium, Dallas, TX, 2/21/20.
- 260) Chronic Inflammatory Demyelinating Polyneuropathy: assessing the application of intravenous and subcutaneous immunoglobulin, featuring a patient perspective. Pharmacy Times continuing education program, Asembia, 5/27/20.
- 261) COVID-19 and Neuromuscular Medicine  
Mini Grand Rounds COVID-19 Series, Great Lakes Health System of Western NY, Buffalo, NY, 8/19/20.
- 262) Myasthenia Gravis: Updates in Research  
Muscular Dystrophy Association Engage Myasthenia Gravis Virtual Symposium, 9/12/20.
- 263) Neuromuscular Junction Disorders: Thymectomy  
16<sup>th</sup> International Congress on Neuromuscular Diseases, Virtual Plenary Session, 9/13/20.
- 264) COVID-19 and Neuromuscular Medicine  
Dept. of Neurology Grand Rounds, Jacobs School of Medicine and Biomedical Sciences, Univ. at Buffalo/SUNY, Buffalo, NY, 9/17/20.
- 265) Reiner Lecture: Therapeutic Landscape and Novel Therapies for Myasthenia Gravis  
American Association of Neuromuscular and Electrodiagnostic Medicine Annual Scientific Meeting, 10/9/20.
- 266) MGTX: A Closer Look into Outcomes from the Thymectomy Trial in Myasthenia Gravis  
Dept. of Medicine Grand Rounds, Oakland University William Beaumont School of Medicine, Auburn Hills, MI, 1/20/21.
- 267) Therapeutic Landscape and Novel Therapies for Myasthenia Gravis  
Neuroscience Lecture Series, MIND Clinic, Budapest, Hungary, 1/29/21.
- 268) Therapeutic Landscape and Novel Therapies for Myasthenia Gravis  
Dept. of Neurology Grand Rounds, Penn State College of Medicine, Hershey, PA, 2/5/21.
- 269) Minimal Manifestation Status and Prednisone Withdrawal in the MGTX Trial  
Clinical and Translational Science Institute Annual Forum, Univ. at Buffalo, Buffalo, NY, 3/17/21.
- 270) Therapeutic Landscape and Novel Therapies for Myasthenia Gravis  
Dept. of Neurology Grand Rounds, St. Louis University School of Medicine, St. Louis, MO, 4/1/21.
- 271) Core Concepts in Pain Management  
Virtual Annual Meeting, American Academy of Neurology, 4/21/21.
- 272) Therapeutic Landscape and Novel Therapies for Myasthenia Gravis  
Advanced Practice Provider education series, American Association of Neuromuscular and Electrodiagnostic Medicine, 5/26/21.
- 273) Emerging Developments in the Treatment of Generalized Myasthenia Gravis  
Excel CME program, 6/7/21.
- 274) The 2020 Update of the Consensus International Treatment Recommendations for Myasthenia Gravis

- Keynote address: 1<sup>st</sup> Chinese Summit on Innovative Medicine and Public Welfare in Myasthenia Gravis and Neurology, The Chinese University of Hong Kong, China, 7/2/21.
- 275) U.S. Roundtable on Immunoglobulin Use  
Plasma Protein Therapeutics Association program, 9/9/21.
- 276) New Developments in Managing Myasthenia Gravis  
3<sup>rd</sup> Annual International Congress on the Future of Neurology, New York, NY, 9/17/21.
- 277) Core Concepts in Neuropathic Pain Management  
Dept. of Neurology Grand Rounds, Univ. at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, 9/23/21.
- 278) Overview of Neuromuscular Disorders  
School of Pharmacy, D'Youville College, Buffalo, NY, 9/27/21.
- 279) Therapeutic Landscape and Novel Therapies for Myasthenia Gravis  
Dept. of Neurology Grand Rounds, The Ohio State University Wexner Medical Center, 9/28/21.
- 280) Therapeutic Landscape and Novel Therapies for Myasthenia Gravis  
Dept. of Neurology Grand Rounds, Northwestern University Feinberg School of Medicine, 10/7/21.
- 281) Autoantibodies and the Evolving MG Treatment Landscape: The 2020 Update of the Consensus International Treatment Recommendations for MG  
AANEM Annual Meeting, Aurora, Colorado, 10/15/21.
- 282) Research and Clinical Trials Update in Myasthenia Gravis  
Northeast Regional Conference, Myasthenia Gravis Foundation of America, 11/6/21.
- 283) Evolving Therapeutic Landscapes in the Management of Myasthenia Gravis  
Philippine Neurological Association 43<sup>rd</sup> Annual Convention, 11/12/21.
- 284) Therapeutic Landscape and Novel Therapies for Myasthenia Gravis  
Dept. of Neurology Grand Rounds, Univ. of Texas Health Science Center at Houston, 11/19/21.
- 285) The Evolving Therapeutic Landscape of Myasthenia Gravis  
Kansas City Clinical Neuroscience Society, Kansas City, MO, 12/2/21.
- 286) Optimizing Multidisciplinary Care in Myasthenia Gravis  
Muscular Dystrophy Association Grand Rounds, Webinar, 1/5/22.
- 287) The Evolving Therapeutic Landscape of Myasthenia Gravis  
Dept. of Neurology Grand Rounds, NYU Grossman School of Medicine, NYU Langone Medical Center, New York, NY, 1/25/22.
- 288) New Treatments in Myasthenia Gravis: When and Should I?  
National Patient Conference, Myasthenia Gravis Foundation of America, 2/11/22.
- 289) Spinoza vs. Leibniz: Science, Reason & God in 1676  
Dept. of Jewish Thought, Univ. at Buffalo, Buffalo, NY 2/27/22.
- 290) Treatment Decisions for Disorders with Multiple Therapies: Myasthenia Gravis  
Muscular Dystrophy Association Clinical and Scientific Conference 2022, Nashville, TN, 3/15/22.

- 291) Treatment Decisions for Myasthenia Gravis  
Dept. of Neurology Grand Rounds, Univ. at Buffalo Jacobs School of Medicine and Biomedical Sciences,  
Buffalo, NY, 3/24/22.
- 292) Core Concepts in Neuropathic Pain Management: Safe and Appropriate Opioid Prescribing in Neurology  
Annual Meeting Education Program, American Academy of Neurology, Seattle, WA, 4/7/22.
- 293) Myasthenia Gravis: The Evolving Therapeutic Landscape  
10<sup>th</sup> Annual Mathilda Karel Spak Lecture, Univ. of California Irvine Health Neuromuscular Colloquium,  
Irvine, CA, 6/3/22.
- 294) Evolving Autoantibodies and Treatment Landscape in Myasthenia Gravis: The 2020 Update of the Consensus  
Treatment Recommendations for MG  
17<sup>th</sup> International Congress on Neuromuscular Diseases, Brussels, Belgium, 7/9/22.
- 295) Myasthenia Gravis: The Evolving Therapeutic Landscape  
International Academic Seminar on Progress in Myasthenia Gravis, Hebei Medical University, Shijiazhuang,  
China, 7/16/22.
- 296) Looking Ahead in Myasthenia Gravis: Expert Perspectives on Current Standards and Next Frontiers  
Medscape Education Global CME program, July-August, 2022.
- 297) A Changing Treatment Paradigm of Myasthenia Gravis: A Focus on Novel Targeted Treatments  
Clinical Care Options CME program, 9/1/22.
- 298) The Role of Neonatal Fc Receptor Blocking Therapeutics in the Management of Patients with Generalized  
Myasthenia Gravis; 6<sup>th</sup> Annual Meeting of The Illinois State Neurological Society, Chicago, IL, 9/17/22.
- 299) New Treatments in MG and Drug Development Roundtable  
Muscular Dystrophy Association Engage: Myasthenia Gravis Symposium, 10/18/22
- 300) Case Presentation and Therapeutic Update in Myasthenia Gravis  
Icahn School of Medicine at Mt. Sinai, Dept. of Neurology Neuromuscular Conference, New York, NY  
11/14/22.
- 301) Myasthenia Gravis in 2022: A Year in Review  
Rare Disease Connect in Neurology Annual Meeting, Madrid, Spain, 12/1/22.
- 302) Myasthenia Gravis Pathogenesis: What is the Role of the Thymus  
Rare Disease Connect in Neurology Annual Meeting, Madrid, Spain, 12/1/22.
- 303) Looking Ahead in Myasthenia Gravis  
Dept. of Neurology Grand Rounds, Univ. at Buffalo Jacobs School of Medicine and Biomedical Sciences,  
Buffalo, NY, 12/15/22.
- 304) Neuromuscular Junction Disorders  
Neuromuscular Review Course 2023, University of Kansas Medical Center, virtual presentation, 3/4/23,  
4/8/23.
- 305) Core Concepts in Neuropathic Pain Management: Safe and Appropriate Opioid Prescribing in Neurology  
Annual Meeting Education Program, American Academy of Neurology, Boston, MA, 4/24/23.
- 306) Navigating and Interacting with Hospital Partners and Large Healthcare Systems: Private Main Teaching Hospitals  
AUPN Spring Neurology Chairs Session, 5/12/23.



- 307) Landscape and Future of MG Therapeutics  
Penn Neuromuscular Symposium 2023, Univ. of Pennsylvania Perelman School of Medicine, Philadelphia, PA,  
5/20/23.
- 308) International Treatment Recommendations for MG and the Evolving Therapeutic Landscape  
6<sup>th</sup> Ottawa International Conference on Neuromuscular Disease and Biology, Univ. of Ottawa, Ontario, Canada,  
9/8/23.
- 309) Neurology and Autoimmune Phenomena: Thymoma and Clinical Neurology  
13<sup>th</sup> International Thymic Malignancy Interest Group Annual Meeting, Memorial Sloan Kettering Cancer Center, New York, NY, 10/4/23.
- 310) New Treatment for Myasthenia Gravis  
National patient webinar, Myasthenia Gravis Foundation of America, 10/25/23.
- 311) Clinical Update for Individualized Treatment Plans for Patients with Generalized Myasthenia Gravis  
New York State Neurological Society Annual Meeting, New York City, NY, 11/11/23.
- 312) Dr. Morris B. Bender Grand Rounds: Myasthenia Gravis: the Evolving Therapeutic Landscape  
Dept. of Neurology, Icahn School of Medicine at Mt. Sinai, New York City, NY 1/5/24.
- 313) Looking Ahead in Myasthenia Gravis: Expert Perspectives on Current Standards and Next Frontiers  
Dept. of Neurology Grand Rounds, Univ. at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, 1/18/24.
- 314) Novel Strategies for Clinical Trial Recruitment and Participation: A Path Forward  
MDA Clinical and Scientific Conference, Orlando, FL, 3/5/24.

### Activities

Postgraduate:

Princeton University Book Award for high school students, Judge, 1995-1996  
Ralph B. Rogers Alumni Award selection committee, member,  
St. Mark's School of Texas, 1999  
Campaign Chair, Class of '89, UT Southwestern Medical School student center drive; Class qualified for Cornerstone Society, 1999-2000  
Congregation Anshai Torah, Member, Board of Directors, 2000-2002;  
Rabbi Liaison Committee Co-Chair, 2006 to 2011  
UT Southwestern Medical School, Interviewer for applicants, 2004-2006  
Kol Rina, Congregation Anshai Torah male choir, 2005 to present.  
Jewish Federation of Greater Dallas, annual campaign volunteer fundraiser, medical division, 2007 to 2010  
Plano, Texas ISD, Science Fair Judge, district level, 2009 to 2011  
Buffalo Jewish Federation,  
Annual Campaign Cabinet Member, Medical Division, 2012 to present  
Board of Governors, 2014-2020, 2021 to present  
Hillel Oversight Task Force, 2016-2017  
Partnership Leadership Council, 2020 to present  
Chair of General Campaign, 2021-2023  
Thursday Club, member, Buffalo, NY, 2012 to present  
Temple Beth Tzedek, service award, July 2013  
Board of Trustees, 2015-2018

Men's Club, Board Member, 2021 to present  
Princeton University Admissions Office, Interviewer for Western NY,  
2014 to present  
Bike Committee, University at Buffalo/SUNY, 2018 to present  
Guest Judge, D'Youville College 6<sup>th</sup> Annual Research and Scholarship Day, 2019  
Medical Student Research Forum Judge, Univ. at Buffalo/SUNY, 2024

Residency: Organized Grand Rounds for the Department of Neurology,  
University of Pennsylvania Medical Center, July 1992 - June 1993

Medical School: Senior Writer, The Senior Film, 1988-89  
Vice President of AOA chapter, 1988-89  
Editor, The Scutpuppy Times (MS3 newsletter), 1987-88  
Class representative, UT Southwestern Medical School  
Curriculum Committee, 1985-87

Undergraduate: The Daily Princetonian (Princeton University newspaper)  
Managing Editor, 1984-85; Senior Writer, 1982-84; Staff Writer, 1981-82

**References** Available upon request

**BIBLIOGRAPHY**

Gil I. Wolfe, M.D.

**Original Publications**

- 1) **Wolfe G.I.** and Ross E.D. Sensory aprosodia with left hemiparesis from subcortical infarction: Right hemisphere analogue of sensory type aphasia with right hemiparesis? Archives of Neurology, 1987; 44:668-671 [PMID:3579688].
- 2) **Wolfe G.I.**, Taylor C.L., Flamm E.S., Gray L.G., Raps E.C. and Galetta S.L. Ocular tilt reaction resulting from vestibuloacoustic nerve surgery. Neurosurgery, 1993; 32:417-421 [PMID:8455767].
- 3) **Wolfe G.I.**, Galetta S.L. and Mollman J.E. Spontaneous remission of papilledema and sixth nerve palsy in acute lymphoblastic leukemia. Journal of Neuro-Ophthalmology, 1994; 14:91-94 [PMID:7951935].
- 4) **Wolfe G.I.**, Raps E.C., Galetta S.L., Siderowf A.D., Brown M.J. and Bird S.J. Systemic non-Hodgkin's lymphoma manifesting as neurogenic respiratory failure. Neurology, 1995; 45:589-590 [PMID:7898725].
- 5) **Wolfe G.I.**, Galetta S.L., Teener J.W., Katz J.S. and Bird S.J. Site of autonomic dysfunction in a patient with Ross' syndrome and postganglionic Horner's syndrome. Neurology, 1995; 45:2094-2096 [PMID:7501165].
- 6) Katz J.S., **Wolfe G.I.**, Burns D.K., Bryan W.W., Fleckenstein J.L. and Barohn R.J. Isolated neck extensor myopathy: a common cause of dropped head syndrome. Neurology, 1996; 46:917-921 [PMID:8780064].
- 7) Amato A.A., Gronseth G.S., Jackson C.E., **Wolfe G.I.**, Katz J.S., Bryan W.W. and Barohn R.J. Inclusion-body myositis: clinical and pathological boundaries. Annals of Neurology, 1996;40:581-586 [PMID:8871577].
- 8) Haley R.W., Hom J., Roland P.S., Bryan W.W., Van Ness P.C., Bonte F.J., Devous M.D., Mathews D., Fleckenstein J.L., Wians F.H., **Wolfe G.I.** and Kurt T.L. Evaluation of neurologic function in Gulf War veterans: a blinded case-control study. JAMA, 1997; 277:223-230 [PMID:9005272].
- 9) Katz J.S., **Wolfe G.I.**, Bryan W.W., Jackson C.E., Amato A.A. and Barohn R.J. Electrophysiologic findings in multifocal motor neuropathy. Neurology, 1997; 48:700-707 [PMID:9065551].
- 10) **Wolfe G.I.**, El-Feky W.H., Katz J.S., Bryan W.W., Wians F.H. and Barohn R.J. Antibody panels in idiopathic polyneuropathy and motor neuron disease. Muscle Nerve, 1997; 20:1275-1283 [PMID:9324084].
- 11) **Wolfe G.I.**, Burns D.K., Krampitz D. and Barohn R.J. Cylindrical spirals of myofilamentous origin associated with exertional cramps and rhabdomyolysis. Neuromuscular Disorders, 1997; 7:536-538 [PMID:9447613].
- 12) Katz J.S., **Wolfe G.I.**, Bryan W.W., Tintner R. and Barohn R.J. Acetylcholine receptor antibodies in the Lambert-Eaton myasthenic syndrome. Neurology, 1998; 50:470-475 [PMID:9484374].
- 13) **Wolfe G.I.** and Barohn R.J. Cryptogenic sensory and sensorimotor polyneuropathies. Seminars in Neurology, 1998; 18:105-111 [PMID:9562672].
- 14) Barohn R.J., McIntire D., Herbelin L., **Wolfe G.I.**, Nations S. and Bryan W.W. Reliability testing of the quantitative myasthenia gravis score. Annals NY Academy of Science, 1998; 841:769-772 [PMID:9668327].
- 15) Jackson C.E., Amato A.A., Bryan W.W., **Wolfe G.I.**, Sakhaee K. and Barohn R.J. Primary hyperparathyroidism and ALS: is there a relation? Neurology, 1998; 50:1795-1799 [PMID:9633730].

- 16) Wasay M., **Wolfe G.I.**, Herrold J.M., Burns D.K. and Barohn R.J. Chloroquine myopathy and neuropathy with elevated CSF protein. Neurology, 1998; 51:1226-1227 [PMID:9781573].
- 17) Krampitz D.E., **Wolfe G.I.**, Fleckenstein J.L. and Barohn R.J. Charcot-Marie-Tooth disease type 1A presenting as calf hypertrophy and muscle cramps. Neurology, 1998; 51:1508-1509 [PMID:9818900].
- 18) Amato A.A., Kagan-Hallet K., Jackson C.E., Lampkin S., **Wolfe G.I.**, Ferrante M., Bigio E.H. and Barohn R.J. The wide spectrum of myofibrillar myopathy suggests a multifactorial etiology and pathogenesis. Neurology, 1998; 51:1646-1655 [PMID:9855517].
- 19) Nations S.P., **Wolfe G.I.**, Amato A.A., Jackson C.E., Bryan W.W. and Barohn R.J. Distal myasthenia gravis. Neurology, 1999; 52:632-634 [PMID:10025802].
- 20) Katz J.S., **Wolfe G.I.**, Iannaccone S., Bryan W.W. and Barohn R.J. The exercise test in Andersen's syndrome. Archives of Neurology, 1999; 56:352-356 [PMID:10190827].
- 21) **Wolfe G.I.**, Baker N.S., Amato A.A., Jackson C.E., Nations S.P., Saperstein D.S., Cha C.H., Katz J.S., Bryan W.W. and Barohn R.J. Chronic cryptogenic sensory polyneuropathy: clinical and laboratory characteristics. Archives of Neurology, 1999; 56:540-547 [PMID:10328248].
- 22) Saperstein D.S., Amato A.A., **Wolfe G.I.**, Katz J.S., Nations S.P., Jackson C.E., Bryan W.W., Burns D.K. and Barohn R.J. Multifocal acquired demyelinating sensory and motor neuropathy: the Lewis-Sumner syndrome. Muscle Nerve, 1999; 22:560-566 [PMID:10331353].
- 23) **Wolfe G.I.**, Herbelin L., Nations S.P., Foster B., Bryan W.W. and Barohn R.J. Myasthenia gravis activities of daily living profile. Neurology, 1999; 52:1487-1489 [PMID:10227640].
- 24) Katz J.S., **Wolfe G.I.**, Andersson P.B., Saperstein D.S., Elliot J., Nations S.P., Bryan W.W. and Barohn R.J. Amyotrophic brachial diplegia: a neurogenic form of man-in-the-barrel syndrome. Neurology, 1999; 53:1071-1076 [PMID:10496268].
- 25) Lindenbaum Y., Nations S.P., Barohn R.J. and **Wolfe G.I.** Recurrent acute quadriplegic myopathy in an asthmatic patient treated with corticosteroids. Journal of Clinical Neuromuscular Disease, 2000; 1:145-146 [PMID:19078575].
- 26) **Wolfe G.I.**, Baker N.S., Haller R.G., Burns D.K. and Barohn R.J. Case of the Month: McArdle's disease presenting with asymmetric, late-onset arm weakness. Muscle Nerve, 2000; 23:641-645 [PMID:10716777].
- 27) Chudnow R.S., **Wolfe G.I.**, Sparagana S.P., Delgado M.R., Batchelor L. and Roach E.S. Abnormal sudomotor function in the hypomelanotic macules of tuberous sclerosis complex. Journal of Child Neurology, 2000; 15:529-532 [PMID:10961791].
- 28) Van der Sluis R.W., **Wolfe G.I.**, Nations S.P., Bryan W.W., Krampitz D.E., Kissel J.T. and Barohn R.J. Post-radiation lower motor neuron syndrome. Journal of Clinical Neuromuscular Disease, 2000; 2:10-17 [PMID:19078596].
- 29) **Wolfe G.I.**, Brower R.D. and Burns D.K. Perineurial cell hyperplasia in early-onset polyneuropathy with multiple cranial neuropathies. Neuromuscular Disorders, 2000; 10:503-506 [PMID:10996782].
- 30) **Wolfe G.I.** and Kaminski H.J. Autoantibody testing in neuromuscular disorders, part I. Peripheral neuropathies. Journal of Clinical Neuromuscular Disease, 2000; 2:84-95 [PMID:19078611].
- 31) Kaminski H.J., Santillan C. and **Wolfe G.I.** Autoantibody testing in neuromuscular disorders, part II. Neuromuscular junction and muscle disorders. Journal of Clinical Neuromuscular Disease, 2000; 2:96-105 [PMID:19078612].
- 32) Mendell J.R., Barohn R.J., Freimer M.L., Kissel J.T., King W., Nagaraja H.N. and The Working Group on

- Peripheral Neuropathy (appendix listing). Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology, 2001; 56:445-449.
- 33) Katz J.S., Saperstein D.S., **Wolfe G.**, Nations S.P., Alkhersam H., Amato A.A. and Barohn R.J. Cervicobrachial involvement in diabetic radiculoplexopathy. Muscle Nerve, 2001; 24:794-798 [PMID:11360263].
- 34) **Wolfe G.I.** and Nations S.P. Guide to autoantibody testing in peripheral neuropathies. The Neurologist, 2001; 7:195-207.
- 35) Plaster N.M., Tawil R., Tristani-Firouzi M., Canún S., Bendahhou S., Tsunoda A., Donaldson M.R., Iannaccone S.T., Brunt E., Barohn R., Clark J., Deymeer F., George A.L., Fish F.A., Hahn A., Nitu A., Serdaroglu P., Subramony S.H., **Wolfe G.**, Fu Y.H. and Ptáček L.J. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell, 2001; 105:511-519 [PMID:11371347].
- 36) Katz J.S., Barohn R.J., Kojan S., **Wolfe G.I.**, Nations S.P., Saperstein D.S. and Amato A.A. Axonal multifocal motor neuropathy without conduction block or other features of demyelination. Neurology, 2002; 58:615-620 [PMID:11865141].
- 37) **Wolfe G.I.** Chronic idiopathic axonal polyneuropathy and successful aging of the peripheral nervous system. Archives of Neurology, 2002; 59:520-522 [PMID:11939885].
- 38) **Wolfe G.I.** and Barohn R.J. Painful peripheral neuropathy. Current Treatment Options in Neurology, 2002; 4:177-188 [PMID:11931724].
- 39) Fleckenstein J.L. and **Wolfe G.I.** MRI vs. EMG: Which has the upper hand in carpal tunnel syndrome? Neurology, 2002; 58:1583-1584 [PMID:12058080].
- 40) **Wolfe G.I.**, Barohn R. J., Foster B.M., Jackson C.E., Kissel J.T., Day J.W., Thornton C.A., Nations S.P., Bryan W.W., Amato A.A., Freimer M.L., Parry G.J., Mendell J.R and the MG-IVIIG Study Group. Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis. Muscle Nerve, 2002; 26:549-552 [PMID:12362423].
- 41) **Wolfe G.I.**, Hotz S.E. and Barohn R.J. Treatment of painful peripheral neuropathy. Journal of Clinical Neuromuscular Disease, 2002; 4:50-59 [PMID:19078690].
- 42) Weintraub M.I., **Wolfe G.I.**, Barohn R.J., Cole S., Parry G.J., Hayat G., Cohen J.A., Page J.C., Bromberg M.B., Schwartz S.L. and the Magnetic Research-Diabetic Neuropathy Group. Static magnetic field therapy for symptomatic diabetic neuropathy: a randomized, double-blind, placebo-controlled trial. Archives of Physical Medicine and Rehabilitation, 2003; 84:736-746 [PMID:12736891].
- 43) Trivedi J.R., **Wolfe G.I.**, Nations S.P., Burns D.K., Bryan W.W. and Dewey R.B. Adult polyglucosan body disease presenting with levodopa-responsive tremor. Archives of Neurology, 2003; 60:764-766 [PMID:12756142].
- 44) Saperstein D.S., **Wolfe G.I.**, Gronseth G.S., Nations S.P., Herbelin L.L., Bryan W.W. and Barohn R.J. Challenges in the identification of cobalamin-deficiency neuropathy. Archives of Neurology, 2003;60:1296-1301 [PMID:12975298].
- 45) **Wolfe G.I.**, Kaminski H.J., Jaretzki III A., Swan A. and Newsom-Davis J. Development of a thymectomy trial in nonthymomatous myasthenia gravis patients receiving immunosuppressive therapy. Annals NY Academy of Science, 2003; 998:473-480 [PMID:14592916].
- 46) Berger A.R., Bradley W.G., Brannagan T.H., Busis N.A., Cros D.P., Dalakas M.C., Danon M.J., Donofrio P.D., Engel W.K., England J.D., Feldman E.L., Freeman R.L., Kinsella L.J., Lacomis D., Latov N., Menkes D.L., Sander H.W., Thomas F.P., Triggs W.J., Windebank A.J. and **Wolfe G.I.** Guidelines for the diagnosis and treatment of chronic inflammatory demyelinating polyneuropathy. Journal of the Peripheral Nervous

- System 2003; 8:282-284 [PMID:14641652].
- 47) Torabi A.M., Patel R.K., **Wolfe G.I.** Hughes C.S., Mendelsohn D.B., and Trivedi J.R. Transverse myelitis in systemic sclerosis. Archives of Neurology, 2004; 61:126-128 [PMID:14732630].
  - 48) **Wolfe G.I.** and Trivedi J.R. Painful peripheral neuropathy and its non-surgical treatment. Muscle Nerve, 2004; 30:3-19 [PMID:15221874].
  - 49) Haley R.W., Vongpatanasin W., **Wolfe G.I.**, Bryan W.W., Armitage R., Hoffmann R.F., Petty F., Callahan T.S., Charuvastra E., Shell W.E., Marshall W.W. and Victor R.G. Blunted circadian variation in autonomic regulation of sinus node function in veterans with Gulf War Syndrome. American Journal of Medicine, 2004; 117:469-478 [PMID:15464703].
  - 50) **Wolfe G.I.** and Gross B. Treatment review and update for myasthenia gravis. Journal of Clinical Neuromuscular Disease, 2004; 6:54-68 [PMID:19078753].
  - 51) **Wolfe G.I.**, Young P.K., Nations S.P., Burkhead W.Z., McVey A.L. and Barohn R.J. Brachial plexopathy following thoracoscaphular fusion in FSH muscular dystrophy. Neurology, 2005; 64:572-573 [PMID:15699403].
  - 52) Singer M.A., Kojan S., Barohn R.J., Herbelin L., Nations S.P., Trivedi J.R., Jackson C.E., Burns D.K., Boyer P.J. and **Wolfe G.I.** Primary lateral sclerosis: clinical and laboratory features in 25 patients. Journal of Clinical Neuromuscular Disease, 2005; 7:1-9 [PMID:19078775].
  - 53) Hatanaka Y., Hemmi S., Morgan M.B., Scheufele M.L., Claussen G.C., **Wolfe G.I.** and Oh S.J. Non-responsiveness to anticholinesterase agents in patients with MuSK-antibody-positive MG. Neurology, 2005; 65:1508-1509 [PMID:16275854].
  - 54) Oh S.J., LaGanke C., Powers R., **Wolfe G.I.**, Quinton R.A. and Burns D.K. Multifocal motor sensory demyelinating neuropathy: Inflammatory demyelinating polyradiculoneuropathy. Neurology, 2005; 65:1639-1642 [PMID:16301495].
  - 55) Sheth M.N., Nations S.P., **Wolfe G.I.** and Trivedi J. R. Von Hippel-Lindau disease associated with thymoma and myasthenia gravis. Journal of Clinical Neuromuscular Disease, 2005; 7:59-61 [PMID:19078784].
  - 56) Oh S.J., Hatanaka Y., Hemmi S., Young A.M., Scheufele M.L., Nations S.P., Lu L., Claussen G.C. and **Wolfe G.I.** Repetitive nerve stimulation of facial muscles in MuSK antibody-positive myasthenia gravis. Muscle Nerve, 2006; 33:500-504 [PMID:16392120].
  - 57) Vernino S. and **Wolfe G.I.** Antibody testing in peripheral neuropathies. Neurologic Clinics, 2007; 25:29-46 [PMID:17324719].
  - 58) Singer M.A., Statland J.M., **Wolfe G.I.** and Barohn R.J. Primary lateral sclerosis. Muscle Nerve, 2007; 35:291-302 [PMID:17212349].
  - 59) **Wolfe G.I.**, Trivedi J.R. and Oh S.J. Clinical review of muscle-specific tyrosine kinase-antibody positive myasthenia gravis. Journal of Clinical Neuromuscular Disease, 2007; 8:217-224.
  - 60) Singer M.A., Lazaridis C., Nations S.P. and **Wolfe G.I.** Reversible nitrous oxide-induced myeloneuropathy with pernicious anemia: case report and review of the literature. Muscle Nerve, 2008; 37:125-129 [PMID:17623854].
  - 61) Hughes R.A.C., Donofrio P., Bril V., Dalakas M.C., Deng C., Hanna K., Hartung H-P, Latov N., Merkies I.S.J., van Doorn P.A., and the ICE Study Group (appendix listing). Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomized placebo-controlled trial. Lancet Neurology 2008; 7:136-144 [PMID:18178525].

- 62) Wagner K.R., Fleckenstein J.L, Amato A.A., Barohn R.J., Bushby K., Escolar D.M. Flanigan K.M., Pestronk A., Tawil R., **Wolfe G.I.**, Eagle M., Florence J.M., King W.M., Pandya S., Straub V., Juneau P., Meyers K., Csimma C., Araujo T, Allen R., Parsons S.A., Wozney J.M., LaVallie E.R. and Mendell J.R. A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy. Annals of Neurology, 2008; 63:561-571 [PMID:18335515].
- 63) Newsom-Davis J., Cutter G., **Wolfe G.I.**, Kaminski H.J., Jaretzki III A., Minisman G., Aban C. and Conwit R. Status of the thymectomy trial for non-thymomatous myasthenia gravis patients receiving prednisone. Annals NY Academy of Science, 2008; 1132:344-347 [PMID:18567886].
- 64) **Wolfe G.I.** and Oh S.J. Clinical phenotype of muscle-specific tyrosine kinase-antibody-positive myasthenia gravis. Annals NY Academy of Science, 2008; 1132:71-75 [PMID:18567855].
- 65) Mullins L.L., Carpentier M.Y., Paul R. H., Sanders D.B. and the Muscle Study Group (appendix listing). Disease-specific measure of quality of life for myasthenia gravis. Muscle Nerve 2008; 38:947-956 [PMID:18697209].
- 66) Burns T.M., Conaway M.R., Cutter G.R., Sanders D.B. and the Muscle Study Group (appendix listing). Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis. Muscle Nerve 2008; 38:957-963 [PMID:18642357].
- 67) The Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology, 2008; 71:394-399 [PMID:18434639].
- 68) Nations S.P., Boyer P.J., Love L.A., Burritt M.F., Butz J.A., **Wolfe G.I.**, Hynan L.S., Trivedi J.R. Denture cream: an unusual source of excess zinc, leading to hypocupremia and neurologic disease. Neurology, 2008; 71:639-643 [PMID:18525032].
- 69) Aban I.B., **Wolfe G.I.**, Cutter G.R., Kaminski H.J., Jaretzki III A., Minisman G., Conwit R., Newsom-Davis J. MGTX Advisory Committee. The MGTX experience: Challenges in planning and executing an international, multicenter clinical trial. Journal of Neuroimmunology, 2008; 201-202:80-84 [PMID:18675464].
- 70) **Wolfe G.I.**, Barohn R.J., Sanders D.B., McDermott M.P., and the Muscle Study Group. Comparison of outcome measures from a trial of mycophenolate mofetil in myasthenia gravis. Muscle Nerve, 2008; 38:1429-1433 [PMID:18949779].
- 71) Burns T.M., Conaway M.R., Cutter G.R., Sanders D.B. and the Muscle Study Group (appendix listing). Construction of an efficient evaluative instrument for myasthenia gravis: the MG Composite. Muscle Nerve, 2008; 38:1553-1562.
- 72) Meyer D.M., Herbert M.A., Sobhani N.C., Tavakolian P., Duncan A., Bruns M., Korngut K., Williams J., Prince S.L., Huber L., **Wolfe G.I.** and Mack M.J. Comparative clinical outcomes of thymectomy for myasthenia gravis performed by extended transsternal and minimally invasive approaches. Annals of Thoracic Surgery 2009; 87:385-391 [PMID:19161744].
- 73) Bril V., Katzberg H., Donofrio P., Banach M., Dalakas M.C., Deng C., Hanna K., Hartung H-P., Hughes R.A.C., Latov N., Merkies I.S.J., van Doorn P.A. and the ICE Study Group (appendix listing). Electrophysiology in chronic inflammatory demyelinating polyneuropathy with IGIV. Muscle Nerve, 2009; 39:448-455 [PMID:19260050].
- 74) Merkies I.S.J., Bril V., Dalakas M.C., Deng C., Donofrio P., Hanna K., Hartung H-P., Hughes R.A.C., Latov N., van Doorn P.A., and the ICE Study Group (appendix listing). Health-related quality-of-life improvements in CIDP with immune globulin IV 10%. Neurology 2009; 72:1337-1344 [PMID:19365055].
- 75) Burns T.M., Grouse C.K., Conaway M.R., Sanders D.B. and the MG Composite and MG-QOL15 Study Group (appendix listing). Construct and concurrent validation of the MG-QOL15 in the practice setting. Muscle Nerve, 2010; 41:219-226 [PMID:19941339].

- 76) Pasnoor M., **Wolfe G.I.**, Nations S., Trivedi J., Barohn R.J., Herbelin L., McVey A., Dimachkie M., Kissel J., Walsh R., Amato A., Mozaffar T., Hungs M., Chui L., Goldstein J., Novella S., Burns T., Phillips L., Claussen G., Young A., Bertorini T. and Oh S. Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience. Muscle Nerve, 2010; 41:370-374 [PMID:19882635].
- 77) Hughes R.A.C., Gorson K.C., Cros D., Griffin J., Pollard J., Vallat J-M., Maurer S.L., Riester K., Davar G., Dawson K., Sandrock A. for the Avonex CIDP Study Group (appendix listing). Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology, 2010; 74:651-657.
- 78) Burns T.M., Conaway M., Sanders D.B. on behalf of the MG Composite and MG-QOL15 Study Group (appendix listing). The MG Composite: a valid and reliable outcome measure for myasthenia gravis. Neurology, 2010; 74:1434-1440 [PMID:20439845].
- 79) Latov N., Deng C., Dalakas M.C., Bril V., Donofrio P., Hanna K., Hartung H-P, Hughes R.A.C., Merkies I.S.J., van Doorn P.A., ICE Study Group (appendix listing). Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Archives of Neurology, 2010; 67:802-807 [PMID:20457948].
- 80) Sadeghian H. and **Wolfe G.I.** Therapeutic update in nerve, neuromuscular junction and myopathic disorders. Current Opinion in Neurology, 2010; 23: 496-501 [PMID:20664347].
- 81) Muppidi S., Saperstein D.S., Shaibani A., Nations S.P., Vernino S., and **Wolfe G.I.** Isolated neck extensor myopathy: is it responsive to immunotherapy? Journal of Clinical Neuromuscular Disease, 2010; 12:26-29 [PMID:20808161].
- 82) Donofrio P.D., Bril V., Dalakas M.C., Deng C., Hanna K., Hartung H-P, Hughes R., Latov N., Merkies I., van Doorn P. for the IGIV-C CIDP Efficacy (ICE) Study Group (appendix listing). Safety and tolerability of immune globulin intravenous in chronic inflammatory demyelinating polyradiculoneuropathy. Archives of Neurology, 2010; 67:1082-1088 [PMID:20837852].
- 83) Bril V., Banach M., Dalakas M.C., Deng C., Donofrio P., Hanna K., Hartung H-P, Hughes R.A.C., Katzberg H., Latov N., Merkies I.S.J., van Doorn P.A. on behalf of the ICE Study Group (appendix listing). Electrophysiologic correlations with clinical outcomes in CIDP. Muscle Nerve, 2010; 42:492-497 [PMID:20665514].
- 84) Merkies I.S., Hughes R.A., Donofrio P., Bril V., Dalakas M.C., Hanna K., Hartung H.P., Latov N., van Doorn P.A., Deng C. and the ICE Study Group (appendix listing). Understanding the consequences of chronic inflammatory demyelinating polyradiculoneuropathy from impairments of activity and participation restrictions and reduced quality of life: the ICE Study. Journal of the Peripheral Nervous System, 2010; 15:208-215 [PMID:21040143].
- 85) Burns T.M., Grouse C.K., **Wolfe G.I.**, Conaway M.R., Sanders D.B. and the MG Composite and MG-QOL15 Study Group. The MG-QOL15 for following the health-related quality of life of patients with myasthenia gravis. Muscle Nerve, 2011; 43:14-18 [PMID:21082698].
- 86) Lambracht-Washington D. and **Wolfe G.I.** Cytokines in Guillain-Barré syndrome: a lesson in time. Archives of Neurology, 2011; 68:427-428 [PMID:22047648].
- 87) The Muscle Study Group. A randomized, pilot trial of etanercept in dermatomyositis. Annals of Neurology, 2011; 70:427-436 [PMID:21688301].
- 88) Muppidi S., **Wolfe G.I.**, Conaway M., Burns T. M. and the MG Composite and MG-QOL15 Study Group. MG-ADL: still a relevant outcome measure. Muscle Nerve, 2011; 44:727-731 [PMID:22006686].
- 89) Minisman G., Bhanushali M., Conwit R., **Wolfe G.I.**, Aban I., Kaminski H.J., Cutter G. Implementing clinical trials on an international platform: challenges and perspectives. Journal of the Neurological Sciences, 2012; 313:1-6 [PMID:22047648].



- 90) Cupler E.J., Berger K.I., Leshner R.T., **Wolfe G.I.**, Han J.J., Barohn R.J., Kissel J.T. Consensus treatment recommendations for late-onset Pompe disease. Muscle Nerve, 2012; 45:319-333 [PMID:22173792].
- 91) Singer M.A., Vernino S.A., **Wolfe G.I.** Idiopathic neuropathy: new paradigms, new promise. Journal of the Peripheral Nervous System, 2012; 17(suppl): 43-49 [PMID:22548623].
- 92) Benatar M., Sanders D.B., Burns T.M., Cutter G.R., Guptill J.T., Baggi F., Kaminski H.J., Mantegazza R., Meriggioli M., Quan J., **Wolfe G.I.** and the Task Force of MG Study Design of the MSAB of the Myasthenia Gravis Foundation of America. Recommendations for myasthenia gravis clinical trials. Muscle Nerve, 2012; 45:909-917 [PMID:22581550].
- 93) Sadjadi R., Conaway M., Cutter G., Sanders D.B., Burns T.M. and the MG Composite MG-QOL15 Study Group (appendix listing). Psychometric evaluation of the myasthenia gravis composite using Rasch analysis. Muscle Nerve, 2012; 45:820-825 [PMID:22581534].
- 94) Silvestri N.J., **Wolfe G.I.** Myasthenia gravis. Seminars in Neurology, 2012; 32:215-226 [PMID:23119946].
- 95) Benatar M., Sanders D.B., **Wolfe G.I.**, McDermott M.P., Tawil R. Design of the efficacy of prednisone in the treatment of ocular myasthenia (EPITOME) trial. Annals NY Academy of Science, 2012; 1275:17-22 [PMID:23278573].
- 96) Kaminski H.J., Kusner L.L., **Wolfe G.I.**, Aban I., Minisman G., Conwit R., Cutter G. Biomarker development for myasthenia gravis. Annals NY Academy of Science, 2012; 1275:101-106 [PMID:23278584].
- 97) Haley R.W., Charuvastra E., Shell W.E., Buhner D.M., Marshall W.W., Biggs M.M., Hopkins S.C., **Wolfe G.I.** Vernino S. Cholinergic autonomic dysfunction in veterans with Gulf War illness. JAMA Neurology, 2013; 70:191-2000 [PMID:23407784].
- 98) Trivedi J.R., Silvestri N.J., **Wolfe G.I.** Treatment of painful peripheral neuropathy. Neurologic Clinics, 2013; 31:377-403 [PMID:23642715].
- 99) Silvestri N.J., **Wolfe G.I.** Asymptomatic/Pauci-symptomatic creatine kinase elevations (hyperCKemia). Muscle Nerve, 2013; 47:805-815. Chosen by Monograph/Issues and Opinion Committee of American Association of Neuromuscular & Electrodiagnostic Medicine for monograph distribution [PMID:23625835].
- 100) Howard J.F., Barohn R.J., Cutter C.R., Freimer M., Juel V.C., Mozaffar T., Mellion M.L., Benatar M.G., Farrugia M.E., Wang J.J., Malhotra S.S., Kissel J.T. and the MG Study Group (appendix listing). A randomized double-blind, placebo-controlled phase II study of eculizumab in patients with refractory myasthenia gravis. Muscle Nerve, 2013; 48:76-84 [PMID:23512355].
- 101) Pasnoor M., Nascimento O.J.M., Trivedi J., **Wolfe G.I.**, Nations S., Herbelin L., de Freitas M.G., Quintanilha G., Khan S., Dimachkie M., Barohn R. North America and South America (NA-SA) neuropathy project. International Journal of Neuroscience, 2013; 123:563-567 [PMID:23461611].
- 102) Silvestri N.J., **Wolfe G.I.** Treatment-refractory myasthenia gravis. Journal of Clinical Neuromuscular Disease, 2014; 15:167-178 [PMID:24872217].
- 103) Singh K., Gupta R., Kamal H., Silvestri N.J., **Wolfe G.I.** Posterior reversible encephalopathy syndrome secondary to blood transfusion. Journal of Clinical Neuroscience, 2015; 22:592-594 [PMID:25542590].
- 104) Kohli S., Farooq O., Jani R.B., **Wolfe G.I.** Cerebral paragonimiasis: an unusual manifestation of a rare parasitic infection. Pediatric Neurology, 2015; 52:366-369 [PMID:25556153].
- 105) Renton A.E., Pliner H.A., Provenzano C., Evoli A., Ricciardi R., Nalis M.A., Marangi G., Abramzon Y., Arepalli S., Chong S., Hernandez D.G., Johnson J.O., Bartoccioni E., Scuderi F., Maestri M., Gibbs J.R., Errichiello E., Chiò A., Restagno G., Sabatelli M., Macek M., Scholz S.W., Corse A., Chaudhry V., Benatar M., Barohn R.J., McVey A., Pasnoor M., Dimachkie M.M., Rowin J., Kissel J., Freimer M., Kaminski H.J., Sanders D.B., Lipscomb B., Massey J.M., Chopra M., Howard J.F., Koopman W.J., Nicolle M.W., Pascuzzi

- R.M., Pestronk A., Wulf C., Florence J., Blackmore D. Soloway A., Siddiqi Z., Muppidi S., **Wolfe G.**, Richman D., Mezei M.M., Jiwa T., Oger J., Drachman D.B., Traynor B.J. A genome-wide association study of myasthenia gravis. *JAMA Neurology*, 2015; 72:396-404 [PMID:25643325].
- 106) Benatar M., McDermott M.P., Sanders D.B., **Wolfe G.I.**, Barohn R.J., Nowak R.J., Hehir M., Juel V., Katzberg H., Tawil R., and the Muscle Study Group. Efficacy of prednisone for the treatment of ocular myasthenia gravis (EPITOME): a randomized controlled trial. *Muscle Nerve*, 2016; 53:363-369 [PMID:26179124].
- 107) AbdelRazek M.A., Mowla A., Farooq S., Silvestri N., Sawyer R., **Wolfe G.** Fibrocartilaginous embolism: a comprehensive review of an under-studied cause of spinal cord infarction and proposed diagnostic criteria. *Journal of Spinal Cord Medicine*, 2016; 39:146-154 [PMID: 26833287].
- 108) Sanders D.B., **Wolfe G.I.**, Benatar M., Evoli A., Gilhus N.E., Illa I., Kuntz N., Massey J.M., Melms A., Murai H., Nicolle M., Palace J., Richman D.P., Verschuuren J., Narayanaswami P. Executive summary: international consensus guidance for management of myasthenia gravis. *Neurology*, 2016; 87:419-425 [PMID:27358333].
- 109) **Wolfe G.I.**, Kaminski H.J., Aban I.B., Minisman G., Kuo H.-C., Marx A., Ströbel P., Mazia C., Oger J., Cea J.G., Heckmann, J.M., Evoli A., Nix W., Ciafaloni E., Antonini G., Witoonpanich R., King J.O., Beydoun S.R., Chalk, C.H., Barboi A.C., Amato A.A., Shaibani A.I., Katirji B., Lecky B.R.F., Buckley C., Vincent A., Dias-Tosta E., Yoshikawa H., Waddington-Cruz M., Pulley M.T., Rivner M.H., Kostera-Pruszczyk A., Pascuzzi R.M., Jackson C.E., Garcia Ramos G.S., Verschuuren J.J.G.M., Massey J.M., Kissel J.T., Werneck L.C., Benatar M., Barohn R.J., Tandan R., Mozaffar T., Conwit R., Odenkirchen J., Sonett, J.R., Jaretzki III A., Newsom-Davis J., Cutter G.R., on behalf of the MGTX Study Group. Randomized trial of thymectomy in myasthenia gravis. *New England Journal of Medicine*, 2016; 375:511-522 [PMID:27509100].
- 110) Salins S., Teter B., Kavak K., **Wolfe G.I.**, Silvestri N.J. Low-dose medication and long-term outcome in myasthenia gravis. *Journal of Clinical Neuromuscular Disease*, 2016; 18:61-66 [PMID:27861217].
- 111) Burns T.M., Sadjadi R., Utsugisawa K., Gwathmey K.G., Joshi A., Jones S., Bril V., Barnett C., Guptill J.T., Sanders D.B., Hobson-Webb L., Juel V.C., Massey J., Gable K.L., Silvestri N.J., **Wolfe G.**, Cutter G., Nagane Y., Murai H., Masuda M., Farrugia M.E., Carmichael C., Birnbaum S., Hogrel J-Y., Nafissi S., Fatehi F., Ou C., Liu W., Conway M. International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r. *Muscle Nerve*, 2016; 54:1015-1022 [PMID:27220659].
- 112) Allen J.A., Gelinas D.F. Lewis R.A., Nowak R.J., **Wolfe G.I.** Optimizing the use of outcome measures in chronic inflammatory demyelinating polyneuropathy. *US Neurology*, 2017; 13:26-34.
- 113) Howard J.F., Freimer M., O'Brien F., Wang J.J., Collins S.R., Kissel J.T., MG (Phase 2) Study Group, Herbelin L., McVey A.L., Dimachkie M.M., Pasnoor M., Lu D., Waltz A., Chaudhry V., Corse A., Mosmiller E., Klein C., Chopra M., Richardson E., Massey J.M., Hobson-Webb L.D., Guptill J., King W., Wang A.K., Saremi K., Tully P.A., Davis D., Martin V., Pascuzzi R.M., Guingrich S. Micheels A., Pulley M., Hentschel K., Smith L., Calhoun R., Gilchrist J., Sachs G., Crabtree B., Perez E.K., Gorson K., Harrahy Cobb E., Rosseto E., Siddiqi Z., Ahmed S.N., Blackmore D., Butler-Tyler S., Louise Miller S., Carmichael C., Burns T., David W., Donofrio P., Katirji B., Lewis R., Oh S., Richman D., Sivak M., Tandan R., **Wolfe G.**, Bird S., Hilton-Jones D. QMG and MG-ADL correlations: Study of eculizumab treatment in myasthenia gravis. *Muscle Nerve*, 2017; 56:328-330 [PMID:28010051].
- 114) Aggarwal R., Rider L.G., Ruperto N., Bayat N., Erman B., Feldman B.M., Oddis C.V., Amato A.A., Chinoy H., Cooper R.G, Dastmalchi, M., Fiorentino D., Isenberg D., Katz J.D., Mammen A., de Visser M., Ytterberg S.R., Lundberg E.E., Chung L., Danko K., García-De la Torre, I., Song Y.W., Villa L., Rinaldi M., Rockette H., Lachenbruch P.A., Miller F.W., Vencovsky J. for the International Myositis Assessment and Clinical Studies Group and the Paediatric Rheumatology International Trials Organization (appendix listing). 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: an International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation collaborative initiative.

- Annals of the Rheumatic Diseases, 2017; 76:792-801. Also in Arthritis & Rheumatology, 2017; 69:898-910 [PMID:28382787].
- 115) Howard J.F.Jr., Utsugisawa K., Benatar M., Murai H., Barohn R.J., Illa I., Jacob S., Vissing J., Burns T.M., Kissel J.T., Muppidi S., Nowak R.J., O'Brien F., Wang J.J., Mantegazza R., REGAIN Study Group (appendix listing). Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalized myasthenia gravis (REGAIN): a phase 3, randomized, double-blind, placebo-controlled, multicenter study. Lancet Neurology, 2017; 16:976-986 [PMID:29066163].
  - 116) Benatar M., Howard J.F., Barohn R., **Wolfe G.I.**, Cutter G. Learning from the past: reflections on recently completed MG trials. Annals of the New York Academy of Sciences, 2018; 1412:5-13 [PMID:29064567].
  - 117) Sanders D.B., **Wolfe G.I.**, Narayanaswami P. Developing treatment guidelines for myasthenia gravis. Annals of the New York Academy of Sciences, 2018; 1412:95-101 [PMID:29381223].
  - 118) Gwathmey K.G., Sadjadi R., Horton W.B., Conaway M.R., Barnett-Tapia C., Bril V., Russell J.W., Shaibani A., Mauerman M.L., Hehir M.K., Kolb N., Guptill J., Hobson-Webb L., Gable K., Raja S., Silvestri N., **Wolfe G.I.**, Smith A.G., Malik R., Traub R., Joshi A., Elliott M.P., Jones S., Burns T.M. Validation of a simple disease-specific quality of life measure for diabetic polyneuropathy: CAPPRI. Neurology, 2018; 90:e2034-e2041 [PMID:29728528].
  - 119) Weis C.-A., Aban I.B., Cutter G., Kaminski H.J., Scharff C., Griebmann B.W., Deligianni M., Kayser K., **Wolfe G.I.**, Ströbel P., Marx A. Histopathology of thymectomy specimens from the MGTX-trial: Entropy analysis as strategy to quantify spatial heterogeneity of lymphoid follicle and fat distribution. PLOS One, 2018; e0197435 [PMID:29897907].
  - 120) Levine T.D., Katz J.S., Barohn R., Vaughan L.J., Dimachkie M.M., Saperstein D.S., Mozaffar M., **Wolfe G.I.**, Mayo M., Badger G.J., Katzin L., Ritt E., Greer M., DiStefano J., Schmidt P.M. Review process for IVIg treatment: Lessons learned from the INSIGHTS neuropathy study. Neurology Clinical Practice, 2018; 8:429-436 [PMID:30564497].
  - 121) Statland J.M., Moore D., Wang Y., Walsh M., Mozaffar T., Elman L., Nations S.P., Mitsumoto H., Fernandes J.A., Saperstein D., Hayat G., Herbelin L., Karam C., Katz J., Wilkins H.M., Agbas A., Swerdlow R.H., Santella R.M., Dimachkie M.M., Barohn R.J., Rasagiline Investigators of the Muscle Study Group and Western ALS Consortium (appendix listing). Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial. Muscle Nerve, 2019; 59:201-207 [PMID:30192007].
  - 122) **Wolfe G.I.**, Kaminski H.J., Aban I.B., Minisman G., Kuo H.-C., Marx A., Ströbel P., Mazia C., Oger J., Cea J.G., Heckmann, J.M., Evoli A., Nix W., Cifaloni E., Antonini G., Witoonpanich R., King J.O., Beydoun S.R., Chalk, C.H., Barboi A.C., Amato A.A., Shaibani A.I., Katirji B., Lecky B.R.F., Buckley C., Vincent A., Dias-Tosta E., Yoshikawa H., Waddington-Cruz M., Pulley M.T., Rivner M.H., Kostera-Pruszczyk A., Pascuzzi R.M., Jackson C.E., Verschuuren J.J.G.M., Massey J.M., Kissel J.T., Werneck L.C., Benatar M., Barohn R.J., Tandan R., Mozaffar T., Silvestri N.J., Conwit R., Sonett, J.R., Jaretzki III A., Newsom-Davis J., Cutter G.R., on behalf of the MGTX Study Group. Long-term effect of thymectomy in patients with non-thymomatous myasthenia gravis treated with prednisone: 2-year extension of the MGTX randomised trial. Lancet Neurology, 2019; 18:259-268 [PMID:30692052].
  - 123) Muppidi S., Utsugisawa K., Benatar M., Murai H., Barohn R.J., Illa, I., Jacob S., Vissing J., Burns T.M., Kissel J.T., Nowak R.J., Andersen H., Casanovas C., De Blecker J.L., Vu T., Mantegazza R., O'Brien F.L., Wang J.J., Fujita K.P., Howard J.F., REGAIN Study Group (appendix listing). Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve 2019; 60:14-24 [PMID:30767274].
  - 124) Andersen H., Mantegazza R., Wang J.J., O'Brien F., Patra K., Howard J.F., REGAIN Study Group (appendix listing). Eculizumab improves fatigue in refractory generalized myasthenia gravis. Quality Life Research 2019; 28:2247-2254 [PMID:30905021].
  - 125) Silvestri N.J., **Wolfe G.I.** HyperCKemia. Practical Neurology 2019; 19:36-41.

- 126) Murai H., Uzawa A., Suzuki Y., Imai T., Shiraishi H., Suzuki H., Okumura M., O'Brien F., Wang J.-J., Fujita K.P., Utsugisawa K., REGAIN Study Group (appendix listing). Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study. Journal of the Neurological Sciences 2019; 407:116419 [PMID:31698177].
- 127) Allen J.A., Gelinas D.F., Freimer M., Runken M.C., **Wolfe G.I.** Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG? Journal of the Neurological Sciences 2020; 408:116497 [PMID:31765922].
- 128) **Wolfe G.I.**, Silvestri N.J. What's of note from 2019-2020? Neuromuscular update. RRNMF Neuromuscular Journal 2020; 1(1):42-44.
- 129) Howard J.F., Nowak R.J., **Wolfe G.I.**, Freimer M.L., Vu T.H., Hinton J.L., Benatar M., Duda P.W., MacDougall, J.E., Farzaneh-Far R., Kaminski H.J. and the Zilucoplan MG Study Group. Clinical effects of the self-administered subcutaneous inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: Results of a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial. JAMA Neurology 2020; 77:582-592 [PMID:32065623].
- 130) Cheng F., Katz J.S., Barohn R.J., **Wolfe G.I.** Bilateral ptosis and limb myokymia: regional variant of Guillain-Barré syndrome? RRNMF Neuromuscular Journal 2020; 1(2):22-24.
- 131) Vissing J., Jacob S., Fujita K.P., O'Brien F., Howard J.F., REGAIN Study Group (appendix listing). 'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab. Journal of Neurology 2020; 267:1991-2001 [PMID:32189108].
- 132) Cudkowicz M., Chase M.K., Coffey C.S., Ecklund D.J., Thornell B.J., Lungu C., Mahoney K., Gutmann L, Shefner J.M., Staley K.J., Bosch M., Foster E., Long J.D., Bayman E.O., Torner J., Yankey J., Peters R., Huff T., Conwit R.A.; and the NeuroNEXT Clinical Study Sites (appendix listing). Seven-year experience from the National Institute of Neurological Disorders and Stroke-supported network for excellence in neuroscience clinical trials. JAMA Neurology; 2020; 77:755-763 [PMID:32202612].
- 133) McPherson T., Aban I., Duda P.W., Farzaneh-Far R., **Wolfe G.I.**, Kaminski H.J., Cutter G., Lee I., MGTX Study Group. Correlation of Quantitative Myasthenia Gravis and Myasthenia Gravis Activities of Daily Living scales in the MGTX Study. Muscle Nerve; 2020; 62:261-266 [PMID:32369631].
- 134) Lee I., Kuo H.-C., Aban I., Cutter G., McPherson T., Kaminski H., Sussman J., Ströbel P., Oger J., Cea G., Heckmann J., Evoli A., Nix W., Cifaloni E., Antonini G., Witoonpanich R., King J.O., Beydoun S.R., Chalk C., Barboi A.C., Amato A.A., Shaibani A.I., Katirji B., Lecky B.R.F., Buckley C., Vincent A., Dias-Tosta E, Yoshikawa H., Waddington-Cruz M., Pulley M.T., Rivner M.H., Kostera-Pruszczyk A., Pascuzzi R.M., Jackson C.E., Verschuuren J.J., Massey J.M., Kissel J.T., Werneck L.C., Benatar M., Barohn R.J., Tandan R., Mozaffar T., Conwit R., Minisman G., Sonett J., **Wolfe G.I.** Minimal manifestation status and prednisone withdrawal in the MGTX trial. Neurology 2020; 95:e755-766 [PMID:32611638].
- 135) Pike-Lee T.H., Li Y., **Wolfe G.I.** Neuromuscular complications in COVID-19: a review of the literature. RRNMF Neuromuscular Journal 2020; 1(3):13-21.
- 136) Mantegazza R., O'Brien F.L, Yountz M., Howard J.F., REGAIN Study Group (appendix listing). Consistent improvement with eculizumab across muscles groups in myasthenia gravis. Annals of Clinical and Translational Neurology 2020; 22:1327-1339 [PMID:32700461].
- 137) Barohn R.J., Gajewski B., Pasnoor M., Brown A., Herbelin L.L., Kimminau K.S., Mudaranthakam D.P., Jawdat O., Dimachkie M.M., PAIN-CONTRoLS Study Team (appendix listing). Patient assisted intervention for neuropathy: comparison of treatment in real life situations (PAIN-CONTRoLS). JAMA Neurology 2021; 78:68-76 [PMID:32809014].
- 138) Green J.D., Barohn R.J., Bartoccion E., Benatar M., Blackmore D., Chaudhry V., Chopra M., Corse A., Dimachkie M.M., Evoli A., Florence J., Freimer M., Howard J.F., Jiwa T., Kaminski H.J., Kissel J.T., Koopman W.J., Lipscomb B. Maestri M., Marino M., Massey J.M., McVey A., Mezei M.M., Muppidi S., Nicolle M.W., Oger J., Pascuzzi R.M., Pasnoor M., Pestronk A., Provenzano C., Ricciardi R., Richman D.P.,

- Rowin J., Sanders D.B., Siddiqi Z., Soloway A., **Wolfe G.I.**, Wulf C., Drachman D.B., Traynor B.J. Epidemiological evidence for a hereditary contribution to myasthenia gravis: a retrospective cohort study of patients from North America. British Medical Journal Open 2020; doi:10.1136/bmjopen-2020-037909 [PMID:32948566].
- 139) Mantegazza R., **Wolfe G.I.**, Muppidi S., Wiendl H., Fujita K.P., O'Brien F.L., Booth H.D.E., Howard J.F. Post-intervention status in patients with refractory myasthenia gravis treated with eculizumab during REGAIN and its open-label extension. Neurology 2021; 96:e610-618 [PMID:33229455].
- 140) Narayanaswami P., Sanders D.B., **Wolfe G.**, Benatar M., Cea G., Evoli A., Gilhus N.E., Illa I., Kuntz N.L., Massey J.M., Melms A., Murai H., Nicolle M., Palace J., Richman D.P., Verschuuren J. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology 2021; 96:114-122 [PMID:33144515].
- 141) Verma R., **Wolfe G.I.**, Kupersmith M.J. Ocular myasthenia gravis -- How effective is low dose prednisone long term? Journal of the Neurological Sciences 2021; 420:117274 [PMID:33360170].
- 142) Contreras J.P., Salinas R., Vidal C., Hoffmeister L., **Wolfe G.I.**, Cea G. Validation of Spanish version of 15-item myasthenia gravis quality-of-life questionnaire. Acta Neurologica Scandinavica 2021; 144:546-552 [PMID:34131909].
- 143) Bril V., Palace J., Mozaffar T., Gelinas D., Brauer E., Nisbet P., **Wolfe G.I.** Practice patterns in the management of myasthenia gravis: a cross-sectional survey of neurologists in the United States. RRNMF Neuromuscular Journal 2021; 2:29-49.
- 144) Lail N., **Wolfe G.I.**, Herbelin L., Nations S.P., Foster B.M., Silvestri N.J., Peck L.J., Barohn R.J. The correlation between static fatigue testing and the Quantitative Myasthenia Gravis Score and Activities of Daily Living Profile. RRNMF Neuromuscular Journal 2021; 2:50-52.
- 145) **Wolfe G.I.**, Ward E.S., de Haard H., Ulrichs P., Mozaffar T., Pasnoor M., Vidarsson G. IgG regulation through FcRn blocking: a novel mechanism for the treatment of myasthenia gravis. Journal of the Neurological Sciences 2021; 430:118074 [PMID:34563918].
- 146) Siddiqi Z.A., Nowak R.J., Mozaffar T., O'Brien F., Yountz M., Pitti, F., REGAIN Study Group (appendix listing). Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study. Muscle Nerve 2021; 64:662-669 [PMID:34590717].
- 147) Nowak R.J., Coffey C.S., Goldstein J.M., Dimachkie M.M., Benatar M., Kissel J.T., **Wolfe G.I.**, Burns T.M., Friemer M.L., Nations S., Granit V., Smith A.G., Richman D.P., Ciafaloni E., Al-Lozi M.T., Sams L.A., Quan D., Ubogu E., Pearson B., Sharma A., Yankey J.W., Uribe L., Shy M., Amato A.A., Conwit R., O'Connor K.C., Hafler D.A., Cudkowicz M.E., Barohn R.J. Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: The BeatMG Study. Neurology 2022; 98:e376-e389 [PMID:34857535].
- 148) Chia R., Saez-Atienzar S., Murphy N., Chiò A., Biauwendraat C., International Myasthenia Gravis Genomics Consortium (appendix listing), Roda R.H., Tienari P.J., Kaminski H.J., Ricciardi R., Guida M., De Rosa A., Petrucci L., Evoli A., Provenzano C., Drachman D.B., Traynor B.J. Classification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis: a genome-wide association study. Proceedings of the National Academy of Sciences USA 2022; 119:e2108672119 [PMID:35074870].
- 149) Pasnoor M., Bril V., Levine T., Trivedi J., Silvestri N.J., Phadnis M., Katzberg H.D., Saperstein D.S., **Wolfe G.I.**, Herbelin L., Higgs K., Heim A.J., Statland J.M., Barohn R.J., Dimachkie M.M. Phase II trial in acetylcholine receptor antibody-positive myasthenia gravis of transition from intravenous to subcutaneous immunoglobulin: The MGSClg Study. European Journal of Neurology 2023; 30:1417-1424 [PMID:36779862].
- 150) Hamedani A.G., McPherson T.O., Aban I., Lee I., Kupersmith M.J., **Wolfe G.I.**, Kaminski H.J. Attitudes and

- beliefs towards thymectomy in the Myasthenia Gravis Patient Registry. Journal of Clinical Neuromuscular Disease 2023; 24:222-228 [PMID:37219866].
- 151) Lizarraga A.A., Bhai S., **Wolfe G.**, Herbelin L., Nations S., McCreary M., Saperstein D., Barohn R.J. Quantitative sensory testing in a large cohort of neuropathy patients: QST in neuropathy. RRNMF Neuromuscular Journal 2023; 4:29-33.
  - 152) Pasnoor M., Khan S., Jackson C.E., Kissel J., **Wolfe G.I.**, Nations S.P., Trivedi J.R., Singer M.A., Elliott J.L., Vernino S.A., Mummaneni R.B., Herbelin L., Saperstein D.S., Gronseth G., McVey A.L., Dimachkie M.M., Barohn R.J., Database evaluation for muscle and nerve diseases – DEMAND: an academic neuromuscular coding system. RRNMF Neuromuscular Journal 2023; 4:44-67.
  - 153) Sikorski P., Li Y., Cheema M., **Wolfe G.I.**, Kusner L.L., Aban I., Kaminski H.J. Serum metabolomics of treatment response in myasthenia gravis. PLOS One 2023; 18:e0287654 [PMID:37816000].
  - 154) Narayanaswami P, Sanders D.B., Thomas L., Thibault D., Blevins J., Desai R., Krueger A., Bibeau K., Liu B., Guptill J.T., PROMISE-MG Study Group (appendix listing). Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective observational study. Lancet Neurology 2024; 23:267-276 [PMID:38365379].
  - 155) Rozen S.M., **Wolfe G.I.**, Vernino S., Raskin P., Hynan L.S., Wyne K., Fulmer R., Pandian G., Sharma S.K., Mohanty A.J. Effect of lower extremity nerve decompression in patients with painful diabetic peripheral neuropathy: The DNNd randomized, observation group- and placebo surgery-controlled clinical trial. Annals of Surgery 2024; in press [PMID:38328975].
  - 156) **Wolfe G.I.**, Ouf A., Silvestri N.J. Autoimmune phenomena: thymoma and clinical neurology. Mediastinum 2024; in press.

#### Abstracts

- 1) **Wolfe G.I.**, Schotland D.L. and Bank W.J. Fever-associated myoglobinuria in metabolic myopathy. Neurology, 1994; 44:A199.
- 2) **Wolfe G.I.** and Bank W.J. Pseudokypnosis in motor neuron disease corrected by the "pocket sign." Muscle Nerve, 1994; 17:1091 and Electroencephalography and Clinical Neurophysiology, 1995; 97:11P.
- 3) **Wolfe G.I.**, Katz J.S., Bryan W.W. and Barohn R.J. Clinical features of primary lateral sclerosis. Journal of Child Neurology, 1995; 10:167.
- 4) **Wolfe G.I.**, Greenlee R.G. and Barohn R.J. Acute motor axonal neuropathy with hyperreflexia and anti-GM1 antibody. Journal of Child Neurology, 1995; 10:167.
- 5) Jetha N., **Wolfe G.I.**, Bryan W.W. and Barohn R.J. Hereditary neuropathy with liability to pressure palsies presenting as chronic progressive sensory-motor polyneuropathy. Journal of Child Neurology, 1995; 10:162.
- 6) Katz J.S., **Wolfe G.I.**, Bryan W.W., Burns D.K. and Barohn R.J. Isolated benign neck extensor myopathies. Journal of Child Neurology, 1995; 10:162.
- 7) **Wolfe G.I.**, Katz J.S., Bryan W.W., Wians F.H. and Barohn R.J. Antibody panels in idiopathic polyneuropathy and motor neuron disease. Muscle Nerve, 1995;18:1069-1070 and Electroencephalography and Clinical Neurophysiology, 1996; 98:37P.
- 8) **Wolfe G.I.**, Bryan W.W. and Barohn R.J. Clinical and molecular features of X-linked Charcot-Marie-Tooth disease. Journal of Child Neurology, 1996; 11:147.
- 9) Nations S.P., **Wolfe G.I.**, Burns D.K., Bryan W.W. and Barohn R.J. Clinical features of proximal myotonic myopathy. Journal of Child Neurology, 1996; 11:147-148.

- 10) Barohn R.J., Jackson C.E., Bryan W.W., **Wolfe G.I.** and Amato A.A. Is there a relationship between hyperparathyroidism and amyotrophic lateral sclerosis? Journal of Child Neurology, 1996; 11:152.
- 11) Salmon T.H., Katz J.S., **Wolfe G.I.**, Bryan W.W. and Barohn R.J. Concomitant occurrence of myasthenia gravis and the Lambert-Eaton syndrome. Journal of Child Neurology, 1996; 11:152.
- 12) Krampitz D., Iannaccone S.T., **Wolfe G.I.**, Burns D., Bryan W.W. and Barohn R.J. Bethlem myopathy in three generations. Journal of Child Neurology, 1996; 11:147.
- 13) Haller R.G., Bryan W.W., Barohn R.J., **Wolfe G.I.**, Burns D., McKnight R.M. and Farmer S. Recurrent exertional myoglobinuria due to dystrophin deficiency. Journal of Child Neurology, 1996; 11:152-153.
- 14) **Wolfe G.I.**, Katz J.S., Bryan W.W., Jackson C.E., Amato A.A. and Barohn R.J. Is conduction block a necessary finding in patients with multifocal motor neuropathy? Neurology, 1996; 46A234.
- 15) Amato A.A., Gronseth G.S., Jackson C.E., **Wolfe G.I.**, Katz J.S., Bryan W.W. and Barohn R.J. Inclusion-body myositis: pattern of weakness and clinical features and evidence supporting the diagnosis of probable inclusion-body myositis. Neurology, 1996; 46:A486.
- 16) Nations S.P., **Wolfe G.I.**, Amato A.A., Jackson C., Bryan W.W., and Barohn R.J. Myasthenia gravis developing after removal of thymoma. Journal of Child Neurology, 1997; 12:133.
- 17) Wasay M., Herrold J.M., Burns D.K., Kagan-Hallet K., Bryan W.W., Barohn R.J., and **Wolfe G.I.** Chloroquine myopathy and neuropathy with elevated cerebrospinal fluid protein. Journal of Child Neurology, 1997; 12:134-135.
- 18) Nations S.P., **Wolfe G.I.**, Amato A.A., Jackson C.E., Bryan W.W. and Barohn R.J. Clinical features of patients with distal myasthenia gravis. Neurology, 1997; 48:A64
- 19) Jackson C.E., Amato A.A., **Wolfe G.I.**, Nations S.P., Bryan W. and Barohn R.J. A new myasthenia gravis (MG) grading scale: application in a large cohort of patients. Neurology, 1997; 48:A65.
- 20) Katz J.S., Bryan W.W., **Wolfe G.I.** and Barohn R.J. Acetylcholine receptor antibodies in the Lambert-Eaton myasthenic syndrome. Neurology, 1997; 48:A64
- 21) Barohn R.J., McIntire D., Herbelin L., **Wolfe G.I.**, Nations S.P. and Bryan W.W. Reliability testing of the quantitative myasthenia gravis score. Presented at the IXth International Conference on Myasthenia Gravis and Related Disorders, Santa Monica, CA, May 1997.
- 22) Baker N.S., **Wolfe G.I.**, Nations S.P., Bryan W.W. and Barohn R.J. Cryptogenic sensory polyneuropathy: clinical and electrophysiological features. Annals of Neurology, 1997; 42:455.
- 23) Iannaccone S.T., Nations S.P., Bryan W.W., **Wolfe G.I.** and Barohn R.J. CMT with vocal cord paralysis, type 2C. Neuromuscular Disorders, 1997; 7:454-55.
- 24) Krampitz D.E., Barohn R.J. and **Wolfe G.I.** Charcot-Marie-Tooth disease type 1A presenting as calf hypertrophy and muscle cramps. Journal of Child Neurology, 1998; 13:134.
- 25) **Wolfe G.I.**, Burns D.K. and Barohn R.J. Longstanding HTLV-1 myopathy in the absence of spastic paraparesis. Journal of Child Neurology, 1998; 13:134.
- 26) Saperstein D.S., **Wolfe G.I.**, Haller R.G., Bryan W.W., Burns D.K. and Barohn R.J. Hepatitis C infection and polymyositis. Journal of Child Neurology, 1998; 13:141.

- 27) van der Sluis R., **Wolfe G.I.**, Bryan W.W., Krampitz D.E., Nations S.P., Elliot J.L. and Barohn R.J. Atypical motor neuron disease as a late complication of radiation therapy. Journal of Child Neurology, 1998; 13:141-142.
- 28) Barohn R.J., Herbelin L., **Wolfe G.I.**, Nations S.P., Reisch J.S. and Bryan W.W. The correlation between the myasthenia gravis activity of daily living profile and the quantitative myasthenia gravis score. Neurology, 1998; 50:A22.
- 29) Nations S.P., Saperstein D.S., **Wolfe G.I.**, Bryan W.W. and Barohn R.J. Clinical profile of vitamin B12 neuropathy. Neurology, 1998; 50:A208-A209.
- 30) Haley R.W., Armitage R., Bonte F.J., Bryan W.W., Fleckenstein J.L., Frohman E.M., Hoffman R., Marshall W.W., Orsulak P.J., Petty F., Roland P.S., Shoup A.G., Van Ness P.C., Victor R.Q., Vongpatanasin W. and **Wolfe G.I.** Gulf War-associated neurologic dysfunction in a decorated US special forces officer compared with his monozygotic twin. Conference on Federally Sponsored Research, Arlington, VA, June 1998.
- 31) Saperstein D.S., Amato A.A., Katz J.S., **Wolfe G.I.**, Nations S.P., Bryan W.W., Jackson C.E. and Barohn R.J. Multifocal sensory and motor neuropathy differs from multifocal motor neuropathy. Muscle Nerve, 1998; 21:1589.
- 32) Lindenbaum Y., **Wolfe G.I.**, Burns D.K. and Barohn R.J. Critical illness myopathy in the absence of neuromuscular blockers: clinical and histologic features. Journal of Child Neurology, 1999; 14:182-183.
- 33) Alkhersam H., **Wolfe G.I.**, Bryan W.W., Nations S.P. and Barohn R.J. Diabetic radiculoplexopathy involving the cervical more than the lumbosacral region. Journal of Child Neurology, 1999; 14:183.
- 34) Saperstein D.S., Katz J.S., **Wolfe G.I.**, Nations S.P., Burns D.K., Bryan W.W. and Barohn R.J. Distal acquired demyelinating symmetric neuropathy. Journal of Child Neurology, 1999; 14:183.
- 35) Chudnow R.S., **Wolfe G.I.**, Delgado M.R., Sparagana S.P. and Roach E.S. Sudomotor function in the hypomelanotic macules of tuberous sclerosis. Presented at the Southern Pediatric Neurology Society, New Orleans, LA, March 6, 1999. Winner of JCN/Decker Neuroscience Prize.
- 36) Katz J.S., Bryan W.W., Andersson P.B., Elliot J., **Wolfe G.I.**, Nations S.P., Saperstein D.S. and Barohn R.J. The syndrome of amyotrophic brachial diplegia. Neurology, 1999; 52:A83-A84.
- 37) Nations S.P., Lyde C.B., Herbelin L.L., **Wolfe G.I.**, Bryan W.W. and Barohn R.J. Hansen's disease in the U.S: experience in a regional HD clinic. Neurology, 1999; 52:A420.
- 38) Saperstein D.S., Collins M.P., **Wolfe G.I.**, Nations S.P., Haller R.G., Burns D.K., Bryan W.W. and Barohn R.J. Hepatitis C infection and inflammatory myopathy. Neurology, 1999; 52:A451-A452.
- 39) **Wolfe G.I.**, Burns D.K. and Brower R.D. Perineurial cell hyperplasia in hereditary motor and sensory neuropathy with multiple cranial neuropathies. Journal of Child Neurology, 2000; 15:197.
- 40) Kojan S., Goodwin W.E., Bryan W.W., Nations S.P., Burns D.K., Barohn R.J. and **Wolfe G.I.** Clinical and laboratory features of primary lateral sclerosis. Journal of Child Neurology, 2000; 15:200.
- 41) **Wolfe G.I.**, Barohn R.J., Foster B.M., Jackson C.E., Kissel J.T., Day J.W. and Thornton C.A. Intravenous immunoglobulin therapy for generalized myasthenia gravis. Neurology 2000; 54:A137.
- 42) Katz J.S., **Wolfe G.I.**, Alkhersam H., Burns D., Bryan W.W., Amato A.A. and Barohn R.J. Diabetic radiculoplexopathy with cervicobrachial involvement. Neurology 2000; 54:A367.



- 43) Herbelin L.L., Nations S.P., **Wolfe G.I.**, Foster B., Bryan W.W. and Barohn R.J. The correlation between the static fatigue testing and the Quantitative Myasthenia Gravis Score and Activities of Daily Living Profile. Presented at the Myasthenia Gravis Foundation of America Scientific Session, Boston, MA, 10/14/00.
- 44) Tan S.S., Mickey B. and **Wolfe G.I.** Polyneuropathy in neurofibromatosis. Journal of Child Neurology 2001; 16:203-204.
- 45) Kojan S., **Wolfe G.I.**, Nations S.P., Herbelin L., Katz J.S., Burns D.K. and Barohn R.J. Multifocal acquired axonal motor neuropathy. Journal of Child Neurology 2001; 16:208-209.
- 46) Kojan S., Nations S.P., **Wolfe G.I.**, Burns D.K., Herbelin L. and Barohn R.J. Painless, symmetric proximal diabetic amyotrophy in type 1 diabetics: DAM-1. Journal of Child Neurology 2001; 16:209.
- 47) Mathews S., Nations S.P., Barohn R.J. and **Wolfe G.I.** Use of mycophenolate in neuromuscular disorders. Journal of Child Neurology 2001; 16:209.
- 48) Mathews S., **Wolfe G.I.**, Nations S.P. and Barohn R.J. Idiopathic distal acquired demyelinating symmetric neuropathy. Journal of Child Neurology 2001; 16:209-210.
- 49) Trivedi J., **Wolfe G.I.**, Nations S.P., Burns D.K. and Barohn R.J. Clinical spectrum of granulomatous myopathy. Journal of Child Neurology 2001; 16:211.
- 50) Saperstein D.S., Jackson C.E., Nations S.P., **Wolfe G.I.** and Barohn R.J. Uncommon neurologic manifestations of pernicious anemia with cobalamin deficiency. Neurology 2001; 56: A417.
- 51) Herbelin L.L., Nations S.P., **Wolfe G.I.**, Foster B.M., Bryan W.W. and Barohn R.J. The correlation between static fatigue testing and the Quantitative Myasthenia Gravis Score and Activities of Daily Living Profile. Neurology 2001; 56:A63.
- 52) Katz J.S., Amato A.A., Saperstein D.S., Kojan S., Burns D., Nations S., **Wolfe G.I.** and Barohn R.J. Multifocal acquired axonal motor neuropathy. Neurology 2001; 56:A397.
- 53) **Wolfe G.I.**, Foster B.M., Nations S.P., Jackson C.E., Kissel J.T., Thornton C.A., Day J.W., Herbelin L. and Barohn R.J. Electrophysiologic outcome measures in a randomized, placebo-controlled trial of IVIG in myasthenia gravis. Presented at the Myasthenia Gravis Foundation of America Scientific Session, Chicago, IL, 9/30/01. Journal of Child Neurology 2002; 17:8.
- 54) Saperstein D.S., **Wolfe G.I.**, Longeria O., Herbelin L.L., Nations S.P., Jackson C.E., Bryan W.W. and Barohn R.J. Quantitative sensory testing in a large cohort of neuropathy patients. Muscle Nerve 2001; 24:1417-1418.
- 55) Trivedi J.R., **Wolfe G.I.**, Nations S.P., Burns D.K., Bryan W.W. and Dewey R.B. Adult polyglucosan body disease presenting with levodopa-responsive tremor. Journal of Child Neurology 2002; 17:2.
- 56) Khemani P., **Wolfe G.I.**, Burns D.K., Haller R.G., Nations S.P., Herbelin L., Ghafari-Nara B. and Barohn R.J. Focal nodular myopathy of bilateral thigh muscles. Journal of Child Neurology 2002; 17:7.
- 57) Munzir S.M., Nations S.P. and **Wolfe G.I.** Painful neuropathy in patients with rheumatoid arthritis on leflunomide (Arava). Journal of Child Neurology 2002; 17:12.
- 58) Cheema Z.F., **Wolfe G.I.**, Nations S.P., Herbelin L., Akram Y., Bryan W.W. and Barohn R.J. Comparing clinical, electrophysiologic and laboratory features of adult spinal muscular atrophy (SMA) patients with and without survival motor neuron (SMN) gene mutation. Neurology 2002; 58:A465-466.

- 59) Weintraub M.I., **Wolfe G.I.**, Barohn R.J., Cole S., Parry G.J., Hayat G, Cohen J.A., Page J.C., Bromberg M.B., Schwartz S.L. and the Magnetic Research - Diabetic Neuropathy Group. Magnetic field therapy for symptomatic diabetic neuropathy: a randomized, double-blind, placebo-controlled trial. Archives Physical Medicine Rehabilitation 2002; 83:1482 and Neurorehabilitation and Neural Repair 2002; 16:358.
- 60) Khemani P., Burns D.K., Herzog S.P. and **Wolfe G.I.** Unusual cause for painful neuropathy in the setting of HIV infection. Journal of Child Neurology 2003; 18:206.
- 61) Scheufeke M.L., Hotz S.E., Iannaccone S.T., Cannon S.C. and **Wolfe G.I.** Autosomal dominant myotonia congenita with unusual phenotype. Journal of Child Neurology 2003; 18:209.
- 62) Herbelin L.L., Lian G., Saperstein D.S., Gronseth G.S., Barohn R.J., Bryan W.W., Nations S. and **Wolfe G.I.** Two-point stimulation sensory conduction studies: proximal/distal amplitude difference in normal nerve. Journal of Child Neurology 2003; 18:214.
- 63) Saperstein D.S., **Wolfe G.I.**, Gronseth G.S., Nations S.P., Herbelin L.L., Bryan W.W. and Barohn R.J. Identification of Cobalamin deficiency in a neuropathy clinic. Journal of the Peripheral Nervous System 2003; 8:56.
- 64) Cheema Z., **Wolfe G.**, Nations S., Bryan W. and Barohn R. Elusive detection of plasmacytoma in patients with paraprotein associated chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2003; Suppl 12:S12-S13.
- 65) Herbelin L. Lian G., Gronseth G. **Wolfe G.**, Bryan W. Nations S., Barohn R. and Saperstein D. Two point stimulation sensory conduction studies in normal nerves. Muscle Nerve 2003; Suppl 12:S69.
- 66) **Wolfe G.I.**, Kaminski H.J., Jaretzki III A., Swan A. and Newsom-Davis J. Update on plans for a multinational thymectomy trial in nonthymomatous MG patients on prednisone. Presented at the Myasthenia Gravis Foundation of America Scientific Session, San Francisco, CA, 10/18/03.
- 67) **Wolfe G.I.**, Khemani P., Nations S.P., Burkhead W.Z. and Young P.K. Thoracoscapular fusion surgery in facioscapulohumeral dystrophy. Journal of Child Neurology 2004; 19:202.
- 68) Khemani P., Boyer P.J., Burns D.K., Naarden A.L., Joseph J.M. and **Wolfe G.I.** Adult-onset nemaline rod myopathy: clinical and histologic criteria. Journal of Child Neurology 2004; 19:205-6.
- 69) Ohman K.A., Lacritz L.H., **Wolfe G.I.**, Trivedi J.R., Nations S.P., Bonte F.J., Womack K.B. and Lipton A.M. Frontotemporal dementia in primary lateral sclerosis. Journal of Child Neurology 2004; 19:209.
- 70) Saperstein D.S., Grogran P.M., Milford C., McVey A.L., **Wolfe G.I.**, Nations S.P., Herbelin L.L., Barohn R. J., Skikne B., Vogel H. and Katz J.S. Myeloneuropathy in the setting of myelodysplastic syndrome. Neurology 2004; 62:A196.
- 71) Katz J.S., **Wolfe G.I.** and Gorson K.C. Outcome in multifocal motor neuropathy: what is the risk of developing weakness in new nerve distributions over time? Neurology 2004; 62:A495.
- 72) Nguyen T.P., Katz J.S. and the Computerized Criteria for Neuropathy Study Group. Diagnostic criteria for peripheral neuropathies using a Bayesian network. Neurology 2004; 62:A222.
- 73) Boyer P.J., Khemani P., **Wolfe G.I.**, Iannaccone S.T., Naarden A.L., Joseph J.M. and Burns D.K. Nemaline rods in muscle biopsies from adults: clinical and histologic criteria for nemaline rod myopathy. Presented at the American Association of Neuropathology meeting, Cleveland, OH, 6/04.
- 74) Scheufeke M.L., Moore A., Iannaccone S.T., Trivedi J.R., Nations S.P. and **Wolfe G.I.** A series of myasthenia gravis patients with anti-MuSK antibodies. Journal of Child Neurology 2005; 20:264.

- 75) Milligan S.M., **Wolfe G.I.**, Quinton R.A., Burns D.K., LaGanke C., Wang L., Powers R. and Oh S.J. Autopsy findings in multifocal acquired demyelinating sensory and motor neuropathy (MADSAM). Journal of Child Neurology 2005; 20:267.
- 76) Singer M.A., **Wolfe G.I.**, Nations S.P., Trivedi J.R., Burns D.K., Kojan S., Barohn R.J. Primary lateral sclerosis (PLS): clinical and laboratory features in 25 patients. Journal of Child Neurology 2005; 20:270.
- 77) Young A., Hatanaka Y., Hemmi S., Lu L., Claussen G., Oh S., Scheufele M., **Wolfe G.** Abnormalities on electrophysiological studies in MuSK-MG. Presented at the Myasthenia Gravis Foundation of America Scientific Session, San Diego, CA, 9/24/05.
- 78) Newsom-Davis J., Cutter G., **Wolfe G.**, Kaminski H., Jaretzki III A., Minisman G. Thymectomy trial in non-thymomatous MG (MGTX): an update. Presented at the Myasthenia Gravis Foundation of America Scientific Session, San Diego, CA, 9/24/05.
- 79) Sheth M.N., Morrill K.C., **Wolfe G.I.** A patient with Charcot-Marie-Tooth type 1 and spinal cord tumor. Journal of Child Neurology 2006; 21:1.
- 80) Abu-Esneh B.A., Trivedi J.R., Lazaridis C., **Wolfe G.I.** Bilateral retrohumeral radial mononeuropathies. Journal of Child Neurology 2006; 21:7.
- 81) Love L.A., Trivedi J.R., **Wolfe G.I.**, Nations S.P. Neurologic complications of excessive denture cream use. Journal of Child Neurology 2006; 21:11.
- 82) Young Achong A.M., Hatanaka Y., Hemmi S., Scheufele M.L., Nations S.P., Lu L., Claussen G.C., **Wolfe G.I.**, Oh, S.J. Abnormal repetitive nerve stimulation test in the facial muscles is common and most severe in MuSK-antibody-positive myasthenia gravis. Neurology 2006;66:A59.
- 83) Khan S., **Wolfe G.**, Nascimento O., Pasnoor M., Mummaneni R., Trivedi J., Nations S., Vernino S., De Freitas M., Quintanilha G., McVey A., Herbelin L., Saperstein D., Gronseth G., Barohn R. North America and South America (NA-SA) neuropathy project. Neurology 2006;66:A84.
- 84) Khan S.I., Love L., Jackson C., Kissel J., **Wolfe G.**, Nations S., Trivedi J., Singer M., Struyk A., Elliott J., Mummaneni R., Herbelin L., Saperstein D., Gronseth G., McVey A., Barohn R. A common neuromuscular diagnostic database – utilization at four academic centers. Neurology 2006;66:A153.
- 85) Trivedi J.R., **Wolfe G.I.**, Roland P., Nations S.P. A retrospective analysis of electrophysiologic findings and outcome in Bell's palsy. Neurology 2006;66:A359-360.
- 86) Boyer P.J., Nations S.P., Love L.A., Burritt M.F., Butz J.A., **Wolfe G.I.** Hynan L.S., Reisch J.S., Trivedi J.R. Denture cream-related neurologic dysfunction: copper deficiency due to excess zinc ingestion. Brain Pathology 2006;16:S168.
- 87) Newsom-Davis J., Cutter G., Kaminski H.J., **Wolfe G.I.**, Jaretzki A. , Aban C., Birmingham, Minisman G., Conwit R. Thymectomy trial (MGTX) and biomarker study (BioMG) in non-thymomatous myasthenia gravis (MG). Presented at the Myasthenia Gravis Foundation of America Scientific Session, 10/7/06, Chicago, IL.
- 88) Pasnoor M., Barohn R.J., Herbelin L., McVey A., **Wolfe G.I.**, Nations S.P., Trivedi J.R., Kissel J.T., Walsh R., Claussen G.C., Oh S.J. Clinical characteristics of MuSK-antibody positive MG: a U.S. experience. Presented at the Myasthenia Gravis Foundation of America Scientific Session, 10/7/06, Chicago, IL.
- 89) Love L.A., Trivedi J.R., Boyer P.J., **Wolfe G.I.**, Burritt M.F., Butz J.A., Nations S.P. Denture cream overuse: an unusual cause of neurologic disorders. Awarded the 2006 President's Research Initiative Award. Muscle Nerve 2006; 34:523.
- 90) Singh A., Kandimala G., Rubin M., Burns D., **Wolfe G.** Myositis as a manifestation of chronic graft-versus-host disease in multiple myeloma following allogeneic stem cell transplantation. Journal of Clinical Neuromuscular Disease 2007; 8:9.

- 91) Pasnoor M., **Wolfe G.**, Nations S., Trivedi J., Barohn R., Herbelin L., McVey A., Kissel J., Walsh R., Amato A., Mozaffar T., Hungs M., Chui L., Goldstein J., Novella S., Burns T., Phillips L., Claussen G., Oh S. Clinical findings in MuSK-antibody positive myasthenia gravis. Neurology 2007; 68:A299.
- 92) Barohn R.J., Jackson C.E., Pandya S., Gronseth G., Herbelin L. and the Muscle Study Group. Inclusion body myositis functional rating scale. Neurology 2007; 68:A361.
- 93) Sanders D., McDermott M., Thornton C., Tawil A., Barohn R. and the Muscle Study Group. A trial of mycophenolate mofetil (MMF) with prednisone as immunotherapy in myasthenia gravis (MG). Neurology 2007; 68:A107.
- 94) **Wolfe G.I.**, Barohn R.J., Sanders D.B. and the Muscle Study Group. Correlation of outcome measures from a controlled study of mycophenolate mofetil in generalized myasthenia gravis. Presented at the 11<sup>th</sup> International Conference on Myasthenia Gravis and Related Disorders, Chicago, IL, May 15, 2007.
- 95) Pasnoor M., **Wolfe G.**, Nations S., Trivedi J., Young A., Barohn R., Herbelin L., McVey A., Kissel J., Walsh R., Amato A., Mozaffar T., Hungs M., Chui L., Goldstein J., Novella S., Burns T., Phillips L., Claussen G., Bertorini, T., Oh S. Clinical findings in MuSK-antibody positive myasthenia gravis. Presented at the 11<sup>th</sup> International Conference on Myasthenia Gravis and Related Disorders, Chicago, IL, May 15, 2007.
- 96) Burns T.M., Conaway M., Sanders D.B. and the Muscle Study Group. Correlation of quality-of-life with regional symptoms and signs in MG: Muscle Study Group Cellcept trial experience. Presented at the 11<sup>th</sup> International Conference on Myasthenia Gravis and Related Disorders, Chicago, IL, May 15, 2007.
- 97) Cutter G., Kaminski H.J., **Wolfe G.I.**, Jaretzki III A., Aban C., Minisman G., Conwit R., Newsom-Davis J. MGTX recruitment in a surgical clinical trial. Presented at the Myasthenia Gravis Foundation of America Scientific Session, Washington, DC, 10/6/07.
- 98) Nguyen C., Iannaccone S.T., **Wolfe G.**, Burns D., Selcen D, Engel A. Rapsyn mutation-associated congenital myasthenic syndrome in an infant presenting with hypotonia and arthrogryposis multiplex congenital. Journal of Clinical Neuromuscular Disease 2008; 9:365.
- 99) Kandimala G., Taneja A., Nations S., Burns D., **Wolfe G.** Mycophenolate mofetil and tacrolimus: an alternative therapy for dermatomyositis. Journal of Clinical Neuromuscular Disease 2008; 9:366.
- 100) Nagineni L.V., Nations S.P., Trivedi J.R., **Wolfe G.I.** Guillain-Barré syndrome after influenza vaccination. Journal of Clinical Neuromuscular Disease 2008; 9:371.
- 101) Burns T., **Wolfe G.**, Nations S., Trivedi J., Phillips L.T., Phillips L., Fifer M., Young A., Oh S. Variable MuSK antibody positive rates among seronegative MG in the United States. Neurology 2008; 70:A302.
- 102) Saperstein D.S., Levine T.D., Gorson K.G., **Wolfe G.I.**, Muppidi S., Shaibaini A., Hehir M.K., Burns T., Hunt M., Pasnoor M., Dimachkie M.M., McVey A.L., Barohn R.J. IVIG treatment response of suspected CIDP patients not meeting standard diagnostic criteria. Journal of the Peripheral Nervous System 2008; 13:182.
- 103) **Wolfe G.I.** MGTX: Rationale for the thymectomy trial in non-thymomatous myasthenia gravis. Journal of Neuroimmunology 2008; 203:220.
- 104) Beeravolu L.R., Trivedi J.R., Nations S.P., Herndon E.S., Burns D.K., **Wolfe G.I.** Neuropathy in a patient with PMP22 and GDAP1 sequence alterations. Journal of Clinical Neuromuscular Disease 2009; 10:2.
- 105) Alkawadri R., Karunapusha C.A., **Wolfe G.I.**, Vernino S. Autoimmune autonomic ganglionopathy with anisocoria. Journal of Clinical Neuromuscular Disease 2009; 10:6-7.
- 106) Muppidi S., Nations S.P., Vernino S., **Wolfe G.I.** Isolated neck extensor myopathy: is it responsive to immunotherapy? Journal of Clinical Neuromuscular Disease 2009; 10:12.

- 107) Muppidi S., Nations S.P., Vernino S., **Wolfe G.I.** Isolated neck extensor myopathy: is it responsive to immunotherapy? Neurology 2009; 72:A20-A21.
- 108) Burns T.M., Grouse C.K., Conaway M.R., Sanders D.B. and the MG Composite and MG-QOL15 Study Group (appendix listing). Validation and reliability testing of the MG Composite in the clinical setting. Euromyasthenia meeting, Paris, France. Presented December 1-2, 2009.
- 109) Burns T.M., Grouse C.K., Conaway M.R., Sanders D.B. and the MG Composite and MG-QOL15 Study Group (appendix listing). Construct and concurrent validation of the MG-QOL15 in the practice setting. Euromyasthenia meeting, Paris, France. Presented December 1-2, 2009.
- 110) Stevenson M.T., Winston N., Nations S.P., Burns D.K., **Wolfe G.I.** Nemaline myopathy with ataxia. Journal of Clinical Neuromuscular Disease 2010; 11:168.
- 111) Gilbreath H., Iannaccone S.T., Moore S.A., Finkel R., **Wolfe G.I.** and Zinser W. A 10 year-old boy with limb-girdle muscular dystrophy. Journal of Clinical Neuromuscular Disease 2010; 11:169.
- 112) Singer M., Nakonezny P., Vernino S. and **Wolfe G.I.** Investigating treatable conditions associated with chronic idiopathic axonal polyneuropathy. Journal of Clinical Neuromuscular Disease 2010; 11:181.
- 113) Aban I.B., Cutter G.R., **Wolfe G.I.**, Kaminski H.J., Jaretzki III A., Minisman G., Gao H., Conwit R., Newsom-Davis J. Incidence of MG based on screening data of MGTX study. Muscle Nerve 2010; 42:690-691.
- 114) Burns T.M., Grouse C.K., **Wolfe G.I.**, Conaway M.R., Sanders D.B. and the MG Composite and MG-QOL15 Study Group. The MG-QOL15 for following the health-related quality of life of patients with myasthenia gravis. Muscle Nerve 2010; 42:694.
- 115) Muppidi S., **Wolfe G.I.**, Conaway M.R., Burns T.M. and the MG Composite and MG-QOL15 Study Group. MG-ADL: is it still a relevant outcome measure? Muscle Nerve 2010; 42:691-692.
- 116) Ding K., Mammen P.P.A., Drazner M.H., Vernino S., **Wolfe G.I.** Experience with cardiac transplantation in muscular dystrophy patients. Journal of Clinical Neuromuscular Disease 2011; 12:178-179.
- 117) Taneja A., Nations S., **Wolfe G.I.**, Burns D.K., Herndon E., Trivedi J.R. Statin induced immune-mediated necrotizing myopathy. Journal of Clinical Neuromuscular Disease 2011; 12:189.
- 118) Amato A., McDermott M., Tawil A, Barohn R., Kissel J., King W., Pandya S., Cupler E., **Wolfe G.**, Briemberg H., Weiss M., Wagner K., Roe K., Smirnow A., Griggs R. A pilot study of etanercept in dermatomyositis. Neurology 2011; 76:A365
- 119) Saperstein D.S., Levine T.D., Gorson K.G., **Wolfe G.I.**, Muppidi S., Shaibani A., Hehir M.K., Burns T., Sharma K.R., Pasnoor M., Dimachki M., McVey A.L., Barohn R.J. Treatment response of suspected CIDP patients not meeting standard diagnostic criteria. Journal of the Peripheral Nervous System 2011; 16(suppl 3):S124.
- 120) **Wolfe G.I.**, Cutter G.R., Minisman G., Aban I., Jaretzki III A., Conwit R. and Kaminski H.J. Thymectomy Trial in on-thymomatous myasthenia gravis patients receiving prednisone (MGTX). Presented at Immune Globe International Conference of Nervous System Autoimmunity, Bangalore, India, 1/30/12.
- 121) Absalom N., **Wolfe G.I.**, Nations S., Trivedi J., Muppidi S. Clinical and electrophysiological evaluation of chronic and critical ischemic monomelic neuropathy following revascularization. Journal of Clinical Neuromuscular Disease 2012; 13:184-185.
- 122) Samuel G., Muppidi S., **Wolfe G.I.** Inpatient EMG studies: do they help with patient care? Journal of Clinical Neuromuscular Disease 2012; 13:185.

- 123) Vora A., Sparagana S.P., Ezaki M., Burns D.K., **Wolfe G.I.** Multifocal upper limb neuropathy with myxomatous infiltration and calcification on radial nerve biopsy. Journal of Clinical Neuromuscular Disease 2012; 13:187-188.
- 124) Samuel G., Muppidi S., **Wolfe G.** Inpatient EMG studies. Do they help with patient care? Neurology 2012; 78 (suppl 1):P01.197.
- 125) Absalom N., **Wolfe G.**, Nations S., Trivedi J., Muppidi S. Clinical and electrophysiologic characterization of chronic and critical ischemic monomelic neuropathy after revascularization.: a case series. Neurology 2012; 78 (suppl 1):P07.151.
- 126) Sadjadi R., Sanders D.B., Massey J.M., Fisk F., Burns T.M. and the MG Composite and MG-Qol 15 Study Group. Psychometric evaluation of MG Manual Muscle Testing (MG-MMT) using Rasch analysis. Presented at the 12<sup>th</sup> International Conference on Myasthenia Gravis and Related Disorders, New York, NY, 5/21/12.
- 127) Benatar M., McDermott M.P., Tawil R., **Wolfe G.I.** Sanders D.B. Efficacy of prednisone in the treatment of ocular myasthenia-EPITOME. Presented at the 12<sup>th</sup> International Conference on Myasthenia Gravis and Related Disorders, New York, NY, 5/22/12.
- 128) **Wolfe G.I.**, Cutter G.R., Kaminski H.J., Jaretzki III A., Minisman G., Aban I., Conwit R. MGTX: update on the thymectomy trial in non-thymomatous myasthenia gravis. Presented at the 12<sup>th</sup> International Conference on Myasthenia Gravis and Related Disorders, New York, NY, 5/23/12.
- 129) Silvestri N.J., **Wolfe G.I.** Highlights from 12<sup>th</sup> International Conference on Myasthenia Gravis and Related Disorders. Muscle Nerve 2012; 46:622 (MGFA section).
- 130) Neelakantan A., Silvestri N., **Wolfe G.I.** Effect of hypovitaminosis D on nerve conduction studies in diabetic neuropathy. Journal of Clinical Neuromuscular Disease 2013; 14:156.
- 131) Silvestri N.J., Heffner R., Balos L. **Wolfe G.I.** An uncommon presentation of polymyositis. Journal of Clinical Neuromuscular Disease 2013; 14:157.
- 132) Katz J., Levine T., Barohn R., Mozaffar T., **Wolfe G.**, Saperstein D., Katzin L., Ritt E., Vaughan L., Greer M. Understanding IVIg prescribing habits through INSIGHTS (immunological and neurological study of immune globulin habits, treatments and standards. Neurology 2013; 80 (suppl 1):P01.153.
- 133) Katz J., Levine T., Barohn R., Mozaffar T., **Wolfe G.**, Saperstein D., Katzin L, Ritt E., Vaughan L., Greer M. Immunoglobulin treatment outcomes assessment and clinical guidelines study (the INSIGHTS study): preliminary findings on scope of practice from the INSIGHTS database. Muscle Nerve 2013; 48:675.
- 134) Salins S., Teter B., Kavak, K., Silvestri N.J., **Wolfe G.I.** Low-dose medication and long-term outcome in myasthenia gravis. Muscle Nerve 2013; 48:690.
- 135) Silvestri N., **Wolfe G.** Asymptomatic hyperCKemia: How far to go? Journal of Clinical Neuromuscular Disease 2014; 15(3):13.
- 136) Levine T., Katz J., Barohn R., Mozaffar T., Saperstein D., Katzin L., Dimachkie M., Ritt E., Vaughan L., Greer M., **Wolfe G.I.** Immunoglobulin treatment outcomes assessment and clinical guidelines study (INSIGHTS): preliminary findings on scope of practice in the U.S. Presented at the 7<sup>th</sup> International Immunoglobulin Conference, Interlaken, Switzerland, 4/4/14-4/5/14.
- 137) Salins S., Teter B., Kavak K., Silvestri N., **Wolfe G.** Low dose medication and long-term outcome in myasthenia gravis. Neurology 2014; 82(10):P2.085.
- 138) Levine T., Katz J., Barohn R., Mozaffar T., **Wolfe G.**, Saperstein D., Katzin L., Dimachkie M., Ritt E.,

- Vaughan L., Greer M. Ig Treatment Outcomes Assessment and Clinical Guidelines Study (the 'INSIGHTS Study'): preliminary findings on scope of practice from the INSIGHTS database. Neurology 2014; 82(10):P7.099.
- 139) Levine T., Katz J., Barohn R., Mozaffar T., **Wolfe G.**, Saperstein D., Katzin L., Dimachkie, M., Ritt E., Vaughan L., Greer, M. Immunoglobulin Treatment Outcomes Assessment and Clinical Guidelines Study (The 'INSIGHTS Study'): Preliminary findings on scope of practice from the INSIGHTS database. Muscle Nerve 2014; 50:666
- 140) Sanders D.B., **Wolfe G.I.** International task force for treatment guidelines in myasthenia gravis. Muscle Nerve 2014; 50:715.
- 141) Silvestri N., Balos L., **Wolfe G.** Unusual presentations of polymyositis in myasthenia gravis. Journal of Clinical Neuromuscular Disease 2015; 16(3):191.
- 142) Levine T., Katz J., Barohn R., Saperstein D., Dimachkie M., **Wolfe G.**, Katzin L., Mozaffar T., Vaughn L., Greer M. Clinical response of neuromuscular patients to IVIG: an interim analysis of the INSIGHTS registry. Neurology 2015; 84:P2.020.
- 143) AbdelRazek M., Mowla A., Silvestri N., Farooq S., Kamal H., Abdelhamid N., Sawyer R., **Wolfe G.** Fibrocartilaginous embolism, an underdiagnosed cause of spinal cord infarction; critical review of literature, new diagnostic criteria, mechanisms. Neurology 2015; 84:P2.020.
- 144) Benatar M., McDermott M., Sanders D., **Wolfe G.**, Barohn R., Nowak R., Hehir M., Juel V., Katzberg H., Tawil A. Effectiveness of prednisone in the treatment of ocular myasthenia (EPITOME). Neurology 2015; 84:P7.048.
- 145) **Wolfe G.I.**, Silvestri N.J. What's new in treatment strategies for MG in the new era. Presented at Japanese Society of Neurology 56<sup>th</sup> Annual Meeting, Niigata, Japan, 5/20/15.
- 146) **Wolfe G.I.** Management dilemmas in neuroimmunological conditions: thymectomy in MG. 2<sup>nd</sup> World Congress on NeuroTherapeutics: Dilemmas, Debates, Discussions. Prague, Czech Republic, 2015; S24:37-38.
- 147) Levine T., Katz J., Barohn R., Mozaffar T., **Wolfe G.**, Saperstein D., Katzin L., Dimachkie M., Ritt E., Vaughan L., Greer M. Clinical response of neuromuscular patients to intravenous immunoglobulin: an interim analysis of the INSIGHTS registry. Muscle Nerve 2015; 52:S112.
- 148) Sanders D., **Wolfe G.**, Narayanaswami P., MGFA Task Force on International Treatment Guidelines for Myasthenia Gravis. Developing consensus-based treatment guidelines for myasthenia gravis. Muscle Nerve 2015; 52:S114.
- 149) Dimachkie M.M., Levine T., Trivedi J., Bril V., Silvestri N.J., Saperstein D., Nations S., Katzberg H., **Wolfe G.I.**, Glenn M., Pasnoor M., Statland J., McVey A.L., Rico G., Herbelin L., Miller P., Harrington A., Abuzinadah A., Barohn R.J. Open label study of subcutaneous immunoglobulin (SCIg) in myasthenia gravis: study design and progress update. Muscle Nerve 2015; 52:S142.
- 150) Kamal H., **Wolfe G.**, Hafeez M.U., Bushra A., Singh K., Silvestri N. Neuro-Behçet's disease masquerading as brain abscesses on MRI. Presented at the American Society of Neuroimaging 39th Annual Meeting, Orlando, FL, January 2016.
- 151) Kamal H., Kolb C., Eckert S., Arora A., Silvestri N., **Wolfe G.** Relapsing Miller Fisher syndrome. Journal of Clinical Neuromuscular Disease 2016; 17(3):173.
- 152) Levine T., Vaughn L., Badger G., **Wolfe G.**, Katzin L., Saperstein D., Mozaffar T., Barohn R, Katz J., Dimachkie M., Greer M., Ritt E. INSIGHTS: Analysis of the IVIG responsiveness in patients with myasthenia

- gravis. Neurology 2016; 86:P3.171.
- 153) Cutter G.R., Kaminski H., **Wolfe G.**, Aban I., MGTX Trial Research Group. Thymectomy in non-thymomatous myasthenia gravis: Results from MGTX, a randomized, controlled trial. Neurology 2016; 86:S28.003.
- 154) Levine T., Katz J., Barohn R., Saperstein D., **Wolfe G.**, Katzin L., Mozaffar T., Dimachkie M., Badger G., Vaughn L., Ritt E., Greer M., Response to IVIG in patients with CIDP: The INSIGHTS quality improvement registry. Neurology 2016; 86:P5.013
- 155) **Wolfe G.I.**, Kaminski H.J., Aban I.B., Cutter G.R. and the MGTX Study Group. Results of the thymectomy trial in myasthenia gravis. Journal of Neuromuscular Diseases 2016; 3(suppl 1):S4-S5.
- 156) **Wolfe G.I.** Treatment of myasthenia gravis: general treatment approaches. Journal of Neuromuscular Diseases 2016; 3(suppl 1):S22.
- 157) Levine T., Katz J., Barohn R., Saperstein D., **Wolfe G.**, Katzin L., Mozaffar T., Dimachkie M., Badger G., Vaughan L., Ritt E., Greer M. Response to intravenous immunoglobulin in patients with chronic inflammatory demyelinating polyneuropathy: the INSIGHTS quality improvement project. Muscle Nerve 2016;54:526. Winner of Best Abstract Award.
- 158) Levine T., Vaughan L., Badger G., **Wolfe G.**, Katzin L., Saperstein D., Mozaffar T., Barohn R., Katz J., Dimachkie M., Greer M., Ritt E. INSIGHTS: analysis of intravenous immunoglobulin responsiveness in patients with myasthenia gravis. Muscle Nerve 2016;54:621, 646.
- 159) Sanders D., Massey J., **Wolfe G.**, Benatar M., Evoli A., Gilhus N.E., Illa I., Kuntz N., Melms A., Murai H., Nicolle M., Palace J., Richman D., Verschuuren J., Narayanaswami P. International consensus guidance for the management of myasthenia gravis. Muscle Nerve 2016;54:647.
- 160) Rozen S., **Wolfe G.**, Raskin P., Vernino S., Pandian G., Wyne K., Reisch J., Hynan L., Fulmer R., Salvatore A. DNND (Diabetic Neuropathy Nerve Decompression) Study – a controlled, randomized, double blinded prospective study on the role of surgical decompression of lower extremity nerves for the treatment of patients with symptomatic diabetic neuropathy with chronic nerve compression. American Diabetes Association 77<sup>th</sup> Scientific Sessions, June 2017.
- 161) **Wolfe G.**, Salins S., Teter B., Kavak K., Silvestri N. Low-dose immunotherapy and eventual outcome in MG. Journal of Clinical Neuromuscular Disease 2017; 18:196-197.
- 162) **Wolfe G.I.**, Kaminski H.J., Aban I.B., Minisman G., Kuo H.-C., Marx A., Ströbel P., Mazia C., Oger J., Cea J.G., Heckmann, J.M., Evoli A., Nix W., Cifaloni E., Antonini G., Witoonpanich R., King J.O., Beydoun S.R., Chalk, C.H., Barboi A.C., Amato A.A., Shaibani A.I., Katirji B., Lecky B.R.F., Buckley C., Dias-Tosta E., Yoshikawa H., Waddington-Cruz M., Pulley M.T., Rivner M.H., Kostera-Pruszczyk A., Pascuzzi R.M., Jackson C.E., Garcia Ramos G.S., Verschuuren J.J.G.M., Massey J.M., Kissel J.T., Werneck L.C., Benatar M., Barohn R.J., Tandan R., Mozaffar T., Conwit R., Odenkirchen J., Sonett, J.R., Vincent A., Jaretzki III A., Newsom-Davis J., Cutter G.R., and the MGTX Study Group. MGTX primary and secondary outcomes. Presented at the 13<sup>th</sup> International Conference on Myasthenia Gravis and Related Disorders, New York, NY, May 15-17, 2017.
- 163) Benatar M., Howard J.F., Barohn R., **Wolfe G.** Learning from the past: reflections on recently completed MG trials. Presented at the 13<sup>th</sup> International Conference on Myasthenia Gravis and Related Disorders, New York, NY, May 15-17, 2017.
- 164) Sanders D.B., **Wolfe G.I.**, Narayanaswami P. International consensus guidance statements for myasthenia gravis treatment. Presented at the 13<sup>th</sup> International Conference on Myasthenia Gravis and Related Disorders, New York, NY, May 15-17, 2017.



- 165) Mozaffar T., Vaughn L., Badger G., **Wolfe G.**, Katzin L., Saperstein D., Levine T., Barohn R., Katz J., Dimachkie M., Greer M., Ritt E. INSIGHTS: Analysis of responsiveness of IVIg in patients with myasthenia gravis. Presented at the 13<sup>th</sup> International Conference on Myasthenia Gravis and Related Disorders, New York, NY, May 15-17, 2017.
- 166) Leite M.I., Jacobson L., Buckley C., **Wolfe G.I.**, Aban I.B., Minisman G., Kuo H-C, Hilton-Jones D., Cutter G.R., Kaminski H.J., Vincent A. Serum acetylcholine-receptor antibody concentrations in 71 patients included in the randomized trial of thymectomy in myasthenia gravis (MGTX). Presented at the 13<sup>th</sup> International Conference on Myasthenia Gravis and Related Disorders, New York, NY, May 15-17, 2017.
- 167) Howard J.F., Kaminski H.J., Nowak R.J., **Wolfe G.I.**, Benatar M.G., Ricardo A., Hoarty M.D., DeMarco S.J., Farzaneh R., Duda P.W. RA101495-02.201: A phase 2 study with RA101495 in patients with generalized myasthenia gravis. To be presented at the 2018 MDA Clinical Conference, Arlington, VA, May 11-14, 2018.
- 168) **Wolfe G.**, Silvestri N., Gross B., Ciafaloni E., Herrmann D. CMT phenotype with scapular winging. Journal of Clinical Neuromuscular Disease 2018; 19:171.
- 169) Ricardo A., **Wolfe G.**, Nowak R., DeMarco S.J., Benatar M., Hoarty M.D., Duda P., Farzaneh-Far R., Kaminski H., Howard J. RA101495, a subcutaneously administered peptide inhibitor of complement component 5 (C5) for the treatment of generalized myasthenia gravis (gMG): Phase 1 results and Phase 2 design. Neurology 2018; 90:S31.006.
- 170) **Wolfe G.I.** Overview of treatment guidelines: going forward. Journal of Neuromuscular Diseases 2018; 5:S33-34.
- 171) **Wolfe G.I.**, Kaminski H.J., Aban I.B., Minisman G., Kuo H.-C., Sonett J.R., Marx A., Weis C.-A., Cutter G.R. Randomized controlled trial of thymectomy: a deeper dive into data. Journal of Neuromuscular Diseases 2018; 5:S39.
- 172) Nowak R.J., Coffey C., Goldstein J.M., Dimachkie M., Benatar M., Huq S., Pearson B., Yankey J.W., Uribe L., Herbelin L., Burns T.M., O'Connor K.C., Conwit R., Kissel J.T., **Wolfe G.I.**, Hafler D.A., Cudkowicz M.E., Barohn R.J. B cell targeted treatment in myasthenia gravis (BEATMG) – a phase 2 trial of rituximab in MG: topline results. Journal of Neuromuscular Diseases 2018; 5:S341.
- 173) Mantegazza R., **Wolfe G.**, Muppidi S., Wiendl H., Fujita K.P., O'Brien F., Howard J.F. Achievement of minimal manifestations in eculizumab-treated AChR-positive refractory myasthenia gravis patients. Journal of Neuromuscular Diseases 2018; 5:S355-356.
- 174) Howard J.F., Kaminski H.J., Nowak R.J., **Wolfe G.I.**, Benatar M.G., Ricardo A., Hoarty M.D., DeMarco S.J., Farzaneh-Far R., Duda P.W. Complement C5 inhibitor RA101495 for the treatment of myasthenia gravis. European Journal of Neurology 2018; 25:336.
- 175) Mantegazza R., **Wolfe G.**, Muppidi S., Wiendl H., Fujita K., O'Brien F., Howard J. Minimal manifestations with eculizumab in myasthenia gravis. Muscle Nerve 2018; 58:S98.
- 176) **Wolfe G.**, Kaminski H., Aban I., Cutter G., MGTX Study Group. Results from the MGTX Extension Study of thymectomy in myasthenia gravis. Muscle Nerve 2018; 58:S105.
- 177) Dimachkie M., Bril V., Levine T., Trivedi J., Silvestri N., Phadnis M., Saperstein D., Nations S., Katzberg H., **Wolfe G.**, Barohn R., Higgs K., Heim A., Pasnoor M., Herbelin L. Subcutaneous immunoglobulin in myasthenia gravis: a North American open label study. Muscle Nerve 2018; 58:S116.
- 178) Khezri N., Eckert S., **Wolfe G.**, Silvestri N. Subacute weakness in the setting of non-Hodgkin lymphoma. Journal of Clinical Neuromuscular Disease 2019; 20:S10.
- 179) **Wolfe G.**, Kaminski H., Aban I., Minisman G., Kuo H., Cutter G. Results from the MGTX Extension Study. Journal of Clinical Neuromuscular Disease 2019; 20:S16-S17.

- 180) Howard J.F., Nowak R.J., **Wolfe G.I.**, Benatar M.G., Duda P.W., MacDougall J., Farzaneh-Far R., Kaminski H.J., Zilucoplan MG Study Group. Zilucoplan, a subcutaneously self-administered peptide inhibitor of C5, improved outcome measures in patients with generalized myasthenia gravis. Presented at the 2019 MDA Clinical and Scientific Conference, Orlando, FL, April 15, 2019.
- 181) McPherson T., Aban I., Duda P., Farzaneh-Far R., **Wolfe G.**, Kaminski H., Cutter G. Comparison of the Quantitative Myasthenia Gravis (QMG) and Myasthenia Gravis Activities of Daily Living (MG-ADL) scores in the MGTX Randomized Trial. Neurology 2019; 92:P2.2-102.
- 182) Khezri N., Eckert S., **Wolfe G.**, Silvestri N. Severe subacute motor neuronopathy associated with non-Hodgkin B cell lymphoma. Neurology 2019; 92:P2.4-020.
- 183) Dimachkie M., Bril V., Levine T., Trivedi J., Silvestri N., Phadnis M., Saperstein D., Nations S., Katzberg H., **Wolfe G.**, Herbelin L., Higgs K., Heim A., McVey A., Rico G., Statland J., Barohn R., Pasnoor M. Subcutaneous immunoglobulin in myasthenia gravis: results of a North American open label study. Neurology 2019; 92:N4.002.
- 184) Howard J., Nowak R., **Wolfe G.**, Benatar M., Duda P., MacDougall J., Farzaneh-Far R., Kaminski H. Zilucoplan, a self-administered subcutaneous peptide inhibitor of complement component 5 (C5) for the treatment of generalized myasthenia gravis: Phase 2 results. Muscle Nerve 2019; 60:S129.
- 185) Lee I., Kuo H.-C., Aban I., Cutter G., McPherson T., Kaminski H., Sussman J., **Wolfe G.**, Ströbel P., Oger J., Cea G., Heckmann J.M., Evoli A., Nix W., Ciafaloni E., Antonini G., Witoonpanich R., King J.O., Beydoun S.R., Chalk C.H., Barboi A.C., Amato A.A., Shaibani A.I., Katirji B., Lecky B.R.F., Buckley C., Vincent A., Dias-Tosta E., Yoshikawa H., Waddington-Cruz M., Pulley M., Rivner M.H., Kostera-Pruszczyk A., Pascuzzi R.M., Jackson C., Verschuuren J.J.G., Massey J.M., Kissel J.T., Werneck L.C., Benatar M., Barohn R.J., Tandan R., Mozaffar T., Conwit R., Minisman G., Sonett J., MGTX Study Group. Minimal manifestations of status and prednisone withdrawal in the MGTX Trial. Muscle Nerve 2019; 60:S130-S131.
- 186) Nowak R., Coffey C., Goldstein J., Yankey J., Uribe L., Dimachkie M., Benatar M., **Wolfe G.**, Burns T., O'Connor K., Conwit R., Kissel J., Hafler D., Cudkowicz M., Barohn R. Rituximab in patients with moderate to severe myasthenia gravis: a subgroup analysis of the BeatMG Study. Muscle Nerve 2019; 60:S139.
- 187) Bril V., Palace J., Mozaffar T., Gelinas D., Brauer E., Nisbet P., **Wolfe G.I.** Generalized myasthenia gravis management and practice guidelines: cross-sectional survey of community neurologists in the United States. Muscle Nerve 2021; 64:S55.
- 188) Ruzhansky K., Li Y., **Wolfe G.**, Muppidi S., Guptill J., Hehir M., Dimachkie M.M., Kaminski H., Howard J., Narayanaswami P., MGFA task force for standardization of MG outcome measures in clinical practice. Muscle Nerve 2022; 65:S15.
- 189) **Wolfe G.I.**, Sanders D.B., Narayanaswami P. The 2020 update of the international consensus-based treatment recommendations for myasthenia gravis. Journal of Neuromuscular Diseases 2022; 9:S54.
- 190) Narayanaswami P., Sanders D., Guptill J., Bibeau K., Krueger A., Venitz J., Li F., Liu B., Desai R., PROMISE-MG Study Group. PROMISE MG: Results of a multicenter comparative effectiveness study of myasthenia gravis treatments. Journal of Neuromuscular Diseases 2022; 9:S242-243.
- 191) Hernandez I., Mozaffar T., Kaplan S., Habib A., Vincent A., Jacobson L., Aban I., Cutter G., Kaminski H., **Wolfe G.** Clinical improvement mirrored antibody reduction in myasthenia gravis. Muscle Nerve 2022; 66:S132.
- 192) Lawton C., **Wolfe G.I.**, Barnett-Tapia C., Hamedani A., Kupersmith M., Amato A., Kaminski H. Evaluation of measures for ocular manifestations in myasthenia gravis. Presented at the JSMBS Community Research Day, Univ. at Buffalo, Buffalo, NY, 4/14/23.

- 193) **Wolfe G.**, Sacca F., Phillips G., Brauer E., Qi C., Yang H., Du M., Chen X., Muppidi S., Barnett-Tapia C., Vu T., Peric S., Narayanaswami P. Network meta-analysis of treatment options in generalized myasthenia gravis: impact on health-related quality of life outcome. Muscle Nerve 2023; 68:658-659.
- 194) Qi C., Narayanaswami P., **Wolfe G.**, Smith A.G., Brauer E., Bergin C., Osipa L., Goyal A., Suthagar T.B., Sato M., Phillips G. Real-world outcomes of patients living with generalized myasthenia gravis initiating efgartigimod treatment in the United States. Muscle Nerve 2023; 68:655.

### Book Chapters

- 1) **Wolfe G.I.** and Barohn R.J. Corticosteroid myopathies. In: Gilman S., Goldstein G.W. and Waxman S.G., eds. Neurobase. San Diego: Arbor Publishing, 3rd ed., 1995. Revised 1996, 1997.
- 2) **Wolfe G.I.** and Barohn R.J. Myopathies associated with thyroid disease. In: Gilman S., Goldstein G.W. and Waxman S.G., eds. Neurobase. San Diego: Arbor Publishing, 3rd ed., 1995. Revised 1996, 1997.
- 3) **Wolfe G.I.**, Barohn R.J. and Galetta S.L. Drugs for the diagnosis and treatment of myasthenia gravis. In: Zimmerman T., Kooner K. Sharir M., and Fechtner, R.D., eds. Textbook of Ocular Pharmacology. Philadelphia: Lippincott-Raven Press, 1997, pp. 837-848.
- 4) **Wolfe G.I.** and Barohn R.J. Neuromuscular junction disorders of childhood. In: Swaiman K.F. and Ashwal S., eds. Swaiman's Pediatric Neurology: Principles and Practice, 3rd ed. Philadelphia: Mosby, 1999, pp 1216-1234.
- 5) Saperstein D.S. and **Wolfe G.I.** Corticosteroid myopathies. In: Gilman S., Goldstein G.W. and Waxman S.G., eds. Neurobase. San Diego: Arbor Publishing, 4th ed., 1998. Revised 1999, 2000.
- 6) Saperstein D.S. and **Wolfe G.I.** Myopathies associated with thyroid disease. In: Gilman S., Goldstein G.W. and Waxman S.G., eds. Neurobase. San Diego: Arbor Publishing, 4th ed., 1998. Revised 1999, 2000.
- 7) **Wolfe G.I.** and Barohn R.J. Peripheral neuropathies. In: Rakel R.E. and Bope E.T., eds. Conn's Current Therapy. Philadelphia: W.B. Saunders, 2001; pp 986-994.
- 8) **Wolfe G.I.** Quantitative sensory testing: basic principles and clinical applications. In: Dumitru D., Amato A.A. and Zwarts M.J., eds. Electrodiagnostic Medicine. Philadelphia: Hanley & Belfus, 2<sup>nd</sup> ed., 2001; pp 429-437.
- 9) **Wolfe G.I.** and Trivedi J.R. Idiopathic sensory and sensorimotor neuropathies. In: Gilman S., Goldstein G.W. and Waxman S.G., eds. MedLink-Neurology. San Diego: MedLink Co., 2001. Revised 2002, 2003, 2004, 2005.
- 10) Cheema Z.F. and **Wolfe G.I.** Idiopathic neuropathies. In: Aminoff M.J. and Daroff R.B., eds. Encyclopedia of the Neurological Sciences. San Diego: Academic Press, 2003; pp 544-550.
- 11) Nations S.P., Trivedi J.R. and **Wolfe G.I.** Infectious and granulomatous neuropathies. In: Bromberg M.B. and Smith A.G., eds. Handbook of Peripheral Neuropathy. Boca Raton, FL: Taylor & Francis Group, 2005; pp 293-313.
- 12) Trivedi J.R. and **Wolfe G.I.** Polyneuropathy associated with anti-sulfatide antibodies. In: Gilman S., Goldstein G.W. and Waxman S.G., eds. MedLink-Neurology. San Diego: MedLink Co. 2003. Revised 2004, 2005.
- 13) Trivedi J.R. and **Wolfe G.I.** Peripheral neuropathies. In: Rakel R.E. and Bope E.T., eds. Conn's Current Therapy. Philadelphia: W.B. Saunders, 2005; pp 1086-1096.
- 14) **Wolfe G.I.** and Barohn R.J. Diseases of the neuromuscular junction. In: Swaiman K.F., Ashwal S. and Ferriero

- D.M., eds. Pediatric Neurology: Principles and Practice, 4th ed. Philadelphia: Mosby Elsevier Inc., 2006; pp 1941-1968.
- 15) **Wolfe G.I.** and Barohn R.J. Myasthenia gravis: classification and outcome measurements. In: Kaminski H.J., ed. Myasthenia Gravis and Related Disorders, 2<sup>nd</sup> ed. New York:Humana Press, 2009; pp 293-302.
  - 16) **Wolfe G.I.**, Pleasure D.E., Bird S.J., Scherer S.S., Sladky J.T. and Burns D.K. Neuromuscular disease. In: Rosenberg R.N., ed. Atlas of Clinical Neurology, 3<sup>rd</sup> ed. Philadelphia: Current Medicine LLC, 2009; pp 423-440.
  - 17) Muppidi S. and **Wolfe G.I.** Muscle-specific tyrosine kinase-antibody positive and seronegative myasthenia gravis. In: Pourmand R., ed. Immune-Mediated Neuromuscular Diseases, Frontiers of Neurology and Neuroscience Vol 26, Basel, Switzerland: Karger, 2009; pp 109-119 [PMID:19349708].
  - 18) Trivedi J.R. and **Wolfe G.I.** MG therapy and thymectomy. In: Christadoss P., ed. Myasthenia Gravis: Disease Mechanisms and Immune Intervention. New York: Linus Publications, 2010; pp 55-80.
  - 19) Muppidi S, **Wolfe G.I.** Pediatrics: Myasthenia gravis in clinical decision support: Pediatrics. In: McMillan J.M., Barrett D.J., Boney C.M. and Jones M.D., eds. Decision Support in Medicine, LLC, Wilmington, DE: 2011.
  - 20) Muppidi S., **Wolfe G.I.** and Barohn R.J. Diseases of the neuromuscular junction. In: Swaiman K.F., Ashwal S., Ferriero D.M., Schor N.F., eds. Pediatric Neurology: Principles and Practice, 5th ed. Philadelphia: Elsevier Saunders, Inc., 2012; pp 1549-1569.
  - 21) Silvestri N.J., Barohn R.J., **Wolfe G.I.** Acquired disorders of the neuromuscular junction. In: Finkel R.S., Gropman A., eds. Swaiman's Pediatric Neurology: Principles and Practice, 6th ed. Philadelphia: Elsevier Saunders, Inc., 2017; pp 1098-1105.
  - 22) Silvestri N.J., **Wolfe G.I.** Myasthenia gravis: classification and outcome measurements. In: Kaminski H.J., Kusner L.L., eds. Myasthenia Gravis and Related Disorders, 3<sup>rd</sup> ed. New York: Humana Press, 2018; pp 307-318.
  - 23) **Wolfe G.I.**, Balos L.L., Fine E.J., Bönnemann C.G., Silvestri N.J. Neuromuscular disease. In: Rosenberg R.N., ed. Atlas of Clinical Neurology, 4<sup>th</sup> ed. Switzerland: Springer Nature, 2019; pp 573-595.
  - 24) Mi W., Silvestri N.S., **Wolfe G.I.** A neurologist's perspective on thymectomy for myasthenia gravis: Current perspective and future trials. In: Sonett J.R., ed. Thymectomy for Myasthenia Gravis, Thoracic Surgery Clinics, Philadelphia: Elsevier, Inc., 2019; pp 143-150 [PMID:30927995].
  - 25) Lee I., **Wolfe G.I.** Advances in treating myasthenia gravis. In: Smith R.A., Kaspar B., Svendsen C., eds. The Development of Neurotherapeutics in the Era of Translational Medicine. San Diego: Elsevier, submitted.
  - 26) Pasnoor M., **Wolfe G.I.**, Barohn R.J. Autoimmune myasthenia. In: Hanna M.G., ed. Handbook of Clinical Neurology: Neurological Channelopathies. Amsterdam: Elsevier Science Direct, submitted.

#### Edited Contributions

- 1) **Wolfe G.I.**, Meriggioli M.N., Ciafaloni E., Ruff R.L. Introduction for Myasthenia Gravis and Related Disorders. Annals NY Academy of Science; 2012; 1274: vii-viii [PMID:23252910].
- 2) **Wolfe G.I.**, Meriggioli M.N., Ciafaloni E., Ruff R.L., eds. Myasthenia Gravis and Related Disorders I and II. Annals NY Academy of Science; 2012; vol. 1274 & 1275 [PMID:23278589].

**Editorials, Letters to the Editor, Correspondence, Contributions**

- 1) Katz J.S., **Wolfe G.I.**, Burns D.K., Bryan W.W., Fleckenstein J.L. and Barohn R.J. Dropped head syndrome: reply from the authors. Neurology, 1997; 48:551-552.
- 2) Haley R.W., Kurt T.L., **Wolfe G.I.**, Bryan W.W., Hom J., Roland P.S., Van Ness P.C., Bonte F.J., Devous M.D., Mathews D., Fleckenstein J.L., Wians F.H. Identification of Gulf War syndrome: methodological issues and medical illnesses. In reply. JAMA, 1997; 278:385-387.
- 3) **Wolfe G.I.** Book review: Use and Interpretation of Laboratory Tests in Neurology. Archives of Neurology, 1998; 55:256.
- 4) Katz J.S., Jackson C.E., Amato A.A., **Wolfe G.I.**, Bryan W.W. and Barohn R.J. Electrophysiologic findings in multifocal motor neuropathy: reply from the authors. Neurology, 1998; 50:1936-1937.
- 5) **Wolfe G.I.** Foreword. In: Senneff J.A. Numb Toes and Aching Soles: Coping with Peripheral Neuropathy, San Antonio, TX: MedPress, 1999.
- 6) **Wolfe G.I.**, Barohn R.J. and Amato A.A. Chronic cryptogenic sensory polyneuropathy: reply from the authors. Archives of Neurology, 2000; 57:760 [PMID:10815151].
- 7) **Wolfe G.I.**, Van der Sluis R.W., Nations S.P., and Barohn R.J. Post-radiation lower motor neuron syndrome: reply from the authors. Journal of Clinical Neuromuscular Disease, 2000; 2:116 [PMID:19078616].
- 8) **Wolfe G.I.**, Nations S.P., Burns D.K., Herbelin L.L. and Barohn R.J. Benefit of IVIG for long-standing ataxic sensory neuronopathy with Sjögren's syndrome. Neurology, 2003; 61:873 [PMID:14723230].
- 9) **Wolfe G.I.** Book review: Clinical Evaluation and Diagnostic Tests for Neuromuscular Disorders. Archives of Neurology, 2003; 60:1487.
- 10) **Wolfe G.** John Newsom-Davis, MD, FRS, CBE, 1932-2007 (obituary). Journal of Clinical Neuromuscular Disease 2008; 9:377.
- 11) Sanders D.B., Hart I.K., Mantegazza R., Shula S.S., Siddiqi Z.A., De Baets M.H.V., Melms A., Nicolle M.W., Solomons N., Richman D.P. (appendix listing). An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 2008, 71:400-406.
- 12) Kaminski H., Cutter G., Ruff R.L., **Wolfe G.** Evidence-based guideline update: plasmapheresis in neurological disorders. Neurology 2011; 77:e101-102 [PMID:22135813].
- 13) El-Dokla A., Silvestri N.J. **Wolfe G.I.**, Lacomis D. What's in the literature? Journal of Clinical Neuromuscular Disease 2013; 15:77-86.
- 14) El-Dokla A., Silvestri N.J. **Wolfe G.I.**, Lacomis D. What's in the literature? Journal of Clinical Neuromuscular Disease 2014; 15:129-142.
- 15) England J.D., Franklin G., Swain-Eng R., Brannagan T.H., David W.S., Dubinsky R.M., Smith B.E. (appendix listing). Quality improvement in neurology: Distal symmetric polyneuropathy quality measures. Neurology 2014; 82:1745-1748.
- 16) Silvestri N.J., El-Dokla A., **Wolfe G.I.**, Lacomis D. What's in the literature? Journal of Clinical Neuromuscular Disease 2014; 15:179-190.
- 17) **Wolfe G.I.**, Rowland L.P. Obituary. Alfred Jaretzki III, MD. Muscle Nerve 2014;50: 311-312 [PMID:25042516].

- 18) Lacomis D., Silvestri N.J., **Wolfe G.I.** What's in the literature? Journal of Clinical Neuromuscular Disease 2014; 16:32-41 [PMID:25137515].
- 19) Silvestri N.J., **Wolfe G.I.**, Lacomis D. What's in the literature? Journal of Clinical Neuromuscular Disease 2014; 16:108-119 [PMID:25415525].
- 20) Burns T.M., Sanders D.B., Kaminski H.J., **Wolfe G.I.**, Narayanaswami P., Venitz J.. Two steps forward, one step back; mycophenolate mofetil use for myasthenia gravis in the United States. Muscle Nerve 2015; 51:635-637 [PMID:25704880].
- 21) Silvestri N.J., Zivkovik S., **Wolfe G.I.**, Lacomis D. What's in the literature? Journal of Clinical Neuromuscular Disease 2015; 16:170-179. [PMID:25695923].
- 22) Bromberg M.B., Lacomis D., Silvestri N.J., **Wolfe G.I.** What's in the literature? Journal of Clinical Neuromuscular Disease 2015; 16:229-238 [PMID:25996973].
- 23) Lacomis D., Silvestri N.J., **Wolfe G.I.**, Bromberg M.B. What's in the literature? Journal of Clinical Neuromuscular Disease 2015; 17:36-46 [PMID:26301380].
- 24) Burns T.M., Smith G.A., Allen J.A., Amato A.A., Arnold W.D., Barohn R., Benatar M., Bird S.J., Bromberg M., Chahin N., Ciafaloni E., Cohen J.A., Corse A., Crum B.A., David W.S., Dimberg E., De Sousa E. A. Donofrio P.D., Dyck P.J.B., Engel A.G., Ensrud E.R., Ferrante M., Freimer M., Gable K.L., Gibson S., Gilchrist J.M., Goldstein J.M., Gooch C.L., Goodman B.P., Gorelov D., Gospe S.M., Goyal N.A., Guidon A.C., Guptill J.T., Gutmann L., Gutmann L., Gwathmey K., Harati Y., Harper C.M., Hehir M.K., Hobson-Webb L.D., Howard J.F., Jackson C.E., Johnson N., Jones S.M., Juel V.C., Kaminski H.J., Karam C., Kennelly K.D., Khella S., Khoury J., Kincaid J.C., Kissel J.T., Kolb N., Lacomis D., Ladha S., Larriviere D., Lewis R.A., Li Y., Litchy W.J., Logigian E., Lou J-S., MacGowen D.J.L., Masseli R., Massey J.M., Mauermann M.L., Mathews K.D., Meriggioli M.N., Miller R.G., Moon J-S., Mozaffar T., Nations S.P., Nowak R.J., Ostrow L.W., Pascuzzi R.M., Peltier A., Ruzhansky K., Richman D.P., Ross M.A., Rubin D.I., Russell J.A., Sachs G.M., Salajegheh M.K., Saperstein D.S., Scelsa S, Selcen D., Shaibani A., Shieh P.B., Silvestri N.J., Singleton J.R., Smith B.E., So Y.T., Solorzano G., Sorenson E.J. Srinivasen J., Tavee J., Tawil R., Thaisetthawatkul P., Thornton C., Trivedi J., Vernino S., Wang A.K., Webb T.A., Weiss M.D., Windebank A.J., **Wolfe G.I.** Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine. Muscle Nerve, 2016; 53:165-168 [PMID:26662952].
- 25) **Wolfe G.I.**, Silvestri N.J. Salbutamol: a means to an endplate. Neurology; 2016; 86:693 [PMID:26791151].
- 26) Silvestri N.J., **Wolfe G.I.**, Bromberg, M., Lacomis D. What's in the literature? Journal of Clinical Neuromuscular Disease 2016; 17:146-157 [PMID:26905916].
- 27) Silvestri N.J., **Wolfe G.I.**, Bromberg, M., Lacomis D. What's in the literature? Journal of Clinical Neuromuscular Disease 2016; 17:227-238 [PMID:27224441].
- 28) Silvestri N.J., **Wolfe G.I.**, Lacomis D., Bromberg, M. What's in the literature? Journal of Clinical Neuromuscular Disease 2016; 18:47-59 [PMID:27552392].
- 29) **Wolfe G.I.**, Kaminski H.J., Cutter G.R. Randomized trial of thymectomy in myasthenia gravis. New England Journal of Medicine, 2016; 375:2005-2007 [PMID:27959593].
- 30) Silvestri N.J., **Wolfe G.I.**, Lacomis D. What's in the literature? Journal of Clinical Neuromuscular Disease 2016; 18:108-117 [PMID:27861229].
- 31) **Wolfe G.I.**, Kaminski H.J., Sonnett J.R., Aban I.B., Kuo H.-C., Cutter G.R. Randomized trial of thymectomy in myasthenia gravis. Journal of Thoracic Disease 2016; 8:E1782-E1783.
- 32) Silvestri N.J., **Wolfe G.I.** Rituximab in treatment-refractory myasthenia gravis. JAMA Neurology, 2017; 74:21-23 [PMID:27892981].

- 33) Sanders D.B., **Wolfe G.I.**, Narayanaswami P. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 2017; 88:505-506 [PMID:28138082].
- 34) Lacomis D., Silvestri N.J., E.J. Fine, **Wolfe G.I.** What's in the literature? Journal of Clinical Neuromuscular Disease 2017; 18:165-175 [PMID:28221312].
- 35) Silvestri N.J., **Wolfe G.I.** Start high, then go low: an effective strategy in the treatment of myasthenia gravis. Muscle Nerve 2017; 55:773-774 [PMID:28345201].
- 36) **Wolfe G.I.** Foreword. In: Silvestri N.J. Neuromuscular Disorders: A Symptoms and Signs Approach to Differential Diagnosis and Treatment, New York, NY: Springer/Demos Medical, 2018.
- 37) Molin C.J., Sabre L., Weis C.-A., Punga T., Punga A.R. Thymectomy lowers the myasthenia gravis biomarker miR-150-5p. Acknowledgement. Neurol Neuroimmunol Neuroinflamm 2018; 5:e450.
- 38) Piehl F., **Wolfe G.I.** Is the treatment of myasthenia gravis improving? Why not ask our patients? Neurology 2020; 95:509-510 [PMID:32759197].
- 39) Narayanaswami P., Sanders D.B., **Wolfe G.** Author response: International consensus guidance for management of myasthenia gravis. Neurology 2021; in press.
- 40) Lacomis D., **Wolfe G.I.** What is in the neuromuscular junction literature? Journal of Clinical Neuromuscular Disease 2021; 22:147-154 [PMID:33595998].
- 41) **Wolfe G.I.** Foreword. In: Shaibani A., Zahra A., Al Sultani H. Coping with Myasthenia Gravis. Bloomington, IN: AuthorHouse, 2021.
- 42) Granit V., Benatar M., Kurtoglu M, Miljković M.D., Chahin N., Sahagian G., Feinberg M.H., Slansky A., Vu T., Jewell C.M., Singer M.S., Kalayoglu M.V., Howard J.F., Mozaffar T., MG-001 Study Team. Safety and efficacy of autologous RNA chimeric antigen receptor T-cell (rCAR-T) therapy in myasthenia gravis: a prospective, multicenter, open-label, non-randomised phase 1b/2a study. Acknowledgement. Lancet Neurology 2023; 22:578-590 [PMID:37353278].

### Medical Journalism

- 1) **Wolfe G.I.** Rare disease strikes him down -- readers give him a lift (a story on Guillain-Barré syndrome). The Orange County Register, 7/2/84.
- 2) **Wolfe G.I.** Safety caps a nuisance, but they work. The Orange County Register, 8/1/84.
- 3) **Wolfe G.I.** Surfers, sailors need sunglasses to cut ultraviolet, prevent pterygium. The Orange County Register, 8/8/84.
- 4) Barohn R., **Wolfe G.**, Belzer S. and Wians F. Polyneuropathy: detecting the elusive monoclonal protein. The Southwestern Lab Bulletin, Vol. 1, No. 11, 9/1/94.
- 5) Kaminski H.J., **Wolfe G.I.** and Newsom-Davis J. Study of thymectomy for treatment of myasthenia gravis. Foundation Focus, Myasthenia Gravis Foundation of America national newsletter, Fall 2001.
- 6) Kaminski H.J., **Wolfe G.I.**, Jaretzki A., Cutter G., Minisman G., Newsom-Davis, J. Study of thymectomy for treatment of myasthenia gravis. Foundation Focus, Myasthenia Gravis Foundation of America national newsletter, Spring 2006.
- 7) Jaretzki A., **Wolfe G.**, Cutter G., Kaminski H., Minisman G., Aban I., Odenkirchen J., Conwit R., Newsom-Davis J. Update on the thymectomy trial in non-thymomatous MG. Foundation Focus, Myasthenia Gravis

- Foundation of America national newsletter, Spring 2008.
- 8) Bromberg M.B., Brannagan III T.H. and **Wolfe G.I.** Diagnosis and therapeutic consensus: taking a stand on neuromuscular disease. CME Web Spotlight, sponsored by DIME. October 2009.
  - 9) Burns T., Howard J. and **Wolfe G.I.** What the patient and caregiver should know about prescription drugs and MG. Myasthenia Gravis Foundation of America podcast. February 2010.
  - 10) **Wolfe G.I.** Immunotherapies for myasthenia gravis. American Academy of Neurology podcast. November 2010.
  - 11) **Wolfe G.I.**, Sanders D. and Burns T. Five important things to know about myasthenia gravis. Myasthenia Gravis Foundation of America podcast. November 2010.
  - 12) Koski C.L., Dalakas M.C. and **Wolfe G.I.** Clinical decision making in autoimmune neuromuscular disease: diagnosis, treatment, and management. CME Web Spotlight, sponsored by DIME. October 2010.
  - 13) **Wolfe G.I.**, Carter G.C. and Ensrud, E.R. Advances in the treatment of autoimmune neuromuscular disease: from diagnostic challenges to long-term management. CME Web Spotlight, sponsored by DIME. November 2011.
  - 14) Greer M., **Wolfe G.I.** Diagnosing and treating chronic inflammatory demyelinating polyneuropathy. IG Living magazine, October-November 2012, pp 24-27.
  - 15) **Wolfe G.I.** International Conference on Myasthenia Gravis and Related Disorders. Foundation Focus, Myasthenia Gravis Foundation of America national newsletter, Fall, 2012, pg 3.
  - 16) **Wolfe G.I.**, Kaminski H.J., Jaretzki A III, Minisman G., Aban C., Cowit R., Cutter G. Thymectomy in MG research study (MGTX). Update: international investigator team still needs your help. Foundation Focus, Myasthenia Gravis Foundation of America national newsletter, Fall, 2012, pg 7.
  - 17) Brannagan T.H., **Wolfe G.I.** Ensuring proper diagnosis and management of autoimmune neuromuscular diseases: case-based discussion on CIDP and MMN. Univ. of Florida College of Medicine and PeerView Institute for Medical Education CME activity, June 2013.
  - 18) Silvestri N.J., **Wolfe G.I.** What's hot off the press in neuromuscular junction disorders? Foundation Focus, Myasthenia Gravis Foundation of America national newsletter, Fall, 2013, pp 16-17.
  - 19) **Wolfe G.I.**, Silvestri N.J. My burning feet and toes: treatment for neuropathic pain. Buffalo Healthy Living, March 2014, pg 17.
  - 20) Silvestri, N.J., **Wolfe G.I.** What's hot off the press in neuromuscular junction disorders? Foundation Focus, Myasthenia Gravis Foundation of America national newsletter, Spring, 2014, pp 13-14.
  - 21) **Wolfe G.I.**, Rowland L.P. In memoriam: Alfred Jaretzki III, MD. Myasthenia Gravis Foundation of America, <http://www.myasthenia.org/Home.aspx>, June 2014.
  - 22) **Wolfe G.I.** Diabetic neuropathy. FP Audio. American Academy of Family Physicians. Volume 426. November 2014.
  - 23) Silvestri, N.J., **Wolfe G.I.** What's hot off the press in neuromuscular junction disorders? Foundation Focus, Myasthenia Gravis Foundation of America national newsletter, Fall, 2014, pp 19-20.



- 24) **Wolfe G.I.**, Koski C.L, Ensrud E.R. Treatment optimization in autoimmune neuropathies. Academy for Continued Healthcare Learning, CME program via Indiana University School of Medicine, November-December 2014.
- 25) **Wolfe G.I.**, Silvestri N.J. My burning feet and toes: treatment for neuropathic pain. Buffalo Healthy Living.- UBMD Special Issue, January 2015, pg 18.
- 26) Silvestri N.J., **Wolfe G.I.** What's hot off the press in neuromuscular junction disorders? Foundation Focus, Myasthenia Gravis Foundation of America national newsletter, Spring, 2015, pp 20-21.
- 27) Silvestri N.J., **Wolfe G.I.** What's hot off the press in neuromuscular junction disorders? Foundation Focus, Myasthenia Gravis Foundation of America national newsletter, Fall, 2015, pp 25-26.
- 28) Silvestri N.J., **Wolfe G.I.** What's hot off the press in neuromuscular junction disorders? Foundation Focus, Myasthenia Gravis Foundation of America national newsletter, Spring, 2016, pp 17-18.
- 29) **Wolfe G.I.** Podcast: Randomized trial of thymectomy in myasthenia gravis. American Association of Neuromuscular & Electrodiagnostic Medicine, released 11/4/16.
- 30) **Wolfe G.I.** Webinar: Thymectomy or not? Myasthenia Gravis Foundation of America, 11/28/16.
- 31) **Wolfe G.I.** Podcast: Randomized trial of thymectomy in myasthenia gravis. American Academy of Neurology, released, winter 2016.
- 32) **Wolfe G.I.**, Kaminski H.J., Aban I., Cutter G.R. Thymectomy study results. Foundation Focus, Myasthenia Gravis Foundation of America national newsletter, Fall, 2016, pp 4-5.
- 33) Silvestri N.J., **Wolfe G.I.** What's hot off the press in neuromuscular junction disorders? Foundation Focus, Myasthenia Gravis Foundation of America national newsletter, Fall, 2016, pp 23-24.
- 34) **Wolfe G.I.** Podcast: Overview of myasthenia gravis and related disorders of neuromuscular transmission. Raremark. 5/3/17.
- 35) Silvestri N.J., **Wolfe G.I.** What's hot off the press in neuromuscular junction disorders? Focus on MG, Myasthenia Gravis Foundation of America national newsletter, Spring, 2017, pp 20-23.
- 38) Silvestri N.J., **Wolfe G.I.** What's hot off the press in neuromuscular junction disorders? Focus on MG, Myasthenia Gravis Foundation of America national newsletter, Fall, 2017, pp 21-24.
- 39) **Wolfe G.I.** Prof. Gil I. Wolfe: don't be afraid to say "yes" even if you feel your plate is pretty full. Journal of Thoracic Disease; 2018, doi: 10.21037/jtd.2018.06.14.
- 40) **Wolfe G.I.** New York Neurosociety demonstrates growth at meeting. Capitol Hill Report, American Academy of Neurology, 1/21/19.
- 41) The expanding therapeutic landscape for myasthenia gravis: A Q&A with **Gil I. Wolfe**, MD. Quest (MDA magazine), issue 2, 2020, pp 12-13.
- 42) Smith J. The fast changing world of myasthenia gravis treatment: Interviews with Richard J. Nowak and **Gil I. Wolfe**. Supplement to Neurology Reviews, April 2021, pp 25-27.
- 43) **Wolfe G.I.**, Silvestri N.J. Neurology Video Journal Club: Corticosteroid-sparing Effects of Immunoglobulin in Myasthenia Gravis. American Academy of Neurology, 4/17/23.

- 44) **Wolfe G.I.**, Silvestri N.J. InDiscussion Podcast on Myasthenia Gravis: Thymectomy. Medscape, 7/17/23.
- 45) **Wolfe G.I.**, Bird S.J. Clinical Conversations: Finding Clarity in Myasthenia Gravis Treatment Choice. Projects in Knowledge, powered by Kaplan, 10/18/23.